10-Q

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended Nov. 30, 2013

or

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from to

Commission file number 001-16167

MONSANTO COMPANY

(Exact name of registrant as specified in its charter)

Delaware	43-1878297
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
800 North Lindbergh Blvd.,	63167
St. Louis, MO	(Zip Code)
(Address of principal executive offices)

(314) 694-1000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	o
Non-accelerated filer	o  (Do not check if a smaller reporting company)	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 524,876,699 shares of Common Stock, $0.01 par value, outstanding as of January 6, 2014.

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

In the interests of our investors, and in accordance with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, this section of our report explains some of the important reasons that actual results may be materially different from those that we anticipate. In this report, and from time to time throughout the year, we share our expectations for our company’s future performance. These forward-looking statements include statements about our business plans; the potential development, regulatory approval, and public acceptance of our products; our expected financial performance, including sales performance, and the anticipated effect of our strategic actions; the anticipated benefits of recent acquisitions; the outcome of contingencies, such as litigation and the previously announced SEC investigation; domestic or international economic, political and market conditions; and other factors that could affect our future results of operations or financial position, including, without limitation, statements under the captions “Overview — Executive Summary — Outlook,” “Seeds and Genomics Segment,” “Agricultural Productivity Segment,” “Financial Condition, Liquidity, and Capital Resources,” “Outlook,” “Critical Accounting Policies and Estimates” and “Legal Proceedings.” Any statements we make that are not matters of current reportage or historical fact should be considered forward-looking. Such statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “will,” and similar expressions. By their nature, these types of statements are uncertain and are not guarantees of our future performance.

Since these statements are based on factors that involve risks and uncertainties, our company’s actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company’s exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company’s research and development activities; the outcomes of major lawsuits; developments related to foreign currencies and economies; successful operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company’s estimates related to distribution inventory levels; the company’s ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company’s facilities; and other risks and factors described or referenced in Part II — Item 1A — Risk Factors — below and Part I — Item 1A of our Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

Our forward-looking statements represent our estimates and expectations and are based on currently available information at the time that we make those statements. However, circumstances change constantly, often unpredictably, and many events beyond our control will determine whether the expectations encompassed in our forward-looking statements will be realized. As a result, investors should not place undue reliance on these forward-looking statements. We disclaim any current intention or obligation to revise or update any forward-looking statements, or the factors that may affect their realization, whether in light of new information, future events or otherwise, and investors should not rely on us to do so.

1

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

TABLE OF CONTENTS

PART I—FINANCIAL INFORMATION		Page
Item 1.	Financial Statements	3
	Statements of Consolidated Operations	4
	Statements of Consolidated Comprehensive Income (Loss)	5
	Statements of Consolidated Financial Position	6
	Statements of Consolidated Cash Flows	7
	Statements of Consolidated Shareowners’ Equity	8
	Notes to Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	31
	Overview	31
	Results of Operations	33
	Seeds and Genomics Segment	35
	Agricultural Productivity Segment	36
	Financial Condition, Liquidity and Capital Resources	36
	Outlook	40
	Critical Accounting Policies and Estimates	42
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	42
Item 4.	Controls and Procedures	43
PART II—OTHER INFORMATION
Item 1.	Legal Proceedings	44
Item 1A.	Risk Factors	44
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	44
Item 6.	Exhibits	44
SIGNATURE		45
EXHIBIT INDEX		46

2

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The Statements of Consolidated Operations of Monsanto Company and its consolidated subsidiaries for the three months ended Nov. 30, 2013, and Nov. 30, 2012, the Statements of Consolidated Comprehensive Income (Loss) for the three months ended Nov. 30, 2013, and Nov. 30, 2012, the Statements of Consolidated Financial Position as of Nov. 30, 2013, and Aug. 31, 2013, the Statements of Consolidated Cash Flows for the three months ended Nov. 30, 2013, and Nov. 30, 2012, the Statements of Consolidated Shareowners’ Equity for the three months ended Nov. 30, 2013, and year ended Aug. 31, 2013, and related Notes to the Consolidated Financial Statements follow. Unless otherwise indicated, “Monsanto” and the “company” are used interchangeably to refer to Monsanto Company or to Monsanto Company and its consolidated subsidiaries, as appropriate to the context. Unless otherwise indicated, “earnings per share” and “per share” mean diluted earnings per share. In the notes to the consolidated financial statements, all dollars are expressed in millions, except per share amounts. Unless otherwise indicated, references to “Roundup herbicides” mean Roundup branded herbicides, excluding all lawn-and-garden herbicides, and references to “Roundup and other glyphosate-based herbicides” exclude all lawn-and-garden herbicides.

3

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

Statements of Consolidated Operations

Unaudited (Dollars in millions)	Three Months Ended
	Nov. 30, 2013			Nov. 30, 2012
Net Sales	$	3,143		$	2,939
Cost of goods sold	1,580			1,542
Gross Profit	1,563			1,397
Operating Expenses:
Selling, general and administrative expenses	589			542
Research and development expenses	409			346
Total Operating Expenses	998			888
Income from Operations	565			509
Interest expense	53			51
Interest income	(24		)	(23		)
Other expense, net	20			17
Income from Continuing Operations Before Income Taxes	516			464
Income tax provision	152			122
Income from Continuing Operations Including Portion Attributable to Noncontrolling Interest	$	364		$	342
Discontinued Operations:
Income from operations of discontinued businesses	14			11
Income tax provision	5			4
Income from Discontinued Operations	9			7
Net Income	$	373		$	349
Less: Net income attributable to noncontrolling interest	5			10
Net Income Attributable to Monsanto Company	$	368		$	339
Amounts Attributable to Monsanto Company:
Income from continuing operations	$	359		$	332
Income from discontinued operations	9			7
Net Income Attributable to Monsanto Company	$	368		$	339
Basic Earnings per Share Attributable to Monsanto Company:
Income from continuing operations	$	0.68		$	0.62
Income from discontinued operations	0.02			0.01
Net Income Attributable to Monsanto Company	$	0.70		$	0.63
Diluted Earnings per Share Attributable to Monsanto Company:
Income from continuing operations	$	0.67		$	0.62
Income from discontinued operations	0.02			0.01
Net Income Attributable to Monsanto Company	$	0.69		$	0.63
Weighted Average Shares Outstanding:
Basic	526.9			534.8
Diluted	532.6			540.4
Dividends Declared per Share	$	—		$	—

The accompanying notes are an integral part of these consolidated financial statements.

4

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

Statements of Consolidated Comprehensive Income (Loss)

Unaudited (Dollars in millions)	Three Months Ended
	Nov. 30, 2013			Nov. 30, 2012
Comprehensive Income Attributable to Monsanto Company
Net Income Attributable to Monsanto Company	$	368		$	339
Other Comprehensive Income, Net of Tax:
Foreign currency translation, net of tax of $(8) and $0, respectively	127			52
Postretirement benefit plan activity, net of tax of $5 and $7, respectively	8			11
Unrealized net gains on investment holdings, net of tax of $3 and $3, respectively	5			6
Realized net gains on investment holdings, net of tax of $0 and $1, respectively	—			1
Unrealized net derivative losses, net of tax of $(25) and $(6), respectively	(43		)	(12		)
Realized net derivative gains (losses), net of tax of $3 and $(5), respectively	5			(10		)
Total Other Comprehensive Income, Net of Tax	102			48
Comprehensive Income Attributable to Monsanto Company	$	470		$	387
Comprehensive Income (Loss) Attributable to Noncontrolling Interests
Net Income Attributable to Noncontrolling Interests	5			10
Other Comprehensive (Income) Loss
Foreign currency translation	5			(4		)
Total Other Comprehensive Income (Loss)	5			(4		)
Comprehensive Income Attributable to Noncontrolling Interests	$	10		$	6
Total Comprehensive Income	$	480		$	393

The accompanying notes are an integral part of these consolidated financial statements.

5

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

Statements of Consolidated Financial Position

Unaudited (Dollars in millions)	As of
	Nov. 30, 2013			Aug. 31, 2013
Assets
Current Assets:
Cash and cash equivalents (variable interest entity restricted - 2014: $31 and 2013: $140)	$	4,496		$	3,668
Short-term investments	249			254
Trade receivables, net (variable interest entity restricted - 2014: $116 and 2013: $0)	2,283			1,715
Miscellaneous receivables	774			748
Deferred tax assets	631			579
Inventory, net	3,873			2,947
Other current assets	190			166
Total Current Assets	12,496			10,077
Total property, plant and equipment	9,660			9,491
Less accumulated depreciation	4,974			4,837
Property, Plant and Equipment, Net	4,686			4,654
Goodwill	4,325			3,520
Other Intangible Assets, Net	1,367			1,226
Noncurrent Deferred Tax Assets	484			454
Long-Term Receivables, Net	153			237
Other Assets	566			496
Total Assets	$	24,077		$	20,664
Liabilities and Shareowners’ Equity
Current Liabilities:
Short-term debt, including current portion of long-term debt	$	262		$	51
Accounts payable	853			995
Income taxes payable	101			91
Accrued compensation and benefits	281			492
Accrued marketing programs	756			1,078
Deferred revenues	2,866			517
Grower production accruals	634			60
Dividends payable	—			228
Customer payable	2			12
Miscellaneous short-term accruals	943			812
Total Current Liabilities	6,698			4,336
Long-Term Debt	3,057			2,061
Postretirement Liabilities	348			357
Long-Term Deferred Revenue	113			138
Noncurrent Deferred Tax Liabilities	544			469
Long-Term Portion of Environmental and Litigation Liabilities	186			193
Other Liabilities	392			382
Shareowners’ Equity:
Common stock (authorized: 1,500,000,000 shares, par value $0.01)
Issued 602,861,098 and 601,631,267 shares, respectively
Outstanding 524,936,480 and 529,029,712 shares, respectively	6			6
Treasury stock 77,924,618 and 72,601,555 shares, respectively, at cost	(4,701		)	(4,140		)
Additional contributed capital	10,887			10,783
Retained earnings	7,556			7,188
Accumulated other comprehensive loss	(1,176		)	(1,278		)
Total Monsanto Company Shareowners’ Equity	12,572			12,559
Noncontrolling Interest	167			169
Total Shareowners’ Equity	12,739			12,728
Total Liabilities and Shareowners’ Equity	$	24,077		$	20,664

The accompanying notes are an integral part of these consolidated financial statements.

6

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

Statements of Consolidated Cash Flows

Unaudited (Dollars in millions)	Three Months Ended
	Nov. 30, 2013			Nov. 30, 2012
Operating Activities:
Net Income	$	373		$	349
Adjustments to reconcile cash provided by operating activities:
Items that did not require (provide) cash:
Depreciation and amortization	162			152
Bad-debt expense	11			7
Stock-based compensation expense	27			24
Excess tax benefits from stock-based compensation	(15		)	(15		)
Deferred income taxes	(6		)	13
Equity affiliate (income) expense, net	3			(2		)
Net gain on sales of a business or other assets	(1		)	(12		)
Other items	20			(16		)
Changes in assets and liabilities that required cash, net of acquisitions:
Trade receivables, net	(478		)	(196		)
Inventory, net	(898		)	(740		)
Deferred revenues	2,319			2,426
Accounts payable and other accrued liabilities	332			(341		)
Pension contributions	(23		)	(16		)
Other items	(128		)	(64		)
Net Cash Provided by Operating Activities	1,698			1,569
Cash Flows (Required) Provided by Investing Activities:
Purchases of short-term investments	(105		)	(118		)
Maturities of short-term investments	110			110
Capital expenditures	(303		)	(133		)
Acquisition of businesses, net of cash acquired	(917		)	—
Purchases of long-term debt and equity securities	(12		)	—
Technology and other investments	(21		)	(23		)
Other proceeds	7			68
Net Cash Required by Investing Activities	(1,241		)	(96		)
Cash Flows Provided (Required) by Financing Activities:
Net change in financing with less than 90-day maturities	117			60
Short-term debt proceeds	2			—
Short-term debt reductions	—			(7		)
Long-term debt proceeds	999			16
Long-term debt reductions	(1		)	—
Payments on other financing	(39		)	—
Debt issuance costs	(8		)	—
Treasury stock purchases	(561		)	(27		)
Stock option exercises	64			31
Excess tax benefits from stock-based compensation	15			16
Tax withholding on restricted stock and restricted stock units	(2		)	(3		)
Dividend payments	(228		)	(201		)
Dividend payments to noncontrolling interests	(12		)	(1		)
Net Cash Provided (Required) by Financing Activities	346			(116		)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	25			(3		)
Net Increase in Cash and Cash Equivalents	828			1,354
Cash and Cash Equivalents at Beginning of Period	3,668			3,283
Cash and Cash Equivalents at End of Period	$	4,496		$	4,637

See Note 1 — Background and Basis of Presentation and Note 19 — Supplemental Cash Flow Information for further details.

The accompanying notes are an integral part of these consolidated financial statements.

7

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

Statements of Consolidated Shareowners’ Equity

	Monsanto Shareowners
Unaudited (Dollars in millions, except per share data)	Common Stock		Treasury Stock			Additional Contributed Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss) (1)			Non-Controlling Interest			Total
Balance as of Aug. 31, 2012	$	6	$	(3,045	)	$	10,371		$	5,537		$	(1,036	)	$	203		$	12,036
Net income	—		—			—			2,482			—			43			2,525
Other comprehensive loss for 2013	—		—			—			—			(242		)	(27		)	(269		)
Treasury stock purchases	—		(1,095		)	—			—			—			—			(1,095		)
Restricted stock withholding	—		—			(10		)	—			—			—			(10		)
Issuance of shares under employee stock plans	—		—			257			—			—			—			257
Excess tax benefits from stock-based compensation	—		—			69			—			—			—			69
Stock-based compensation expense	—		—			97			—			—			—			97
Cash dividends of $1.56 per common share	—		—			—			(831		)	—			—			(831		)
Dividend payments to noncontrolling interest	—		—			—			—			—			(174		)	(174		)
Acquisition of noncontrolling interest	—		—			(1		)	—			—			(9		)	(10		)
Proceeds from noncontrolling interest	—		—			—			—			—			133			133
Balance as of Aug. 31, 2013	$	6	$	(4,140	)	$	10,783		$	7,188		$	(1,278	)	$	169		$	12,728
Net income	—		—			—			368			—			5			373
Other comprehensive income for 2014	—		—			—			—			102			5			107
Treasury stock purchases	—		(561		)	—			—			—			—			(561		)
Restricted stock withholding	—		—			(2		)	—			—			—			(2		)
Issuance of shares under employee stock plans	—		—			64			—			—			—			64
Excess tax benefits from stock-based compensation	—		—			15			—			—			—			15
Stock-based compensation expense	—		—			27			—			—			—			27
Dividend payments to noncontrolling interest	—		—			—			—			—			(12		)	(12		)
Balance as of Nov. 30, 2013	$	6	$	(4,701	)	$	10,887		$	7,556		$	(1,176	)	$	167		$	12,739

(1) See Note 17 — Accumulated Other Comprehensive Loss — for further details of the components of accumulated other comprehensive income (loss).

The accompanying notes are an integral part of these consolidated financial statements.

8

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED

NOTE 1. BACKGROUND AND BASIS OF PRESENTATION

Monsanto Company, along with its subsidiaries, is a leading global provider of agricultural products for farmers. Monsanto’s seeds, biotechnology trait products, and herbicides provide farmers with solutions that improve productivity, reduce the costs of farming, and produce better foods for consumers and better feed for animals.

Monsanto manages its business in two segments: Seeds and Genomics and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and related traits businesses, biotechnology platforms and precision agriculture. Through the Seeds and Genomics segment, Monsanto produces leading seed brands, including DEKALB, Asgrow, Deltapine, Seminis and De Ruiter, and Monsanto develops biotechnology traits that assist farmers in controlling insects and weeds. Monsanto also provides other seed companies with genetic material and biotechnology traits for their seed brands. Through the Agricultural Productivity segment, the company manufactures Roundup and Harness brand herbicides and other herbicides. See Note 21 — Segment Information — for further details.

In the fourth quarter of 2008, the company announced plans to divest its animal agricultural products business, which focused on dairy cow productivity (the Dairy business) and was previously reported as part of the Agricultural Productivity segment. This transaction was consummated on Oct. 1, 2008. As a result, financial data for this business has been presented as discontinued operations.

Certain reclassifications of prior year amounts within the operating activities section of the Statement of Consolidated Cash Flows have been made to conform to current year presentation. The company has evaluated the impact and does not consider the reclassifications to be material to the consolidated financial statements.

The accompanying consolidated financial statements have not been audited but have been prepared in conformity with accounting principles generally accepted in the United States for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods reported. This Report on Form 10-Q should be read in conjunction with Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013. Financial information for the first three months of fiscal year 2014 should not be annualized because of the seasonality of the company’s business.

NOTE 2. NEW ACCOUNTING STANDARDS

In July 2013, the FASB issued accounting guidance requiring entities to present unrecognized tax benefits as a reduction to any related deferred tax assets for net operating losses, similar tax losses, or tax credit carryforwards if such settlement is required or expected in the event an uncertain tax position is disallowed. Currently, U.S. Generally Accepted Accounting Principles ("U.S. GAAP") does not provide explicit guidance on the topic. This new presentation guidance will become effective prospectively for fiscal years, and interim periods within those years, beginning after Dec. 15, 2013. Accordingly, Monsanto will adopt this standard in the first quarter of fiscal year 2015. While the company is evaluating the impact this standard will have on the presentation of unrecognized tax benefits in the company's consolidated balance sheet, it will not affect the company's results of operations, financial condition or cash flows.

In February 2013, the Financial Accounting Standards Board ("FASB") issued "Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income," which requires entities to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, entities are required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, entities are required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail on these amounts. This standard is effective prospectively for reporting periods beginning after Dec. 15, 2012. Accordingly, Monsanto adopted this standard in the first quarter of fiscal year 2014. See Note 17 - Accumulated Other Comprehensive Loss - for additional disclosures.

In December 2011 and February 2013, the FASB issued an amendment to the Balance Sheet topic of the Accounting Standards Codification ("ASC"), which requires entities to disclose both gross and net information about both derivatives and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting agreement. The objective of the disclosure is to facilitate comparison between those entities that prepare their financial statements on the basis of U.S. GAAP and those entities that prepare their financial statements on the basis of International Financial Reporting Standards. This standard is effective for fiscal years, and interim periods within those years,

9

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

beginning on or after Jan. 1, 2013. Retrospective presentation for all comparative periods presented is required. Accordingly, Monsanto adopted this amendment in the first quarter of fiscal year 2014. See Note 14 - Financial Instruments - for additional disclosures.

NOTE 3. BUSINESS COMBINATIONS

2014 Acquisitions: In November 2013, Monsanto acquired 100 percent of the outstanding stock of The Climate Corporation, a San Francisco, California based company. The Climate Corporation is a leading data analytics company with core capabilities around hyper local weather monitoring, weather simulation and agronomic modeling which has allowed them to develop risk management tools and agronomic decision support tools for growers. The acquisition will combine The Climate Corporation's expertise in agriculture risk-management with Monsanto’s R&D capabilities, and is expected to further enable farmers to significantly improve productivity and better manage risk from variables that could limit agriculture production. The acquisition of the company qualifies as a business under the Business Combinations topic of the ASC. Acquisition costs were $17 million, of which $1 million was recorded in the first quarter of 2014. These costs were classified as selling, general and administrative expenses. The total fair value of the acquisition was $932 million and the total cash paid for the acquisition was $917 million (net of cash acquired). The fair value was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is not deductible for tax purposes.

The business operations and employees of the acquired entity described above were included in the Seeds and Genomics reportable segment results upon acquisition. The estimated fair value of the assets and liabilities, summarized in the table below, represents the preliminary purchase price allocation. This allocation will be finalized as soon as the information becomes available, however, not to exceed one year from the acquisition date.

(Dollars in millions)	2014 Acquisition
Current Assets	$	59
Property, Plant & Equipment	9
Goodwill	785
Other Intangible Assets	145
Total Assets Acquired	998
Current Liabilities	10
Other Liabilities	56
Total Liabilities Assumed	66
Net Assets Acquired	$	932
Supplemental Information:
Net assets acquired	$	932
Cash acquired	15
Cash paid, net of cash acquired	$	917

Pro forma information related to the 2014 acquisition is not presented because the impact of the acquisition on Monsanto's consolidated results of operations is not significant.

The following table presents details of the definite life acquired identifiable intangible assets:

(Dollars in millions)	Weighted-Average Life (Years)	Useful Life (Years)	2014 Acquisition
Acquired Intellectual Property	10	10	$	141
Customer Relationships	1	1	4
Other Intangible Assets			$	145

2013 Acquisitions: In August 2013, Monsanto acquired certain assets and manufacturing capabilities of Dieckmann GmbH & Co. KG, a business based in Germany which specializes in the breeding of oilseed rape and rye seeds. The acquisition, which

10

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing activities in the breeding, production and marketing of oilseed rape in Europe. Acquisition costs were approximately $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations.  The total fair value and cash paid for the acquisition was $30 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles.  The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology.  The goodwill is deductible for tax purposes.

In June 2013, Monsanto acquired 100 percent of the outstanding stock of GrassRoots Biotechnology, Inc., a business based in Durham, North Carolina that is focused on gene expression and other agriculture technologies. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. Acquisition costs were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total fair value and cash paid for the acquisition was $15 million (net of cash acquired). The fair value of the acquisition was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is not deductible for tax purposes.

In March 2013, Monsanto acquired substantially all of the assets of Rosetta Green Ltd., a business based in Israel which specializes in the identification and use of unique genes to guide key processes in major crops including corn, soybeans and cotton. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. Acquisition costs were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total fair value and cash paid for the acquisition was $35 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is deductible for tax purposes.

In January 2013, Monsanto acquired select assets of Agradis, Inc., a business focused on developing sustainable agricultural solutions. The acquisition, which qualifies as a business under the Business Combinations topic of the ASC, is intended to support Monsanto's efforts to provide farmers with sustainable biological products to improve crop health and productivity. Acquisition costs incurred were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total cash paid and the fair value of the acquisition was $85 million, and the purchase price was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is deductible for tax purposes.

For the acquisitions described above, the business operations and employees of the acquired entities were included in the Seeds and Genomics reportable segment results upon acquisition.

Pro forma information related to the 2013 acquisitions is not presented because the impact of these acquisitions, either individually or in the aggregate, on Monsanto's consolidated results of operations is not expected to be significant.

NOTE 4. CUSTOMER FINANCING PROGRAMS

Monsanto participates in customer financing programs as follows:

	As of
(Dollars in millions)	Nov. 30, 2013		Aug. 31, 2013
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)
Outstanding balance	$	128	$	348
Maximum future payout under recourse provisions	9		19
European and Latin American agreements to sell trade receivables(2)
Outstanding balance	$	28	$	44
Maximum future payout under recourse provisions	28		41
Agreements with Lenders(3)
Outstanding balance	$	60	$	45
Maximum future payout under the guarantee	44		32

11

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

The gross amount of receivables sold under transactions that qualify for sales treatment were:

	Gross Amount of Receivables Sold
	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)	$	23	$	2
European and Latin American agreements to sell trade receivables(2)	7		—

(1) Monsanto has an agreement in the United States to sell trade receivables up to a maximum outstanding balance of $500 million and to service such accounts. These receivables qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The agreement includes recourse provisions and thus a liability is established at the time of sale that approximates fair value based upon the company’s historical collection experience and a current assessment of credit exposure.

(2) Monsanto has various agreements in European and Latin American countries to sell trade receivables, both with and without recourse. The sales within these programs qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The liability for the guarantees for sales with recourse is recorded at an amount that approximates fair value, based on the company’s historical collection experience for the customers associated with the sale of the receivables and a current assessment of credit exposure.

(3) Monsanto has additional agreements with lenders to establish programs that provide financing for select customers in the United States, Brazil, Latin America and Europe. Monsanto provides various levels of recourse through guarantees of the accounts in the event of customer default. The term of the guarantee is equivalent to the term of the customer loans. The liability for the guarantees is recorded at an amount that approximates fair value, based on the company’s historical collection experience with customers that participate in the program and a current assessment of credit exposure. If performance is required under the guarantee, Monsanto may retain amounts that are subsequently collected from customers.

In addition to the arrangements in the above table, Monsanto also participates in a financing program in Brazil that allowed Monsanto to transfer up to 1 billion Brazilian reais (approximately $430 million) for select customers in Brazil to a revolving financing program. Under the arrangement, a recourse provision requires Monsanto to cover the first credit losses within the program up to the amount of our investment. The company evaluated its relationship with the entity under the guidance within the Consolidation topic of the ASC and, as a result, the entity has been consolidated. For further information on this topic, see Note 5 — Variable Interest Entities.

There were no significant recourse or non-recourse liabilities for all programs as of Nov. 30, 2013, and Aug. 31, 2013. There were no significant delinquent loans for all programs as of Nov. 30, 2013, and Aug. 31, 2013.

NOTE 5. VARIABLE INTEREST ENTITIES

Monsanto is involved with entities that are deemed to be variable interest entities (VIEs). Monsanto has determined that the company holds variable interests in an entity that is established as a revolving financing program. In addition, Monsanto has various variable interests in biotechnology companies that focus on plant gene and agricultural fungicide research, development and commercialization. These variable interests have also been determined to be VIEs.

In December 2013, Monsanto entered into an agreement with a newly founded company that is focused on agricultural solutions that may enhance Monsanto’s biologicals platform. Monsanto is evaluating the accounting treatment of the transaction, including whether the newly founded entity will be deemed a VIE.

Consolidated VIEs

Monsanto has a financing program in Brazil that is recorded as a consolidated VIE. For the most part, the VIE consists of a revolving financing program that is funded by investments from the company and other third parties, primarily investment funds, and have been established to service Monsanto’s customer receivables. A 91 percent senior interest in the entity is held by third parties, primarily investment funds, as of Nov. 30, 2013, and Aug. 31, 2013, and Monsanto holds the remaining 9 percent interest. Under the arrangement, Monsanto is required to maintain an investment in the VIE of at least 9 percent and could be required to provide additional contributions to the VIE. Monsanto currently has no unfunded commitments to the VIE. See Note 4 — Customer Financing Programs — for additional information regarding the revolving financing arrangement.

Creditors have no recourse against Monsanto in the event of default by the VIE. The company’s financial or other support provided to the VIE is limited to its investment. Even though Monsanto holds a subordinate interest in the VIE, the VIE was

12

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

established to service transactions involving the company and the company determines the receivables that are included in the revolving financing program. Therefore, the determination is that Monsanto has the power to direct the activities most significant to the economic performance of the VIE. As a result, the company is the primary beneficiary of the VIE and the VIE has been consolidated in Monsanto’s Consolidated Financial Statements. The assets of the VIE may only be used to settle the obligations of the respective entity. Third-party investors in the VIE do not have recourse to the general assets of Monsanto other than the maximum exposure to loss relating to the VIE. The following table presents the carrying value of assets and liabilities, which are identified as restricted assets and liabilities on the company’s Statements of Consolidated Financial Position, and the maximum exposure to loss relating to the VIE for which Monsanto is the primary beneficiary.

	Financing Program VIE
	As of
(Dollars in millions)	Nov. 30, 2013		Aug. 31, 2013
Cash and cash equivalents	$	31	$	140
Trade receivables, net	116		—
Total Assets	$	147	$	140
Total Liabilities	—		—
Maximum Exposure to Loss	$	14	$	—

In June 2013, Monsanto entered into an agreement with a biotechnology company to establish a jointly-owned subsidiary to focus on research and development specifically related to agricultural fungicides. The subsidiary is recorded as a consolidated VIE of Monsanto. Monsanto's ownership interest in the VIE was 4% as of Nov. 30, 2013, and was less than 1% as of Aug. 31, 2013, with the remaining interest held by a third party. Under the arrangement, Monsanto will fund the operations of the VIE in return for additional equity interests up to 35%. The funding, which may total up to $16 million, will be provided in three separate research phases if research milestones are met. Monsanto also holds a call option to acquire 100% of the equity interests in the VIE from the third party majority owner. The call option was granted by the third party majority owner to Monsanto in return for total aggregate payments of $15 million, of which $7 million had been paid by Monsanto as of Nov. 30, 2013, and Aug. 31, 2013. The remaining payments will be made upon achievement of research milestones by the VIE. Even though Monsanto holds a minority interest in the VIE, the VIE was established to perform agricultural-based research and development activities for the benefit of Monsanto, and Monsanto provides all funding of the VIE's activities. Further, Monsanto has the power to direct the activities most significant to the VIE. As a result, Monsanto is the primary beneficiary of the VIE and the VIE has been consolidated in Monsanto's Consolidated Financial Statements. As of Nov. 30, 2013, and Aug. 31, 2013, the VIE had no significant assets or liabilities. Monsanto's maximum exposure to loss as of Nov. 30, 2013, and Aug. 31, 2013, was $11 million, which includes our current investment in the VIE, the funding required to be provided to the VIE during the current research phase and the initial consideration paid related to the call option. The third party majority owner of the VIE does not have recourse to the general assets of Monsanto beyond Monsanto's maximum exposure to loss at any given time relating to the VIE.

Non-Consolidated VIE

Monsanto has a variable interest through an investment with a software company that develops software with agricultural applications. The company has not provided financial or other support other than its original investment, has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity and is not significant. There were no significant assets or liabilities for the VIE as of Nov. 30, 2013, and Aug. 31, 2013.

NOTE 6. RECEIVABLES

Trade receivables on the Statements of Consolidated Financial Position are net of allowances of $70 million and $68 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively.

The company has financing receivables that represent long-term customer receivable balances related to past due accounts which are not expected to be collected within the current year. The long-term customer receivables were $131 million and $112 million with a corresponding allowance for credit losses on these receivables of $112 million and $104 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively. These long-term customer receivable balances and the corresponding allowance are included in long-term receivables, net on the Statements of Consolidated Financial Position. For these long-term customer

13

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

receivables, interest is no longer accrued when the receivable is determined to be delinquent and classified as long-term based on estimated timing of collection.

The following table displays a roll forward of the allowance for credit losses related to long-term customer receivables.

(Dollars in millions)
Balance as of Aug. 31, 2012	$	141
Incremental Provision	7
Recoveries	(1		)
Write-offs	(47		)
Other(1)	4
Balance as of Aug. 31, 2013	$	104
Incremental Provision	4
Recoveries	—
Write-offs	(1		)
Other(1)	5
Balance as of Nov. 30, 2013	$	112

(1)Includes reclassifications from current receivables and foreign currency translation adjustments.

In addition, the company has long-term contractual receivables. These receivables are collected at fixed and determinable dates in accordance with the customer long-term agreement. The long-term contractual receivables were $134 million and $229 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively, and did not have any allowance recorded related to these balances. These receivables are included in long-term receivables, net on the Statements of Consolidated Financial Position. There are no balances related to these long-term contractual receivables that are past due. These receivables are outstanding with large, reputable companies who have been timely with scheduled payments thus far and are considered to be fully collectible. Interest is accrued on these receivables in accordance with the agreements and is included within interest income in the Statements of Consolidated Operations.

On an ongoing basis, the company evaluates credit quality of its financing receivables utilizing aging of receivables, collection experience and write-offs, as well as evaluating existing economic conditions, to determine if an allowance is necessary.

NOTE 7. INVENTORY

Components of inventory are:

	As of
(Dollars in millions)	Nov. 30, 2013			Aug. 31, 2013
Finished Goods	$	1,820		$	1,079
Goods In Process	1,744			1,619
Raw Materials and Supplies	477			418
Inventory at FIFO Cost	4,041			3,116
Excess of FIFO over LIFO Cost	(168		)	(169		)
Total	$	3,873		$	2,947

NOTE 8. GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the net carrying amount of goodwill for the first three months of fiscal year 2014, by segment, are as follows:

(Dollars in millions)	Seeds and Genomics		Agricultural Productivity			Total
Balance as of Aug. 31, 2013	$	3,461	$	59		$	3,520
Acquisition activity (see Note 3)	785		—			785
Effect of foreign currency translation adjustments	21		(1		)	20
Balance as of Nov. 30, 2013	$	4,267	$	58		$	4,325

14

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

Goodwill increased during the three months endedNov. 30, 2013, due to the acquisition of The Climate Corporation. See Note 3 - Business Combinations - for further information. There were no events or circumstances indicating that goodwill might be impaired as of Nov. 30, 2013. The fiscal year 2014 annual goodwill impairment test will be performed as of March 1, 2014.

Information regarding the company’s other intangible assets is as follows:

	As of Nov. 30, 2013							As of Aug. 31, 2013
(Dollars in millions)	Carrying Amount		Accumulated Amortization			Net		Carrying Amount		Accumulated Amortization			Net
Acquired Intellectual Property	$	1,259	$	(799	)	$	460	$	1,095	$	(791	)	$	304
Acquired Germplasm	1,120		(728		)	392		1,113		(717		)	396
Trademarks	343		(135		)	208		341		(131		)	210
Customer Relationships	314		(186		)	128		306		(179		)	127
Other	170		(95		)	75		177		(91		)	86
Total Other Intangible Assets, Finite Lives	$	3,206	$	(1,943	)	$	1,263	$	3,032	$	(1,909	)	$	1,123
In Process Research & Development, Indefinite Lives	104		—			104		103		—			103
Total Other Intangible Assets	$	3,310	$	(1,943	)	$	1,367	$	3,135	$	(1,909	)	$	1,226

The increase in the carrying amount of acquired intellectual property during the three months endedNov. 30, 2013, is primarily related to the acquisition of The Climate Corporation. Total amortization expense of other intangible assets was $27 million and $28 million for the three months endedNov. 30, 2013, and Nov. 30, 2012, respectively. The estimated intangible asset amortization expense for fiscal year 2014 through fiscal year 2018 is as follows:

(Dollars in millions)	Amount
2014	$	173
2015	171
2016	123
2017	97
2018	87

NOTE 9. INVESTMENTS

As of Nov. 30, 2013, and Aug. 31, 2013, Monsanto has short-term investments outstanding of $249 million and $254 million, respectively. The investments at Nov. 30, 2013, and Aug. 31, 2013, are comprised of commercial paper with original maturities of one year or less. See Note 13 — Fair Value Measurements.

Monsanto has investments in long-term equity securities, which are considered available-for-sale. As of Nov. 30, 2013, and Aug. 31, 2013, these long-term equity securities are recorded in other assets in the Statements of Consolidated Financial Position at a fair value of $43 million and $22 million, respectively. See Note 17 — Accumulated Other Comprehensive Loss.

Monsanto has cost basis investments recorded in other assets in the Statements of Consolidated Financial Position. As of Nov. 30, 2013, and Aug. 31, 2013, these investments were recorded at $68 million and $67 million, respectively. Due to the nature of these investments, the fair market value is not readily determinable. These investments are reviewed for impairment indicators.

No significant impairments were recorded on any investments for each of the three month periods ended Nov. 30, 2013, and Nov. 30, 2012.

NOTE 10. DEFERRED REVENUE

As of Nov. 30, 2013, and Aug. 31, 2013, short-term deferred revenue was $2,866 million and $517 million, respectively. This balance primarily consists of cash received related to Monsanto's prepayment programs in the United States and Brazil. These programs allow Monsanto's customers to receive a discount if they prepay by a certain date, and the short-term deferred revenue balance is consistent with the seasonality of Monsanto's business. Prepayment options are attractive to customers given the discounted pricing and the ability to utilize cash flow from the current year grain harvest to pay for the next season seed

15

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

purchases. The deferred revenue balance related to these prepayment programs is considered short-term in nature and thus classified in current liabilities as the prepayments are for products to be shipped within the next 12 months.

In 2008, Monsanto entered into a corn herbicide tolerance and insect control trait technologies agreement with Pioneer Hi-Bred International, Inc. Among its provisions, the agreement modified certain existing corn license agreements between the parties. Under the agreement, which requires fixed annual payments, the company recorded a receivable and deferred revenue of $635 million in first quarter 2008. Cumulative cash receipts will be $725 million over an eight-year period. Revenue of $20 million was recorded for each of the three months ended Nov. 30, 2013, and Nov. 30, 2012. As of Nov. 30, 2013, and Aug. 31, 2013, the remaining receivable balance is $168 million and $230 million, respectively, of which $85 million is current in both periods and is included in trade receivables, net. The remaining balance is included in long-term receivables, net on the Statements of Consolidated Financial Position. As of Nov. 30, 2013, and Aug. 31, 2013, the remaining deferred revenue balance is $139 million and $159 million, respectively, of which $79 million is included in current deferred revenue in both periods. Interest income recorded on this receivable is $1 million and $2 million for the three months ended Nov. 30, 2013, and Nov. 30, 2012, respectively.    

In 2008, Monsanto and Syngenta entered into a Genuity Roundup Ready 2 Yield Soybean License Agreement, which grants Syngenta access to Monsanto’s Genuity Roundup Ready 2 Yield Soybean technology in consideration of royalty payments from Syngenta, based on sales. The minimum obligation from Syngenta over the nine-year contract period is $81 million. Revenue of $3 million and $4 million related to this agreement was recorded for the three months ended Nov. 30, 2013, and Nov. 30, 2012, respectively. As of Nov. 30, 2013, and Aug. 31, 2013, the remaining receivable balance is $37 million and $58 million, respectively. The majority of this balance is current and is included in trade receivables, net. The remaining balance is included in long-term receivables, net on the Statements of Consolidated Financial Position. As of Nov. 30, 2013, and Aug. 31, 2013, the remaining deferred revenue balance is $31 million and $34 million, respectively, of which $24 million is included in current deferred revenue in both periods.

NOTE 11. INCOME TAXES

Monsanto recorded a tax benefit of $22 million in first quarter 2013 primarily as a result of a capital loss from a deemed liquidation of a subsidiary.

NOTE 12. DEBT AND OTHER CREDIT ARRANGEMENTS

In November 2011, Monsanto filed a new shelf registration with the SEC (2011 shelf registration) that allows the company to issue an unlimited capacity of debt, equity and hybrid offerings. The 2011 shelf registration will expire in November 2014.

In November 2013, Monsanto issued $400 million of Floating Rate Senior Notes which are due on November 7, 2016, (Floating Rate Notes), $300 million of 1.85% Senior Notes which are due on November 15, 2018, (2018 Senior Notes) and $300 million of 4.65% Senior Notes which are due on November 15, 2043, (2043 Senior Notes). All notes were issued under the 2011 shelf registration.

The net proceeds from the sale of the Floating Rate, 2018, and 2043 Senior Notes were used for the acquisition of The Climate Corporation and general corporate purposes.

In July 2012, Monsanto issued $250 million of 2.20% Senior Notes which are due on July 15, 2022, (2022 Senior Notes) and $250 million of 3.60% Senior Notes which are due on July 15, 2042, (2042 Senior Notes). Both were issued under the 2011 shelf registration.

The net proceeds from the sale of the 2022 and 2042 Senior Notes were used for general corporate purposes, including refinancing of the company’s indebtedness.

Monsanto has a $2 billion credit facility agreement with a group of banks that provides a senior unsecured revolving credit facility through April 1, 2016.

As of Nov. 30, 2013, Monsanto had commercial paper borrowings outstanding of $195 million which is included in short-term debt on the Statements of Consolidated Financial Position.

The fair value of the total short-term debt was $262 million and $51 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively. The fair value of the total long-term debt was $3,216 million and $2,231 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively.

16

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

NOTE 13. FAIR VALUE MEASUREMENTS

Monsanto determines the fair market value of its financial assets and liabilities based on quoted market prices, estimates from brokers, and other appropriate valuation techniques. The company uses the fair value hierarchy established in the Fair Value Measurements and Disclosures topic of the ASC, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The hierarchy contains three levels as follows, with Level 3 representing the lowest level of input:

Level 1 — Values based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities.

Level 2 — Values based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, discounted cash flow models, or model-based valuation techniques adjusted, as necessary, for credit risk.

Level 3 — Values generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions would reflect our own estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques could include use of option pricing models, discounted cash flow models and similar techniques.

The following tables set forth by level Monsanto’s assets and liabilities that were accounted for at fair value on a recurring basis as of Nov. 30, 2013, and Aug. 31, 2013. As required by the Fair Value Measurements and Disclosures topic of the ASC, assets and liabilities are classified in their entirety based on the lowest level of input that is a significant component of the fair value measurement. Monsanto’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the classification of fair value assets and liabilities within the fair value hierarchy levels.

	Fair Value Measurements at Nov. 30, 2013, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	3,762	$	—	$	—	$	3,762
Short-term investments	249		—		—		249
Equity securities	43		—		—		43
Derivative assets related to:
Foreign currency contracts	—		18		—		18
Commodity contracts	1		2		—		3
Total Assets at Fair Value	$	4,055	$	20	$	—	$	4,075
Liabilities at Fair Value:
Derivative liabilities related to:
Foreign currency contracts	$	—	$	8	$	—	$	8
Commodity contracts	61		4		—		65
Total Liabilities at Fair Value	$	61	$	12	$	—	$	73
Liabilities Not Recorded at Fair Value:
Short-term debt instruments(1)	$	—	$	262	$	—	$	262
Long-term debt instruments(1)	—		3,216		—		3,216
Total Liabilities Not Recorded at Fair Value	$	—	$	3,478	$	—	$	3,478
Total Liabilities Recorded and Not Recorded at Fair Value	$	61	$	3,490	$	—	$	3,551

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

17

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

	Fair Value Measurements at Aug. 31, 2013, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	2,865	$	—	$	—	$	2,865
Short-term investments	254		—		—		254
Equity securities	22		—		—		22
Derivative assets related to:
Foreign currency contracts	—		5		—		5
Commodity contracts	13		6		—		19
Total Assets at Fair Value	$	3,154	$	11	$	—	$	3,165
Liabilities at Fair Value:
Contingent consideration	$	—	$	—	$	40	$	40
Derivative liabilities related to:
Foreign currency contracts	—		8		—		8
Commodity contracts	73		12		—		85
Total Liabilities at Fair Value:	$	73	$	20	$	40	$	133
Liabilities Not Recorded at Fair Value:
Short-term debt instrument(1)	$	—	$	51	$	—	$	51
Long-term debt instruments(1)	—		2,231		—		2,231
Total Liabilities Not Recorded at Fair Value	$	—	$	2,282	$	—	$	2,282
Total Liabilities Recorded and Not Recorded at Fair Value	$	73	$	2,302	$	40	$	2,415

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

The company’s derivative contracts are measured at fair value, including forward commodity purchase and sale contracts, exchange-traded commodity futures and option contracts, and over the counter (OTC) instruments related primarily to agricultural commodities, energy and raw materials, interest rates, and foreign currencies. Exchange-traded futures and options contracts are valued based on unadjusted quoted prices in active markets and are classified as Level 1. Fair value for forward commodity purchase and sale contracts is estimated based on exchange-quoted prices adjusted for differences in local markets. These differences are generally determined using inputs from broker or dealer quotations or market transactions in either the listed or OTC markets. When observable inputs are available for substantially the full term of the contract, it is classified as Level 2. Based on historical experience with the company’s suppliers and customers, the company’s own credit risk and knowledge of current market conditions, the company does not view nonperformance risk to be a significant input to the fair value for the majority of its forward commodity purchase and sale contracts. The effective portions of changes in the fair value of derivatives designated as cash flow hedges are recognized in the Statements of Consolidated Financial Position as a component of accumulated other comprehensive loss until the hedged items are recorded in earnings or it is probable the hedged transaction will no longer occur. Changes in the fair value of derivatives are recognized in the Statements of Consolidated Operation as a component of net sales, cost of goods sold and other expense, net.

The company’s short-term investments are comprised of commercial paper. The company’s equity securities are comprised of publicly traded equity investments. Commercial paper and publicly traded equity investments are valued using quoted market prices and are classified as Level 1.

The fair value of short-term and long-term debt was determined based on current market yields for our debt traded in the secondary market.

The company’s contingent consideration relates to the Precision Planting acquisition and was settled during the three months endedNov. 30, 2013.

18

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

For the three months endedNov. 30, 2013, and Nov. 30, 2012, the company had no transfers between Level 1, Level 2 and Level 3. Monsanto does not have any assets with fair value determined using Level 3 inputs as of Nov. 30, 2013, and Aug. 31, 2013. The following table summarizes the change in fair value of the Level 3 liability for the three months endedNov. 30, 2013.

(Dollars in millions)	Contingent Consideration
Balance as of Aug. 31, 2013	$	40
Settlement	(40		)
Balance as of Nov. 30, 2013	$	—

There were no significant measurements of assets or liabilities to their implied fair value on a nonrecurring basis during the three months endedNov. 30, 2013, and Nov. 30, 2012.

The recorded amounts of cash, trade receivables, miscellaneous receivables, third-party guarantees, accounts payable, grower production accruals, accrued marketing programs and miscellaneous short-term accruals approximate their fair values as of Nov. 30, 2013, and Aug. 31, 2013.

Management is ultimately responsible for all fair values presented in the company’s consolidated financial statements. The company performs analysis and review of the information and prices received from third parties to ensure that the prices represent a reasonable estimate of fair value. This process involves quantitative and qualitative analysis. As a result of the analysis, if the company determines there is a more appropriate fair value based upon the available market data, the price received from the third party is adjusted accordingly.

NOTE 14. FINANCIAL INSTRUMENTS

Cash Flow Hedges

The company uses foreign currency forward and foreign currency option contracts as hedges of anticipated sales or purchases denominated in foreign currencies. The company enters into these contracts to protect itself against the risk that the eventual net cash flows will be adversely affected by changes in exchange rates.

Monsanto’s commodity price risk management strategy is to use derivative instruments to minimize significant unanticipated earnings fluctuations that may arise from volatility in commodity prices. Price fluctuations in commodities, mainly in corn and soybeans, can cause the actual prices paid to production growers for corn and soybean seeds to differ from anticipated cash outlays. Monsanto uses commodity futures and options contracts to manage these risks. Monsanto’s energy and raw material risk management strategy is to use derivative instruments to minimize significant unanticipated manufacturing cost fluctuations that may arise from volatility in natural gas, diesel and ethylene prices.

Monsanto’s interest rate risk management strategy is to use derivative instruments, such as forward-starting interest rate swaps, to minimize significant unanticipated earnings fluctuations that may arise from volatility in interest rates of the company’s borrowings and to manage the interest rate sensitivity of its debt.

For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

The maximum term over which the company is hedging exposures to the variability of cash flow (for all forecasted transactions) is 21 months for foreign currency hedges and 42 months for commodity hedges. During the next 12 months, a pretax net loss of approximately $34 million is expected to be reclassified from accumulated other comprehensive loss into earnings. During the three months endedNov. 30, 2013, and Nov. 30, 2012, no cash flow hedges were discontinued.

Fair Value Hedges

The company uses commodity futures and options contracts as fair value hedges to manage the value of its soybean inventory. For derivative instruments that are designated and qualify as fair value hedges, both the gain or loss on the derivative and the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings. No fair value hedges were discontinued during the three months endedNov. 30, 2013, and Nov. 30, 2012.

19

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

Derivatives Not Designated as Hedging Instruments

The company uses foreign exchange contracts to hedge the effects of fluctuations in exchange rates on foreign currency denominated third-party and intercompany receivables and payables. Both the gain or loss on the derivative and the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings.

The company uses commodity contracts to hedge anticipated cash payments to growers in the United States, Argentina, Mexico and Brazil, which can fluctuate with changes in commodity price. Because these contracts do not meet the provisions specified by the Derivatives and Hedging topic of the ASC, they do not qualify for hedge accounting treatment. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

To reduce credit exposure in Latin America, Monsanto collects payments on certain customer accounts in grain. Such payments in grain are negotiated at or near the time Monsanto’s products are sold to the customers and are valued at the prevailing grain commodity prices. By entering into forward sales contracts related to grain, Monsanto mitigates the commodity price exposure from the time a contract is signed with a customer until the time a grain merchant collects the grain from the customer on Monsanto’s behalf. The forward sales contracts do not qualify for hedge accounting treatment under the Derivatives and Hedging topic of the ASC. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

Monsanto uses interest rate contracts to minimize the variability of forecasted cash flows arising from the company’s VIE. The interest rate contracts do not qualify for hedge accounting treatment under the Derivatives and Hedging Topic of the ASC. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

Financial instruments are neither held nor issued by the company for trading purposes.

The notional amounts of the company’s derivative instruments outstanding as of Nov. 30, 2013, and Aug. 31, 2013, were as follows:

	As of
(Dollars in millions)	Nov. 30, 2013		Aug. 31, 2013
Derivatives Designated as Hedges:
Foreign exchange contracts	$	315	$	261
Commodity contracts	916		872
Total Derivatives Designated as Hedges	$	1,231	$	1,133
Derivatives Not Designated as Hedges:
Foreign exchange contracts	$	1,667	$	1,188
Commodity contracts	113		217
Interest rate contracts	138		—
Total Derivatives Not Designated as Hedges	$	1,918	$	1,405

20

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

The net presentation of the company’s derivative instruments outstanding were as follows:

			As of Nov. 30, 2013
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Miscellaneous receivables
	Derivatives designated as hedges:
		Foreign exchange contracts	$	3	$	—		$	3		$	—	$	3
	Derivatives not designated as hedges:
		Foreign exchange contracts	15		—			15			—		15
		Commodity contracts	1		—			1			—		1
Total miscellaneous receivables			19		—			19			—		19		$	755	$	774
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	1		(39		)	(38		)	38		—
	Derivatives not designated as hedges:
		Commodity contracts	1		—			1			—		1
Total other current assets			2		(39		)	(37		)	38		1		189		190
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	—		(23		)	(23		)	23		—
Total other assets			—		(23		)	(23		)	23		—		566		566
Total Asset Derivatives			$	21	$	(62	)	$	(41	)	$	61	$	20
Liability Derivatives:
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	$	39	$	(39	)	$	—		$	—	$	—
Total other current assets			39		(39		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	23		(23		)	—			—		—
Total other assets			23		(23		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
		Commodity contracts	2		—			2			—		2
	Derivatives not designated as hedges:
		Foreign exchange contracts	5		—			5			—		5
		Commodity contracts	1		—			1			—		1
Total miscellaneous short-term accruals			11		—			11			—		11		$	932	$	943
Total Liability Derivatives			$	73	$	(62	)	$	11		$	—	$	11

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

21

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

			As of Aug. 31, 2013
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	1	$	(6	)	$	(5	)	$	5	$	—
Total trade receivables, net			1		(6		)	(5		)	5		—		$	1,715	$	1,715
Miscellaneous receivables
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
	Derivatives not designated as hedges:
		Foreign exchange contracts	2		—			2			—		2
		Commodity contracts	4		—			4			—		4
Total miscellaneous receivables			9		—			9			—		9		739		748
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(61		)	(52		)	52		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	5		(4		)	1			—		1
Total other current assets			14		(65		)	(51		)	52		1		165		166
Other assets
	Derivatives designated as hedges
		Commodity contracts(1)	—		(9		)	(9		)	9		—
Total other assets			—		(9		)	(9		)	9		—		496		496
Total Asset Derivatives			$	24	$	(80	)	$	(56	)	$	66	$	10
Liability Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	6	$	(6	)	$	—		$	—	$	—
Total trade receivables, net			6		(6		)	—			—		—
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	61		(61		)	—			—		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	4		(4		)	—			—		—
Total other current assets			65		(65		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(9		)	—			—		—
Total other assets			9		(9		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	1		—			1			—		1
		Commodity contracts	4		—			4			—		4
	Derivatives not designated as hedges:
		Foreign exchange contracts	7		—			7			—		7

22

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

Total miscellaneous short-term accruals			12		—			12		—		12		$	800	$	812
Other liabilities
	Derivatives designated as hedges:
		Commodity contracts	1		—			1		—		1
Total other liabilities			1		—			1		—		1		381		382
Total Liability Derivatives			$	93	$	(80	)	$	13	$	—	$	13

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

The gains and losses on the company’s derivative instruments were as follows:

	Amount of Gain  (Loss) Recognized in AOCI(1) (Effective Portion)						Amount of Gain (Loss) Recognized in Income(2)
	Three Months Ended						Three Months Ended						Statement of Consolidated Operations Classification
(Dollars in millions)	Nov. 30, 2013			Nov. 30, 2012			Nov. 30, 2013			Nov. 30, 2012
Derivatives Designated as Hedges:
Fair value hedges:
Commodity contracts(3)							$	(2	)	$	6		Cost of goods sold
Cash flow hedges:
Foreign currency contracts	$	(2	)	$	(1	)	(2		)	(2		)	Net sales
Foreign currency contracts	(3		)	(4		)	—			3			Cost of goods sold
Commodity contracts(4)	(61		)	(13		)	(3		)	17			Cost of goods sold
Interest rate contracts(5)	(2		)	—			(3		)	(3		)	Interest expense
Total Derivatives Designated as Hedges	(68		)	(18		)	(10		)	21
Derivatives Not Designated as Hedges:
Foreign currency contracts(6)							22			31			Other expense, net
Commodity contracts							2			5			Net sales
Commodity contracts							5			4			Cost of goods sold
Total Derivatives Not Designated as Hedges							29			40
Total Derivatives	$	(68	)	$	(18	)	$	19		$	61

(1) Accumulated other comprehensive income (loss) (AOCI).

(2) For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCI into income during the period.

(3) Loss and gain on fair value hedges includes a loss of $1 million and a loss of less than $1 million from ineffectiveness during the three months endedNov. 30, 2013, and Nov. 30, 2012, respectively.

(4) Loss and gain on commodity cash flow hedges includes a loss of $1 million and a loss of less than $1 million from ineffectiveness for the three months endedNov. 30, 2013, and Nov. 30, 2012, respectively. No gains or losses were excluded from the assessment of hedge effectiveness during the three months endedNov. 30, 2013, and Nov. 30, 2012.

(5) Loss on interest rate cash flow hedges includes a loss of less than $1 million from ineffectiveness for the three months endedNov. 30, 2013.

(6) Gain on foreign currency contracts not designated as hedges is offset by a foreign currency transaction loss of $41 million and $48 million during the three months endedNov. 30, 2013, and Nov. 30, 2012, respectively.

Several of the company’s outstanding foreign currency derivatives are covered by International Swap Dealers’ Association (ISDA) Master Agreements with the counterparties. There are no requirements to post collateral under these agreements; however, should Monsanto’s credit rating fall below a specified rating immediately following the merger of the company with another entity, the counterparty may require all outstanding derivatives under the ISDA Master Agreement to be settled immediately at current market value, which equals carrying value. Foreign currency derivatives that are not covered by

23

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

ISDA Master Agreements do not have credit-risk-related contingent provisions. Most of Monsanto’s outstanding commodity derivatives are listed commodity futures, and the company is required by the relevant commodity exchange to post collateral each day to cover the change in the fair value of these futures in the case of an unrealized loss position. Non-exchange-traded commodity derivatives may be covered by the aforementioned ISDA Master Agreements and would be subject to the same credit-risk-related contingent provisions. The aggregate fair value of all derivative instruments under ISDA Master Agreements that are in a liability position was $4 million and $7 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively, which is the amount that would be required for settlement if the credit-risk-related contingent provisions underlying these agreements were triggered.

Credit Risk Management

Monsanto invests its excess cash in deposits with major banks or money market funds throughout the world in high-quality short-term debt instruments. Such investments are made only in instruments issued or enhanced by high-quality institutions. As of Nov. 30, 2013, and Aug. 31, 2013, the company had no financial instruments that represented a significant concentration of credit risk. Limited amounts are invested in any single institution to minimize risk. The company has not incurred any credit risk losses related to those investments.

The company sells a broad range of agricultural products to a diverse group of customers throughout the world. In the United States, the company makes substantial sales to relatively few large wholesale customers. The company’s business is highly seasonal, and it is subject to weather conditions that affect commodity prices and seed yields. Credit limits, ongoing credit evaluation and account monitoring procedures are used to minimize the risk of loss. Collateral is secured when it is deemed appropriate by the company.

Monsanto regularly evaluates its business practices to minimize its credit risk and periodically engages multiple banks in the United States, Argentina, Brazil and Europe in the development of customer financing options that involve direct bank financing of customer purchases. For further information on these programs, see Note 4 — Customer Financing Programs.

NOTE 15. POSTRETIREMENT BENEFITS — PENSIONS, HEALTH CARE AND OTHER

Most of Monsanto’s U.S. employees hired prior to July 8, 2012, are covered by noncontributory pension plans sponsored by the company. Effective July 8, 2012, the U.S. pension plan was closed to new entrants; there were no changes to the U.S. pension plan for eligible employees hired prior to that date. The company also provides certain postretirement health care and life insurance benefits for retired employees through insurance contracts. The company’s net periodic benefit cost for pension benefits and health care and other postretirement benefits include the following components:

	Three Months Ended Nov. 30, 2013									Three Months Ended Nov. 30, 2012
Pension Benefits (Dollars in millions)	U.S.			Outside the U.S.			Total			U.S.			Outside the U.S.			Total
Service Cost for Benefits Earned During the Period	$	15		$	3		$	18		$	20		$	3		$	23
Interest Cost on Benefit Obligation	23			2			25			22			2			24
Assumed Return on Plan Assets	(35		)	(2		)	(37		)	(40		)	(2		)	(42		)
Amortization of Unrecognized Net Loss	16			1			17			21			1			22
Curtailment and Settlement Charge	—			1			1			—			1			1
Total Net Periodic Benefit Cost	$	19		$	5		$	24		$	23		$	5		$	28

Health Care and Other Postretirement Benefits	Three Months Ended
(Dollars in millions)	Nov. 30, 2013			Nov. 30, 2012
Service Cost for Benefits Earned During the Period	$	3		$	5
Interest Cost on Benefit Obligation	3			3
Amortization of Unrecognized Net Gain	(4		)	(3		)
Total Net Periodic Benefit Cost	$	2		$	5

24

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

Monsanto contributed $15 million to its U.S. qualified plan in the three month period ended Nov. 30, 2013, and $11 million in the three month period ended Nov. 30, 2012. Monsanto contributed $5 million to plans outside the United States in the three month period ended Nov. 30, 2013, and $3 million in the three month period ended Nov. 30, 2012. As of Nov. 30, 2013, management expects to make additional contributions of approximately $45 million and $10 million to the company’s pension plans in the United States and outside the United States, respectively, during the remainder of fiscal year 2014.

NOTE 16. STOCK-BASED COMPENSATION PLANS

The following table shows total stock-based compensation expense included in the Statements of Consolidated Operations for the three months ended Nov. 30,2013, and Nov. 30, 2012. Stock-based compensation cost capitalized in inventory was $3 million and $3 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively.

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013			Nov. 30, 2012
Cost of Goods Sold	$	2		$	4
Selling, General and Administrative Expenses	20			15
Research and Development Expenses	5			5
Pre-Tax Stock-Based Compensation Expense	27			24
Income Tax Benefit	(9		)	(8		)
Net Stock-Based Compensation Expense	$	18		$	16

The following table summarizes stock-based compensation activity for and as of the three months endedNov. 30, 2013, for employees under the Monsanto Company 2005 Long-Term Incentive Plan, as amended and restated effective Jan. 24, 2012; for employees under the Climate Corporation 2006 Stock Plan, as amended on Oct. 30, 2013, collectively defined as Monsanto Stock Plans; and for directors under the Monsanto Non-Employee Director Equity Incentive Compensation Plan (Director Plan):

	Monsanto Stock Plans				Director Plan
	Stock Options		Restricted Stock Units		Deferred Stock		Restricted Stock
Granted	2,264,046		826,959		18,520		2,554
Weighted-average grant date fair value per share	$	38.44	$	101.08	$	97.89	$	97.89
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable in millions	$	105.1	$	120.9	$	1.4	$	0.2
Remaining weighted-average period of expense recognition/requisite service periods in years	3		3		1		1

25

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

NOTE 17. ACCUMULATED OTHER COMPREHENSIVE LOSS

The following table sets forth the after-tax components of accumulated other comprehensive loss and changes thereto recorded during the three months ended Nov. 30, 2013:

(Dollars in millions)	Foreign Currency Translation Adjustments			Net Unrealized Gain on Available for Sale Securities		Cash Flow Hedges			Postretirement Benefit Items			Total Accumulated Other Comprehensive Loss
Balance as of Aug. 31, 2013	$	(831	)	$	8	$	(115	)	$	(340	)	$	(1,278	)
Other comprehensive income (loss) before reclassifications	127			5		(43		)	—			89
Amounts reclassified from accumulated other comprehensive loss	—			—		5			8			13
Net current-period other comprehensive income (loss)	127			5		(38		)	8			102
Balance as of Nov. 30, 2013	$	(704	)	$	13	$	(153	)	$	(332	)	$	(1,176	)

The following table provides additional information regarding items reclassified out of accumulated other comprehensive loss into earnings during the three months ended Nov. 30, 2013:

Details about Accumulated Other Comprehensive Loss components	Amount Reclassified from Accumulated Other Comprehensive Loss			Affected Line Item in the Statement of Consolidated Operations
Cash Flow Hedges:
Foreign Exchange Contracts Net Loss	$	2		Net sales
Commodity Contracts Net Loss	3			Cost of goods sold
Interest Rate Contracts Net Loss	3			Interest expense
	8			Total before income taxes
	(3		)	Income tax provision
	$	5		Net of tax
Postretirement Benefit Items:
Amortization of Unrecognized Net Loss	$	3		Inventory / Cost of goods sold(1)
Amortization of Unrecognized Net Loss	10			Selling and administrative expenses
	13			Total before income taxes
	(5		)	Income tax provision
	$	8		Net of tax
Total Reclassifications For The Period	$	13		Net of tax

(1) The amortization of unrecognized net loss is recorded to net periodic benefit cost, which is allocated to selling, general and administrative expenses and to inventory, which is recognized through cost of goods sold. The company recorded $3 million of net periodic benefit cost to inventory, of which approximately $1 million was recognized in cost of goods sold during the three months ended Nov. 30, 2013. See Note 15 - Postretirement Benefits - Pensions, Health Care and Other - for additional information.

NOTE 18. EARNINGS PER SHARE

Basic earnings per share (EPS) was computed using the weighted-average number of common shares outstanding during the periods shown in the table below. The diluted EPS computation takes into account the effect of dilutive potential common shares, as shown in the table below. Potential common shares consist primarily of stock options, restricted stock, restricted stock units and directors’ deferred shares calculated using the treasury stock method and are excluded if their effect is antidilutive. Of those antidilutive options, certain options were excluded from the computations of dilutive potential common shares as their exercise prices were greater than the average market price of the common shares for the period.

26

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

	Three Months Ended
(Shares in millions)	Nov. 30, 2013	Nov. 30, 2012
Weighted-Average Number of Common Shares	526.9	534.8
Dilutive Potential Common Shares	5.7	5.6
Antidilutive Potential Common Shares	1.8	4.2
Shares Excluded From Computation of Dilutive Potential Shares with Exercise Prices greater than the Average Market Price of Common Shares for the Period	0.1	4.1

NOTE 19.SUPPLEMENTAL CASH FLOW INFORMATION

Cash payments for interest and taxes were as follows:

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
Interest	$	42	$	49
Taxes	102		147

NOTE 20. COMMITMENTS AND CONTINGENCIES

Environmental and Litigation Liabilities: Monsanto is involved in environmental remediation and legal proceedings to which we are party in our own name and proceedings to which our former parent Pharmacia LLC or its former subsidiary Solutia, Inc. is a party but that we manage and for which we are responsible. In addition, Monsanto has liabilities established for various product claims. With respect to certain of these proceedings, Monsanto has a liability recorded of $270 million and $271 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively, for the estimated contingent liabilities. Information regarding the environmental liabilities appears in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

Litigation: The above liability includes amounts related to certain third-party litigation with respect to Monsanto’s business, as well as tort litigation related to Pharmacia’s former chemical business, including lawsuits involving polychlorinated biphenyls (PCBs), dioxins, and other chemical and premises liability litigation. Additional matters that are not reflected in the liability may arise in the future, and Monsanto may manage, settle, or pay judgments or damages with respect thereto in order to mitigate contesting potential liability. Following is a description of one of the more significant litigation matters reflected in the liability.

• As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2013, on Dec. 17, 2004, 15 plaintiffs filed a purported class action lawsuit, styled Virdie Allen, et al. v. Monsanto, et al., in the Putnam County, West Virginia, state court against Monsanto, Pharmacia and seven other defendants. Monsanto is named as the successor in interest to the liabilities of Pharmacia. The alleged class consists of all current and former residents, workers, and students who, between 1949 and the present, were allegedly exposed to dioxins/furans contamination in counties surrounding Nitro, West Virginia. The complaint alleges that the source of the contamination is a chemical plant in Nitro, formerly owned and operated by Pharmacia and later by Flexsys, a joint venture between Solutia and Akzo Nobel Chemicals, Inc. (Akzo Nobel). Akzo Nobel and Flexsys were named defendants in the case but Solutia was not, due to its then pending bankruptcy proceeding. The suit seeks damages for property cleanup costs, loss of real estate value, funds to test property for contamination levels, funds to test for human exposure, and future medical monitoring costs. The complaint also seeks an injunction against further contamination and punitive damages. Monsanto has agreed to indemnify and defend Akzo Nobel and the Flexsys defendant group, but on May 27, 2011, the judge dismissed both Akzo Nobel and Flexsys from the case. The class action certification hearing was held on Oct. 29, 2007. On Jan. 8, 2008, the trial court issued an order certifying the Allen (now Zina G. Bibb et al. v. Monsanto et al., because Bibb replaced Allen as class representative) case as a class action for property damage and for medical monitoring. On Nov. 2, 2011, the court, in response to defense motions, entered an order decertifying the property class. After the trial for the Bibb medical monitoring class action began on Jan. 3, 2012, the parties reached a settlement in principle as to both the medical monitoring and the property class claims. The proposed settlement provides for a 30 year medical monitoring program consisting of a primary fund of up to $21 million and an additional fund of up to $63 million over the life of the program, and a three year property remediation plan with funding up to $9 million. On Feb. 24, 2012, the court preliminarily approved the parties’ proposed settlement. A fairness hearing was held June 18, 2012, resulting in the trial court's final approval of the settlement. Certain plaintiffs objected to the approval of the settlement and appealed to the West Virginia Supreme Court of Appeals. On Nov. 22, 2013, the West Virginia Supreme Court of Appeals dismissed the appeal and upheld the fairness of the class action settlements. On Dec. 20, 2013, the objector moved for a stay, pending his petition for writ of certiorari with the U.S. Supreme Court.

27

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

In October 2007 and November 2009, a total of approximately 200 separate, single plaintiff civil actions were filed in Putnam County, West Virginia, against Monsanto, Pharmacia, Akzo Nobel (and several of its affiliates), Flexsys America Co. (and several of its affiliates), Solutia, and Apogee Coal Company, LLC. These cases allege personal injury occasioned by exposure to dioxin generated by the Nitro Plant during production of 2,4,5T (1949-1969) and thereafter. Monsanto has agreed to accept the tenders of defense in the matters by Pharmacia, Solutia, Akzo Nobel, Flexsys America, and Apogee Coal under a reservation of rights. During the discovery phase of these several claims, the parties reached an agreement in principle to resolve all pending personal injury claims which is reflected in the above liability.

Including litigation reflected in the liability, Monsanto is involved in various legal proceedings that arise in the ordinary course of its business or pursuant to Monsanto’s indemnification obligations to Pharmacia, as well as proceedings that management has considered to be material under SEC regulations. Some of the lawsuits seek damages in very large amounts, or seek to restrict the company’s business activities. Monsanto believes that it has meritorious legal arguments and will continue to represent its interests vigorously in all of the proceedings that it is defending or prosecuting. Management does not anticipate the ultimate liabilities resulting from such proceedings, or the proceedings reflected in the above liability, will have a material adverse effect on Monsanto’s consolidated results of operations, financial position, cash flows or liquidity.

Legal actions have been filed in Brazil that raise issues challenging the right to collect certain royalties for Roundup Ready soybeans. Although Brazilian law clearly states that the pipeline patents protecting these products have the duration of the corresponding U.S. patent (2014 for Roundup Ready soybeans), the duration (and application) of these pipeline patents is currently under judicial review in Brazil. Monsanto believes it has meritorious legal arguments and will continue to represent its interests vigorously in these proceedings. The current estimate of the company’s reasonably possible loss contingency is not material to consolidated results of operations, financial position, cash flows or liquidity.

Other Contingencies: The staff of the SEC is conducting an investigation of financial reporting associated with our customer incentive programs for glyphosate products for the fiscal years 2009 and 2010, and we have received subpoenas in connection therewith.  It is not reasonably possible to assess the outcome of the investigation at this time, but potential outcomes could include the filing of an enforcement proceeding and the imposition of civil penalties as well as non-monetary remedies, which may require the Company to incur future costs. We continue cooperating with the investigation.

Guarantees: Disclosures regarding the guarantees Monsanto provides for certain customer loans in the United States, Brazil, Europe, and Argentina can be found in Note 4 — Customer Financing Programs — of this Form 10-Q. Except as described in that note, there have been no significant changes to guarantees made by Monsanto since Aug. 31, 2013. Disclosures regarding these guarantees made by Monsanto can be found in Note 26 — Commitments and Contingencies — of the notes to the consolidated financial statements contained in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

NOTE 21. SEGMENT INFORMATION

Monsanto conducts its worldwide operations through global businesses, which are aggregated into reportable segments based on similarity of products, production processes, customers, distribution methods and economic characteristics. The operating segments are aggregated into two reportable segments: Seeds and Genomics and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and related traits businesses, biotechnology platforms and precision agriculture. Within the Seeds and Genomics segment, Monsanto’s significant operating segments are corn seed and traits, soybean seed and traits, cotton seed and traits, vegetable seeds and all other crops seeds and traits. The Agricultural Productivity reportable segment consists of the Agricultural Productivity operating segment. EBIT is defined as earnings before interest and taxes and is an operating performance measure for the two reportable segments. EBIT is useful to management in demonstrating the operational profitability of the segments by excluding interest and taxes, which are generally accounted for across the entire company on a consolidated basis. Sales between segments were not significant. Certain SG&A expenses are allocated between segments based on the segment’s relative contribution to total Monsanto operations. Allocation percentages remain relatively consistent for fiscal years 2013 and 2014.

28

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

Data for the Seeds and Genomics and Agricultural Productivity reportable segments, as well as for Monsanto’s significant operating segments, is presented in the table that follows:

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
Net Sales(1)
Corn seed and traits	$	1,054	$	1,139
Soybean seed and traits	267		231
Cotton seed and traits	137		185
Vegetable seeds	157		156
All other crops seeds and traits	61		44
Total Seeds and Genomics	$	1,676	$	1,755
Agricultural productivity	1,467		1,184
Total Agricultural Productivity	$	1,467	$	1,184
Total	$	3,143	$	2,939

Gross Profit
Corn seed and traits	$	650	$	686
Soybean seed and traits	168		118
Cotton seed and traits	92		127
Vegetable seeds	68		83
All other crops seeds and traits	27		11
Total Seeds and Genomics	$	1,005	$	1,025
Agricultural productivity	558		372
Total Agricultural Productivity	$	558	$	372
Total	$	1,563	$	1,397

EBIT(2)(3)
Seeds and Genomics	$	104	$	220
Agricultural Productivity	450		270
Total	$	554	$	490

Depreciation and Amortization Expense
Seeds and Genomics	$	131	$	123
Agricultural Productivity	31		29
Total	$	162	$	152

(1) Represents net sales from continuing operations.

(2) EBIT is defined as earnings before interest and taxes; see the following table for reconciliation. Earnings is intended to mean net income as presented in the Statements of Consolidated Operations under generally accepted accounting principles. EBIT is an operating performance measure for the two reportable segments.

(3) Agricultural Productivity EBIT includes income from operations of discontinued businesses of $14 million and $11 million for the three months ended Nov. 30, 2013, and Nov. 30, 2012, respectively.

29

MONSANTO COMPANY	FIRST QUARTER 2014 FORM 10-Q
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS – UNAUDITED (continued)

A reconciliation of EBIT to net income for each period follows:

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
EBIT(1)	$	554	$	490
Interest Expense — Net	29		28
Income Tax Provision(2)	157		123
Net Income Attributable to Monsanto Company	$	368	$	339

(1) Includes the income from operations of discontinued businesses and pre-tax noncontrolling interests.

(2) Includes the income tax benefit on noncontrolling interest and the income tax provision on discontinued operations.

NOTE 22. SUBSEQUENT EVENTS

On Dec. 9, 2013, the board of directors declared a quarterly dividend on its common shares of 43 cents per share. The dividend is payable on Jan. 31, 2014, to shareholders of record on Jan. 10, 2014.

Other subsequent events are described in Note 5 — Variable Interest Entities.

In December 2013, Monsanto executed the first of a series of incentive agreements with the County of St. Louis, Missouri. Under these agreements the company has transferred the Chesterfield, Missouri facility to St. Louis County and received Industrial Revenue Bonds in the amount of up to $470 million which enables the company to reduce the cost of constructing and operating the expansion by reducing certain state and local tax expenditures. Monsanto will then lease the facility from the County of St. Louis. The payments due to the company in relation to the Industrial Revenue Bonds and owed by the company in relation to the lease of the facilities qualify for the right of offset under the Balance Sheet topic of the ASC, on the Statements of Consolidated Financial Position, and as a result Monsanto will treat the Chesterfield facilities and the expansion as being owned by Monsanto and not include the Industrial Revenue Bonds on the Statements of Consolidated Financial Position as an asset.

30

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

Background

Monsanto Company, along with its subsidiaries, is a leading global provider of agricultural products for farmers. Our seeds, biotechnology trait products and herbicides provide farmers with solutions that help improve productivity, reduce the costs of farming and produce better foods for consumers and better feed for animals.

We manage our business in two segments: Seeds and Genomics and Agricultural Productivity. Through our Seeds and Genomics segment, we produce leading seed brands, including DEKALB, Asgrow, Deltapine, Seminis and De Ruiter, and we develop biotechnology traits that assist farmers in controlling insects and weeds and precision agriculture to assist farmers in decision making. We also provide other seed companies with genetic material and biotechnology traits for their seed brands. Through our Agricultural Productivity segment, we manufacture Roundup and Harness brand herbicides and other herbicides.

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) should be read in conjunction with Monsanto’s consolidated financial statements and the accompanying notes. This Report on Form 10-Q should also be read in conjunction with Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013. Financial information for the first three months of fiscal year 2014 should not be annualized because of the seasonality of our business. The notes to the consolidated financial statements referred to throughout this MD&A are included in Part I — Item 1 — Financial Statements — of this Report on Form 10-Q. Unless otherwise indicated, “Monsanto,” the “company,” “we,” “our” and “us” are used interchangeably to refer to Monsanto Company or to Monsanto Company and its consolidated subsidiaries, as appropriate to the context. Unless otherwise indicated, “earnings per share” and “per share” mean diluted earnings per share. Unless otherwise noted, all amounts and analyses are based on continuing operations. Unless otherwise indicated, references to “Roundup herbicides” mean Roundup branded herbicides, excluding all lawn-and-garden herbicides, and references to “Roundup and other glyphosate-based herbicides” exclude all lawn-and-garden herbicides.

Non-GAAP Financial Measures

MD&A includes financial information prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP), as well as two other financial measures, EBIT and free cash flow, that are considered “non-GAAP financial measures.” Generally, a non-GAAP financial measure is a numerical measure of a company’s financial performance, financial position or cash flows that exclude (or include) amounts that are included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of EBIT and free cash flow information is intended to supplement investors’ understanding of our operating performance and liquidity. Our EBIT and free cash flow measures may not be comparable to other companies’ EBIT and free cash flow measures. Furthermore, these measures are not intended to replace net income (loss), cash flows, financial position, or comprehensive income (loss), as determined in accordance with GAAP.

EBIT is defined as earnings (loss) before interest and taxes. Earnings (loss) is intended to mean net income (loss) attributable to Monsanto as presented in the Statements of Consolidated Operations under GAAP. EBIT is an operating performance measure for our two business segments. We believe that EBIT is useful to investors and management to demonstrate the operational profitability of our segments by excluding interest and taxes, which are generally accounted for across the entire company on a consolidated basis. EBIT is also one of the measures used by Monsanto management to determine resource allocations within the company. See Note 21— Segment Information — for a reconciliation of EBIT to net income for the three months ended Nov. 30, 2013, and Nov. 30, 2012.

We also provide information regarding free cash flow, an important liquidity measure for Monsanto. We define free cash flow as the total of net cash provided or required by operating activities and net cash provided or required by investing activities. Free cash flow does not represent the residual cash flow available for discretionary expenditures. We believe that free cash flow is useful to investors and management as a measure of the ability of our business to generate cash. Once business needs and obligations are met, this cash can be used to reinvest in the company for future growth or to return to our shareowners through dividend payments or share repurchases. Free cash flow is also used by management as one of the performance measures in determining incentive compensation. See the “Financial Condition, Liquidity and Capital Resources - Cash Flow” section of MD&A for a reconciliation of free cash flow to net cash provided by operating activities and net cash required by investing activities on the Statements of Consolidated Cash Flows.

31

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

Executive Summary

Consolidated Operating Results — Net sales increased $204 million, or 7 percent, in the three-month comparison. The primary contributor to the increase in first quarter 2014 is increased pricing as a result of product mix for Roundup and other glyphosate-based herbicides, offset by a decrease in corn seed and traits volumes. Net income attributable to Monsanto Company in the first quarter 2014 was $0.69 per share, compared with $0.63 per share in the first quarter of 2013.

Financial Condition, Liquidity and Capital Resources — In first quarter 2014, working capital was $5,798 million compared with $5,899 million in the first quarter of 2013, a decrease of $101 million, and compared with $5,741 million at Aug. 31, 2013, a increase of $57 million. For a detailed discussion of the factors affecting the working capital comparison, see the "Working Capital and Financial Condition" section of the "Financial Condition, Liquidity and Capital Resources" section in this MD&A.

In the first quarter 2014, net cash provided by operating activities was $1,698 million compared with $1,569 million in first quarter of 2013. Net cash required by investing activities was $1,241 million in the first quarter of 2014 compared with $96 million in the first quarter of 2013. Free cash flow was $457 million in the first quarter of 2014 compared with $1,473 million in the first quarter of 2013. For a detailed discussion of the factors affecting the free cash flow comparison, see the "Cash Flow" section of the "Financial Condition, Liquidity and Capital Resources" section in this MD&A.

In first quarter 2014, our debt-to-capital ratio was 21 percent compared with 14 percent at Aug. 31, 2013, an increase of 7 percentage points, and compared with 15 percent in first quarter 2013, an increase of 6 percentage points. The increases were primarily driven by the $1 billion debt issuance that occurred in November 2013. The proceeds were used primarily to fund the acquisition of The Climate Corporation and for general corporate purposes.

In November 2013, we purchased The Climate Corporation and hold 100 percent of the outstanding stock following the acquisition. The total fair value of the acquisition was $932 million and the total cash paid for the acquisition was $917 million (net of cash acquired). For a detailed discussion see the "Capital Resources and Liquidity" section of the "Financial Condition, Liquidity and Capital Resources" section in this MD&A.

In December 2013, we signed a definitive agreement with Novozymes to launch a BioAg alliance between Novozymes and Monsanto. Monsanto will pay Novozymes an aggregate upfront cash payment of $300 million for recognition of Novozymes ongoing business and capabilities in microbials and for Novozymes' ability to supply the alliance products. For a detailed discussion see the "Capital Resources and Liquidity" section of the "Financial Condition, Liquidity and Capital Resources" section in this MD&A.

Outlook — We plan to continue to innovate and improve our products in order to maintain market leadership and to support near-term performance. We are focused on applying innovation and technology to make our farmer customers more productive and profitable by protecting and improving yields and improving the ways they can produce food, fiber, feed and fuel. We use the tools of modern biology and technology in an effort to make seeds easier to grow, to allow farmers to do more with fewer resources, and to help produce healthier foods for consumers. Our current R&D strategy and commercial priorities are focused on bringing our farmer customers second- and third-generation traits, on delivering multiple solutions in one seed (“stacking”), and on developing new pipeline products. Our capabilities in biotechnology and breeding research are generating a rich product pipeline that is expected to drive long-term growth. The viability of our product pipeline depends in part on the speed of regulatory approvals globally, continued patent and legal rights to offer our products, general public acceptance of the products and the value they will deliver to the market.

Roundup herbicides remain the largest crop protection brand globally. We have oriented the focus of Monsanto’s crop protection business to strategically support Monsanto’s Roundup Ready crops through our weed management platform that delivers weed control offerings for farmers. We are focused on managing the costs associated with our agricultural chemistry business as that sector matures globally.

See the “Outlook” section of MD&A for a more detailed discussion of some of the opportunities and risks we have identified for our business. For additional information related to the outlook for Monsanto, see “Caution Regarding Forward-Looking Statements” at the beginning of this Report on Form 10-Q, Part II — Item 1A — Risk Factors below and Part I — Item 1A of our Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

New Accounting Pronouncements — See Note 2 — New Accounting Standards — for a description of recently issued and adopted accounting pronouncements, including the dates of adoption and impacts on our results of operations, financial position and cash flows, as applicable.

32

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

RESULTS OF OPERATIONS

	Three Months Ended
(Dollars in millions, except per share amounts)	Nov. 30, 2013			Nov. 30, 2012			Change
Net Sales	$	3,143		$	2,939		7	%
Cost of goods sold	1,580			1,542			2	%
Gross Profit	1,563			1,397			12	%
Operating Expenses:
Selling, general and administrative expenses	589			542			9	%
Research and development expenses	409			346			18	%
Total Operating Expenses	998			888			12	%
Income from Operations	565			509			11	%
Interest expense	53			51			4	%
Interest income	(24		)	(23		)	4	%
Other expense, net	20			17			18	%
Income from Continuing Operations Before Income Taxes	516			464			11	%
Income tax provision	152			122			25	%
Income from Continuing Operations Including Portion Attributable to Noncontrolling Interest	364			342			6	%
Discontinued Operations:
Income from operations of discontinued businesses	14			11			NM
Income tax provision	5			4			NM
Income from Discontinued Operations	9			7			NM
Net Income	$	373		$	349		7	%
Less: Net income attributable to noncontrolling interest	5			10			NM
Net Income Attributable to Monsanto Company	$	368		$	339		9	%
Diluted Earnings per Share Attributable to Monsanto Company:
Income from continuing operations	$	0.67		$	0.62		8	%
Income from discontinued operations	0.02			0.01			NM
Net Income Attributable to Monsanto Company	$	0.69		$	0.63		10	%
NM = Not Meaningful
Effective Tax Rate	29		%	26		%
Comparison as a Percent of Net Sales:
Cost of Goods Sold	50		%	52		%
Gross Profit	50		%	48		%
Selling, general and administrative expenses	19		%	18		%
Research and development expenses	13		%	12		%
Total operating expenses	32		%	30		%
Income from continuing operations before income taxes	16		%	16		%
Net income attributable to Monsanto Company	12		%	12		%

33

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

First Quarter Fiscal Year 2014

The following explanations discuss the significant components of our results of operations that affected the quarter-to-quarter comparison of our first quarter income from continuing operations:

Net sales increased $204 million in first quarter2014 from the same quarter a year ago. Our Seeds and Genomics segment net sales decreased 5 percent, and our Agricultural Productivity segment net sales increased 24 percent. The following table presents the percentage changes in first quarter2014 worldwide net sales by segment compared with net sales in the prior-year quarter, including the effect volume, price and currency had on these percentage changes:

	First Quarter 2014 Percentage Change in Net Sales vs. First Quarter 2013
	Volume	Price	Currency	Total
Seeds and Genomics Segment	(11)%	10%	(4)%	(5)%
Agricultural Productivity Segment	8%	21%	(5)%	24%
Total Monsanto Company	(4)%	15%	(4)%	7%

Cost of goods sold for the total company increased $38 million in the three-month comparison. Cost of goods sold as a percent of net sales for the total company decreased 2 percentage points to 50 percent. The following table represents the percentage changes in first quarter2014 worldwide cost of goods sold by segment compared with cost of goods sold in the prior-year quarter, including the effect volume, costs and currency had on these percentage changes:

	First Quarter 2014 Percentage Change in Cost of Goods Sold vs. First Quarter 2013
	Volume	Costs	Currency	Total
Seeds and Genomics Segment	(8)%	2%	(2)%	(8)%
Agricultural Productivity Segment	8%	7%	(3)%	12%
Total Monsanto Company	—%	5%	(3)%	2%

Gross profit increased $166 million in the three-month comparison. Gross profit as a percent of net sales for the total company increased 2 percentage points to 50 percent in the first quarter2014.

For a detailed discussion of the factors affecting net sales, cost of goods sold and gross profit comparison, see the “Seeds and Genomics Segment” and the “Agricultural Productivity Segment” sections.

Operating expenses increased $110 million in first quarter2014 compared to the prior-year comparable quarter. In the first quarter 2014, selling, general and administrative (SG&A) increased $47 million primarily due to The Climate Corporation acquisition and increased activity related to additional growth platforms. In the first quarter 2014, R&D increased $63 million primarily because of The Climate Corporation acquisition, breeding expansion and increased investment in our product pipeline. As a percent of net sales, SG&A expenses increased 1 percentage point to 19 percent, and R&D expenses increased 1 percentage point to 13 percent.

Income tax provision was $152 million in first quarter 2014, an increase of $30 million from the prior-year quarter as a result of the increase in pretax income and an increase in the effective tax rate to 29 percent from 26 percent in first quarter 2013. Monsanto recorded a discrete tax benefit of $7 million during first quarter 2014, primarily as a result of deferred tax adjustments. Monsanto recorded a discrete tax benefit of $22 million during first quarter 2013, primarily as a result of a capital loss from a deemed liquidation of a subsidiary. Without the impact of discrete tax adjustments, our effective tax rate for first quarter 2014 would have been comparable to the first quarter 2013 rate.

34

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

SEEDS AND GENOMICS SEGMENT

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012		Change
Net Sales
Corn seed and traits	$	1,054	$	1,139	(7	)%
Soybean seed and traits	267		231		16	%
Cotton seed and traits	137		185		(26	)%
Vegetable seeds	157		156		1	%
All other crops seeds and traits	61		44		39	%
Total Net Sales	$	1,676	$	1,755	(5	)%
Gross Profit
Corn seed and traits	$	650	$	686	(5	)%
Soybean seed and traits	168		118		42	%
Cotton seed and traits	92		127		(28	)%
Vegetable seeds	68		83		(18	)%
All other crops seeds and traits	27		11		145	%
Total Gross Profit	$	1,005	$	1,025	(2	)%
EBIT(1)	$	104	$	220	(53	)%

(1) EBIT is defined as earnings before interest and taxes. Interest and taxes are recorded on a total company basis. We do not record these items at the segment level. See Note 21 — Segment Information and the “Overview — Non-GAAP Financial Measures” section of MD&A for further details.

Seeds and Genomics Financial Performance — First Quarter Fiscal Year 2014

The net sales decrease of $85 million in corn seed and traits was primarily driven by lower volumes in Brazil and Argentina, partially offset by increased pricing in the United States. The decrease in volume in Brazil was primarily related to lower planted area. The decrease in volume in Argentina was due to shipments earlier in the season to meet customer demand and lower planted area partially offset by share growth. The increase in pricing in the United States was primarily driven by improved germplasm and trait mix.

The net sales increase of $36 million in soybean seed and traits was driven by the launch of Intacta RR2 PRO in Brazil as well as increased pricing in the United States from improved germplasm and trait mix.

The net sales decrease of $48 million in cotton seed and traits was driven by unfavorable foreign currency changes and lower planted area in Australia due to decreased cotton commodity prices.

Cost of goods sold in the Seeds and Genomics segment primarily represents field growing, plant processing and distribution costs. Cost of goods sold decreased $59 million, or 8 percent, to $671 million in the first quarter of 2014 compared to $730 million in the first quarter of 2013. The decrease was primarily the result of lower sales volume as noted in the net sales discussion.

Gross profit as a percent of sales for this segment increased 2 percent to 60 percent in the quarter-over-quarter comparison. Gross profit decreased $20 million in the first quarter of fiscal year 2014.

Gross profit for corn seeds and traits decreased 5 percent compared to the 7 percent decrease in net sales primarily due to product mix and cost of goods improvements in the United States.

Gross profit for soybean seed and traits increased 42 percent compared to the 16 percent increase in net sales primarily due to the increase in Intacta RR2 PRO trait revenue.

Gross profit for cotton seeds and traits decreased 28 percent compared to the 26 percent decrease in net sales primarily due to the lower Australia trait revenue as noted in the net sales discussion.

Gross profit for vegetable seeds decreased 18 percent compared to relatively flat net sales due to increased inventory obsolescence.

35

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

AGRICULTURAL PRODUCTIVITY SEGMENT

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012		Change
Net Sales
Agricultural productivity	$	1,467	$	1,184	24	%
Total Net Sales	$	1,467	$	1,184	24	%
Gross Profit
Agricultural productivity	$	558	$	372	50	%
Total Gross Profit	$	558	$	372	50	%
EBIT(1)	$	450	$	270	67	%

(1) EBIT is defined as earnings before interest and taxes. Interest and taxes are recorded on a total company basis. We do not record these items at the segment level. See Note 21 — Segment Information — and the “Overview — Non-GAAP Financial Measures” section of MD&A for further details.

Agricultural Productivity Financial Performance — First Quarter Fiscal Year 2014

Net sales in our Agricultural Productivity segment increased $283 million in the first quarter of 2014 from increased pricing as a result of product mix of Roundup and other glyphosate-based herbicides in all markets. In addition, sales volumes of Roundup and other glyphosate-based herbicides increased 5 percent in 2014 primarily from increased demand for our products in the United States and Brazil due to increased market size. 

Cost of goods sold in the Agricultural Productivity segment primarily represents material, conversion and distribution costs. Cost of goods sold increased $97 million, or 12 percent, in the first quarter of 2014 to $909 million compared to $812 million in the first quarter of 2013. Roundup and other glyphosate-based herbicides cost of goods sold increased as fiscal year 2014 sales shifted to branded products, which are more costly to produce. Increased volume in our Roundup and other glyphosate-based herbicides business also contributed to this increase.

The net sales and cost of goods sold discussed above resulted in $186 million higher gross profit in the first quarter of 2014. Gross profit as a percent of sales for the Agricultural Productivity segment increased 7 percentage points to 38 percent in 2014 primarily due to the increased average net selling price discussed above.

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Working Capital and Financial Condition
	As of				As of Aug. 31,
(Dollars in millions, except current ratio)	Nov. 30, 2013		Nov. 30, 2012		2013
Cash and Cash Equivalents(1)	$	4,496	$	4,637	$	3,668
Trade Receivables, Net(1)	2,283		2,168		1,715
Inventory, Net	3,873		3,571		2,947
Other Current Assets(1)(2)	1,844		1,684		1,747
Total Current Assets	$	12,496	$	12,060	$	10,077
Short-Term Debt, including current portion of long-term debt	$	262	$	26	$	51
Accounts Payable	853		785		995
Accrued Liabilities(3)	5,583		5,350		3,290
Total Current Liabilities	$	6,698	$	6,161	$	4,336
Working Capital(4)	$	5,798	$	5,899	$	5,741
Current Ratio(4)	1.87:1		1.96:1		2.32:1

(1) May include restrictions as a result of our variable interest entity. See the Statements of Consolidated Financial Position and Note 5 — Variable Interest Entities — for more information.

(2) Includes short-term investments, miscellaneous receivables, deferred tax assets and other current assets.

36

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

(3) Includes income taxes payable, accrued compensation and benefits, accrued marketing programs, deferred revenues, grower production accruals, dividends payable, customer payable and miscellaneous short-term accruals.

(4) Working capital is total current assets less total current liabilities; current ratio represents total current assets divided by total current liabilities.

Nov. 30, 2013, compared with Aug. 31, 2013: Working capital increased $57 million, or 1 percent, between Aug. 31, 2013, and Nov. 30, 2013, primarily because of the following factors:

• Cash and cash equivalents increased $828 million between respective periods primarily because of customer prepayments, offset by marketing program payments that occur in the first quarter of the fiscal year, which is consistent with the seasonality of our business. The net increase was offset by treasury share repurchases and dividends paid during the quarter. See cash flow section in this MD&A for additional detail.

• Trade receivables, net increased $568 million between respective periods primarily due to the seasonality of our business.

• Inventory, net increased $926 million between respective periods primarily because of the seasonality of our U.S. corn and soybean seed business in which the fall harvest of seed products occurs in the first quarter of the fiscal year resulting in a higher inventory balance.

These increases to working capital between Nov. 30, 2013, and Aug. 31, 2013, were partially offset by the following factors:

• Accrued liabilities increased $2,293 million between respective periods primarily due to the following fluctuations:

◦ Deferred revenue increased $2,349 million due to customer prepayments that occur in the first quarter of the fiscal year as discussed above.

◦ Grower production accruals increased $574 million due to corn and soybean deliveries in advance of the 2014 fiscal year commercial selling season due to the seasonality of our business.

These increases in accrued liabilities were offset by the following decreases:

◦ Accrued marketing programs decreased $322 million due to the payout of several programs during the first quarter of 2014 consistent with the seasonality of our programs.

◦ Dividends payable decreased $228 million as there were no dividends declared in the first quarter 2014.

Nov. 30, 2013, compared with Nov. 30, 2012: Working capital decreased $101 million, or 2 percent, between Nov. 30, 2012, and Nov. 30, 2013, primarily because of the following factors:

• Accrued liabilities increased $233 million between respective periods primarily due to the following fluctuation:

◦ Miscellaneous short-term accruals increased $240 million due to the timing of payments to a U.S. customer financing program for which we are the administrator.

• Short-term debt increased $236 million between respective periods due to the use of commercial paper in the first quarter of fiscal year 2014 as discussed below.

These decreases to working capital between Nov. 30, 2013, and Nov. 30, 2012, were partially offset by the following factor:

• Inventory, net increased $302 million primarily due to anticipation of increased sales plans for fiscal year 2014.

Customer Financing Programs: We participate in various customer financing programs in an effort to reduce our receivable risk and to reduce our reliance on commercial paper borrowings. As of Nov. 30, 2013, the programs had $156 million in outstanding balances and we received $30 million of proceeds during the three month period under these programs. Our future maximum payout under the programs, including our responsibility for our guarantees with lenders, was $81 million as of Nov. 30, 2013. See Note 4 — Customer Financing Programs — for further discussion of these programs.

37

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

Cash Flow

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013			Nov. 30, 2012
Net Cash Provided by Operating Activities	$	1,698		$	1,569
Net Cash Required by Investing Activities	(1,241		)	(96		)
Free Cash Flow(1)	457			1,473
Net Cash Provided (Required) by Financing Activities	346			(116		)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	25			(3		)
Net Increase in Cash and Cash Equivalents	828			1,354
Cash and Cash Equivalents at Beginning of Period	3,668			3,283
Cash and Cash Equivalents at End of Period	$	4,496		$	4,637

(1) Free cash flow represents the total of net cash provided or required by operating activities and provided or required by investing activities (see the “Non-GAAP Financial Measures” section in MD&A for a further discussion).

Operating: The increase in cash provided by continuing operations in the first quarter of 2014 compared to the first quarter of 2013 was primarily due to higher accounts payable and accrued liabilities related to the timing of customer financing program and marketing program payments, offset by the following factors:

• Increased trade accounts receivable due to higher sales, offset by increased market funding rebates applied against customer receivables.

• Increased inventory primarily due to larger crop production plans in our seeds and genomics segment.

Investing: The increase in cash required by investing activities in the first quarter of 2014 compared to the first quarter of 2013 was primarily due to the acquisition of The Climate Corporation, see discussion below, and an increase in capital expenditures, also discussed below.

Financing: The increase in cash provided by financing activities in the first quarter of 2014 compared to cash required by financing activities in the first quarter of 2013 was primarily due to the $1 billion debt issuance that occurred in November 2013, as discussed below, offset by increased treasury stock purchases and dividends paid.

Capital Resources and Liquidity

	As of						As of Aug. 31,
(Dollars in millions, except debt-to-capital ratio)	Nov. 30, 2013			Nov. 30, 2012			2013
Short-Term Debt	$	262		$	26		$	51
Long-Term Debt	3,057			2,054			2,061
Total Monsanto Company Shareowners’ Equity	12,572			12,259			12,559
Debt-to-Capital Ratio(1)	21		%	15		%	14		%

(1) Debt-to-Capital ratio represents short-term and long-term debt divided by total Monsanto Company shareowners' equity, short-term and long-term debt.

A major source of our liquidity is operating cash flows, which can be derived from net income. This cash-generating capability and access to long-term investment grade debt financing markets provides us with the financial flexibility we need to meet operating, investing and financing needs. We believe our sources of liquidity will be sufficient to sustain operations and to finance anticipated investments. To the extent that cash provided by operating activities is not sufficient to fund our cash needs, we believe short-term commercial paper borrowings can be used to finance these requirements. At Nov. 30, 2013, we had commercial paper borrowings outstanding of $195 million.

We have a $2 billion credit facility agreement with a group of banks that provides a senior unsecured revolving credit facility through April 1, 2016. As of Nov. 30, 2013, we did not have any borrowings under this credit facility and we were in compliance with all debt covenants.

In November 2013, we issued $1 billion senior notes with a group of banks, primarily to fund the acquisition of The Climate Corporation, as discussed below, and for general business purposes.

38

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

Our debt-to-capital ratio increased 6 percentage points compared with the Nov. 30, 2012 ratio, and 7 percentage points compared with the Aug. 31, 2013 ratio, primarily because of the debt issuance, as discussed above, in the first quarter of fiscal year 2014.

We held cash and cash equivalents and short-term investments of $4,745 million and $3,922 million at Nov. 30, 2013, and Aug. 31, 2013, respectively, of which $2,170 million and $2,319 million was held by foreign entities, respectively. Our intent is to indefinitely reinvest earnings of our foreign operations and our current operating plans do not demonstrate a need to repatriate foreign earnings to fund our U.S. operations. However, if these funds were needed for our operations in the United States, we would be required to accrue and pay any applicable U.S. and local taxes to repatriate these funds.

Dividends: There were no dividends declared in the first quarter of fiscal year 2014.

Capital Expenditures: We expect fiscal year 2014 capital expenditures to be in the range of $1 billion to $1.2 billion compared with $741 million in fiscal year 2013. The primary driver of this increase compared with 2013 is expected global seed manufacturing expansions and additional investment in one of our technology research facilities.

2014 Acquisitions:In November 2013, Monsanto acquired 100 percent of the outstanding stock of The Climate Corporation, a San Francisco, California based company. The Climate Corporation is a leading data analytics company with core capabilities around hyper local weather monitoring, weather simulation and agronomic modeling which has allowed them to develop risk management tools and agronomic decision support tools for growers. The acquisition will combine The Climate Corporation's expertise in agriculture risk-management with Monsanto’s R&D capabilities, and is expected to further enable farmers to significantly improve productivity and better manage risk from variables that could limit agriculture production. The total fair value of the acquisition was $932 million and the total cash paid for the acquisition was $917 million (net of cash acquired). The fair value was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology.

2013 Acquisitions: In August 2013, Monsanto acquired certain assets and manufacturing capabilities of Dieckmann GmbH & Co.KG, a business based in Germany which specializes in the breeding of oilseed rape and rye seeds. The acquisition, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing activities in the breeding, production and marketing of oilseed rape in Europe. The total fair value and cash paid for the acquisition was $30 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles. 

In June 2013, Monsanto acquired 100 percent of the outstanding stock of GrassRoots Biotechnology, Inc., a business based in Durham, North Carolina, that is focused on gene expression and other agriculture technologies. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. The total fair value and cash paid for the acquisition was $15 million (net of cash acquired). The fair value of the acquisition was primarily allocated to goodwill and intangibles.

In March 2013, Monsanto acquired substantially all of the assets of Rosetta Green Ltd., a business based in Israel which specializes in the identification and use of unique genes to guide key processes in major crops including corn, soybeans and cotton. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. The total fair value and cash paid for the acquisition was $35 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles.

In January 2013, Monsanto acquired select assets of Agradis, Inc., a business focused on developing sustainable agricultural solutions. The acquisition, which qualifies as a business under the Business Combinations topic of the ASC, is intended to support Monsanto's efforts to provide farmers with sustainable biological products to improve crop health and productivity. The total cash paid and the fair value of the acquisition was $85 million, and the purchase price was primarily allocated to goodwill and intangibles.

2014 Collaboration: In December 2013, we signed a definitive agreement with Novozymes to launch a BioAg alliance between Novozymes and Monsanto. Novozymes, located in Denmark, is a biotech company focusing on microbial technology, discovery, development and production. The BioAg alliance will focus on the next wave of microbial solutions by bringing together Novozymes' capabilities for discovering, developing and producing microbial solutions with Monsanto's discovery programs, and advanced development, testing and commercial capabilities. Value from commercialization will be shared 50-50 between both companies. Monsanto will pay Novozymes an aggregate upfront cash payment of $300 million for recognition of Novozymes ongoing business and capabilities in microbials and for Novozymes' ability to supply alliance products. Closing is expected to occur in mid fiscal year 2014 subject to customary closing conditions.

2014 Contractual Obligations: Other than the increase in our long-term debt, discussed above, there have been no significant changes to the contractual obligations table as disclosed in our Annual Report on Form 10-K for the year ended Aug. 31, 2013.

39

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

Off-Balance Sheet Arrangement

Under our Separation Agreement with Pharmacia, we are required to indemnify Pharmacia for certain matters, such as environmental remediation obligations and litigation. To the extent we are currently managing any such matters, we evaluate them in the course of managing our own potential liabilities and establish reserves as appropriate. However, additional matters may arise in the future, and we may manage, settle or pay judgments or damages with respect to those matters in order to mitigate contingent liability and protect Pharmacia and Monsanto. See Note 20 — Commitments and Contingencies and Part II — Item 1 — Legal Proceedings — for further information.

We have entered into various customer financing programs which are accounted for in accordance with the Transfers and Servicing topic of the ASC. See Note 4 — Customer Financing Programs — for further information.

We are in the process of making a significant expansion of our Chesterfield, Missouri facility. In December 2013, we executed the first of a series of incentive agreements with the County of St. Louis, Missouri. Under these agreements we have transferred our Chesterfield, Missouri facility to St. Louis County and received Industrial Revenue Bonds in the amount of up to $470 million which enables us to reduce our cost of constructing and operating the expansion by reducing certain state and local tax expenditures. We will then lease the facility from the County of St. Louis. The payments due to us in relation to the Industrial Revenue Bonds and owed by us in relation to the lease of the facilities qualify for the right of offset under ASC 210, Balance Sheet, on our Statements of Consolidated Financial Position, and as a result we will treat the Chesterfield facilities and the expansion as being owned by us and not include the Industrial Revenue Bonds on our Statements of Consolidated Financial Position as an asset. It is anticipated that we will execute certain additional incentive agreements in the future with the State of Missouri in connection with such expansion to provide additional benefits.

OUTLOOK

We believe we have achieved an industry-leading position in the areas in which we compete in both of our business segments. However, the outlook for each part of our business is quite different. In the Seeds and Genomics segment, our seeds and traits business is expected to expand via our investment in new products. In the Agricultural Productivity segment, we expect to deliver competitive products in a more steady-state business.

We believe that our company is positioned to deliver value-added products to growers enabling us to grow our gross profit in the future. We expect to see strong cash flow in the future, and we remain committed to returning value to shareowners through vehicles such as investments that expand the business, dividends and share repurchases. We will remain focused on cost and cash management, both to support the progress we have made in managing our investment in working capital and to realize the full earnings potential of our businesses. We plan to continue to seek additional external financing opportunities for our customers as a way to manage receivables for each of our segments.

Outside of the United States, our businesses will continue to face additional challenges related to the risks inherent in operating in emerging markets. We will continue to consider, assess and address these developments and the challenges and issues they place on our businesses. We believe we have taken appropriate measures to manage our credit exposure, which has the potential to affect sales negatively in the near term. In addition, volatility in foreign currency exchange rates may negatively affect our profitability, the book value of our assets outside the United States, and our shareowners’ equity. We continuously monitor the potential currency devaluation in Venezuela and currency volatility in Argentina and the potential impact on future periods.

Seeds and Genomics

Our capabilities in plant breeding and biotechnology research and development are generating a rich and balanced product pipeline that we expect will drive long-term growth. We plan to continue to invest in the areas of seeds, genomics and biotechnology and to invest in technology arrangements that have the potential to increase the efficiency and effectiveness of our R&D efforts. We believe that our seeds and traits businesses will have significant near-term growth opportunities through a combination of improved breeding and continued growth of stacked and second- and third-generation biotech traits.

We expect advanced breeding techniques combined with improved production practices and capital investments will continue to contribute to improved germplasm quality and yields for our seed offerings, leading to increased global demand for both our branded germplasm and our licensed germplasm. We plan to improve the overall performance of our vegetable seeds business, which has a portfolio focused on 21 crops. While near term financial results for the vegetable business could be affected by lower sales in certain regions experiencing political or economic instability, the business integration into a global platform, along with a number of process improvements, are expected to continue to improve our ability to develop and deliver new innovative products to our customer base. We plan to continue to pursue strategic acquisitions in our seed businesses to grow our branded seed share, expand our germplasm library, and strengthen our global breeding programs. We expect to see

40

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

continued competition in seeds and genomics. We believe we will have a competitive advantage because of our global breeding capabilities and our multiple-channel sales approach in the United States for corn and soybean seeds.

Commercialization of second- and third-generation traits and the stacking of multiple traits in corn, soy and cotton are expected to increase penetration in approved markets, particularly as we continue to price our traits in line with the value growers have experienced. We experienced an increase in competition in biotechnology as more competitors launched traits in the United States and internationally. Acquisitions may also present mid-to-longer term opportunities to increase penetration of our traits. We believe our competitive position continues to enable us to deliver second- and third-generation traits when our competitors are delivering their first-generation traits.

In Brazil, we expect to continue to operate our business model of collecting on the sale of certified seeds, a point-of-delivery payment system (Roundup Ready soybeans and Intacta RR2 PRO soybeans, with the recent China approval) and our indemnification collection system (Bollgard cotton), to capture value on all of our Roundup Ready soybeans and Bollgard cotton crops grown there. Following an adverse ruling from a panel of five judges in the Brazilian Superior Court of Justice denying our term correction for the first generation Roundup Ready patent term to 2014, we continue to defer collection of royalties for first generation Roundup Ready soybeans in Brazil until a final decision is reached by the courts. Growers can agree to gain royalty-free use of first generation Roundup Ready for the 2013-2014 seasons in exchange for a waiver of any claim for refunds for past payments by signing a new Grower License Agreement with a reciprocal release governing Monsanto’s technology. Almost all of the major grower unions in Mato Grosso (a key soybean state in Brazil) have committed to promote the new Grower License Agreements with their membership. The Supreme Court of Brazil has granted certiorari of the patent term correction case.

Longer term, income is expected to grow in Brazil as farmers choose to plant more of our approved traits in soybeans, corn and cotton. The agricultural economy in Brazil could be impacted by global commodity prices, particularly for corn and soybeans. We continue to maintain our strict credit policy, expand our grain-based collection system and focus on cash collection and sales, as part of a continuous effort to manage our risk in Brazil against such volatility.

During 2007, we announced a long-term joint R&D and commercialization collaboration in plant biotechnology with BASF that focuses on high-yielding crops and crops that are tolerant to adverse conditions such as drought. Over the life of the collaboration, which was recently extended, we and BASF will dedicate a joint budget of potentially $2.5 billion to fund a dedicated pipeline of yield and stress tolerance traits for corn, soybeans, cotton, canola and wheat.

Our international traits businesses, in particular, probably will continue to face unpredictable regulatory environments that may be highly politicized. We operate in volatile, and often difficult, economic and political environments. Growth in India's cotton germplasm and traits business continues to be impacted by government controlled pricing and uncertainties in the regulatory approval process for new trait introductions.

Efforts to secure an orderly system in Argentina to support the introduction of new technology products are underway. To achieve this, we are pursuing grower and grain handler agreements to ensure we will be compensated for providing the technology. The majority of grain handlers have enrolled in the point of delivery system, and with the recent China approval, we plan to sell Intacta RR2 PRO in Argentina in this dual-path business model. Intacta RR2 PRO technology has been fully approved by Argentina and export markets. We intend to broaden our grower experience with Ground Breakers in the main production areas and modest commercial sales in the north. We also intend to finalize the last steps of the business model approach to enable farmer payments on new and legally saved seed as already exists in Brazil and Paraguay. We do not plan to collect on first generation Roundup Ready soybeans in Argentina.

In May 2013, the USDA announced an investigation into alleged glyphosate-resistant volunteer wheat reported on a single field on an Oregon farm, and we are cooperating in the investigation. The USDA noted that glyphosate-tolerant wheat does not present a public health or food safety concern as the FDA completed its assessment of the product in 2004. The consultative process at the FDA was completed and the agency concluded that this product is as safe as non-GM wheat currently on the market. Initial development of glyphosate tolerant wheat was discontinued in 2005 under stringent stewardship procedures which were in compliance with USDA regulations. The USDA has reported that there is no indication that the genetically modified wheat product is found in U.S. wheat supplied to domestic or export markets. The USDA's investigation remains ongoing and the agency indicated that civil and criminal penalties could be imposed if circumstances warranted. Lawsuits which assert numerous legal claims have been filed against the company and have been consolidated in the Federal District Court of Kansas. Monsanto properly discontinued the development of the glyphosate-tolerant wheat event in 2005, has meritorious legal arguments against liability and will vigorously represent its interests in this matter.

41

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

Agricultural Productivity

Our Agricultural Productivity businesses operate in markets that are competitive. Gross profit and cash flow levels will fluctuate in the future based on global business dynamics including market supply, demand and manufacturing capacity. We expect to maintain our brand prices at a slight premium over generic products and we believe our Roundup herbicide business will continue to be a sustainable source of cash and gross profit. We have oriented the focus of Monsanto’s crop protection business to strategically support Monsanto’s Roundup Ready crops through our weed management platform that delivers weed control offerings for farmers. In addition, we expect our lawn-and-garden business will continue to be a solid contributor to our Agricultural Productivity segment.

Global glyphosate producers have the capacity to supply the market, but global dynamics including demand, environmental regulation compliance and raw material availability can cause fluctuation in supply and the price of those generic products. We expect the fluctuation in global capacity will impact the selling price and margin of Roundup brands and our third party sourcing opportunities.

The staff of the SEC is conducting an investigation of financial reporting associated with our customer incentive programs for glyphosate products for the fiscal years 2009 and 2010, and we have received subpoenas in connection therewith. It is not reasonably possible to assess the outcome of the investigation at this time, but potential outcomes could include the filing of an enforcement proceeding and the imposition of civil penalties as well as non-monetary remedies, which may require the Company to incur future costs. We continue cooperating with the investigation.

Other Information

As discussed in Note 20 — Commitments and Contingencies — and Part II — Item 1 — Legal Proceedings, Monsanto is involved in a number of lawsuits and claims relating to a variety of issues. Many of these lawsuits relate to intellectual property disputes. We expect that such disputes will continue to occur as the agricultural biotechnology industry evolves. Third parties, including non-governmental organizations, have challenged the validity or enforceability of patents issued to the company regarding our biotechnology products. For additional information related to the outlook for Monsanto, see “Caution Regarding Forward-Looking Statements” at the beginning of this Report on Form 10-Q, Part II — Item 1A — Risk Factors below and Part I — Item 1A of our Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

In preparing our financial statements, we must select and apply various accounting policies. Our most significant policies are described in Part II — Item 8 — Note 2 — Significant Accounting Policies — to the consolidated financial statements contained in our Report on Form 10-K for the fiscal year ended Aug. 31, 2013. In order to apply our accounting policies, we often need to make estimates based on judgments about future events. In making such estimates, we rely on historical experience, market and other conditions, and on assumptions that we believe to be reasonable. However, the estimation process is by its nature uncertain given that estimates depend on events over which we may not have control. If market and other conditions change from those that we anticipate, our financial condition, results of operations or liquidity may be affected materially. In addition, if our assumptions change, we may need to revise our estimates or take other corrective actions, either of which may have a material effect on our financial condition, results of operations or liquidity.

The estimates that have a higher degree of inherent uncertainty and require our most significant judgments are outlined in Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Report on Form 10-K for fiscal year ended Aug. 31, 2013. Had we used estimates different from any of those contained in such Report on Form 10-K, our financial condition, profitability or liquidity for the current period could have been materially different from those presented in this Form 10-Q.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There are no material changes related to market risk from the disclosures in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

42

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of Nov. 30, 2013. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Based upon the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of Nov. 30, 2013.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

43

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are involved in various legal proceedings that arise in the ordinary course of our business, as well as proceedings that we have considered to be material under SEC regulations. These include proceedings to which we are party in our own name and proceedings to which our former parent Pharmacia LLC or its former subsidiary Solutia, Inc. is a party but that we manage and for which we are responsible. Information regarding certain material proceedings and the possible effects on our business of proceedings we are defending is disclosed in Note 20 — Commitments and Contingencies — under the subheading “Environmental and Litigation Liabilities ” and is incorporated by reference herein. Other information with respect to legal proceedings appears in our Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

ITEM 1A. RISK FACTORS

Please see “Caution Regarding Forward-Looking Statements,” at the beginning of this Report on Form 10-Q and Part I — Item 1A of our Report on Form 10-K for the fiscal year ended Aug. 31, 2013, for information regarding risk factors. There have been no material changes from the risk factors previously disclosed in our Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

The following table is a summary of any purchases of equity securities during the first quarter of fiscal year 2014 by Monsanto and any affiliated purchasers, pursuant to SEC rules. 

Period	(a) Total Number of Shares Purchased		(b) Average Price Paid per Share(1)		(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	(d) Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
September 2013:
Sep. 1, 2013, through Sep. 30, 2013	1,400,500		$	103.69	1,400,500	$	1,824,868,472
October 2013:
Oct. 1, 2013, through Oct. 31, 2013	2,898,263		$	105.22	2,898,263	$	1,519,916,985
November 2013:
Nov. 1, 2013, through Nov. 30, 2013	1,071,700	(2)	$	107.70	1,024,300	$	1,409,471,602
Total	5,370,463		$	105.32	5,323,063	$	1,409,471,602

(1) The average price paid per share is calculated on a trade date basis and excludes commission.

(2) Includes 47,400 shares purchased by affiliated purchaser.

In June 2013, the board of directors authorized a new share repurchase program, effective July 1, 2013, for up to $2 billion of the company's common stock over a three-year period. This repurchase program commenced on Aug. 20, 2013.

There were no other publicly announced plans outstanding as of Nov. 30, 2013.

ITEM 6. EXHIBITS

Exhibits: The list of exhibits in the Exhibit Index to this Report is incorporated herein by reference.

44

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MONSANTO COMPANY
	(Registrant)
By:	/s/ NICOLE M. RINGENBERG
	Nicole M. Ringenberg
	Vice President and Controller
	(On behalf of the Registrant and as Principal Accounting Officer)

Date: January 8, 2014

45

MONSANTO COMPANY FIRST QUARTER 2014 FORM 10-Q

EXHIBIT INDEX

These Exhibits are numbered in accordance with the Exhibit Table of Item 601 of Regulation S-K.

Exhibit No.	Description
2	Omitted
3	Omitted
4	Omitted
10.1	Form of Terms and Conditions of Retention and Performance Restricted Stock Unit Grant under the Monsanto Company 2005 Long-Term Incentive Plan [as Amended and Restated as of Jan. 24, 2012].
10.2	Form of Change of Control Employment Security Agreement for Messrs. Begemann, Grant and Preete, and Dr. Fraley, effective Sept. 1, 2010 (incorporated by reference to Exhibit 10 to Form 8-K, filed on Sept. 7, 2010, File No. 1-16167). †
11	Omitted — see Note 18 of Notes to Consolidated Financial Statements — Earnings Per Share.
12	Computation of Ratio of Earnings to Fixed Charges.
15	Omitted
18	Omitted
19	Omitted
22	Omitted
23	Omitted
24	Omitted
31.1	Rule 13a-14(a) Certifications (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, executed by the Chief Executive Officer).
31.2	Rule 13a-14(a) Certifications (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, executed by the Chief Financial Officer).
32	Rule 13a-14(b) Certifications (pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by the Chief Executive Officer and the Chief Financial Officer).
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.
† Represents management contract or compensatory plan or arrangement.

46

EX-10.1

EXHIBIT 10.1

[Form of]

Monsanto Company 2005 Long-Term Incentive Plan

Terms and Conditions

of this Fiscal Year [20_ _ ]

Retention and Performance Restricted Stock Unit Grant

You have received an Award of Restricted Stock Units (the “Units”) under the Monsanto Company 2005 Long-Term Incentive Plan [as Amended and Restated as of January 24, 2012] (the “Plan”). The Grant Date and the number of Units covered by this Award are set forth in the document you have received entitled “Restricted Stock Units Statement.” The Restricted Stock Units Statement and these terms and conditions collectively constitute the Award Certificate for the Units, and describe the provisions applicable to the Units.

1.Definitions. Each capitalized term not otherwise defined herein has the meaning set forth in the Plan or, if not defined in the Plan, in the attached Restricted Stock Units Statement. The “Company” means Monsanto Company, a Delaware corporation incorporated February 9, 2000.

2.Nature of Units. The Units represent the right to receive, in certain circumstances, a number of Shares determined in accordance with the Restricted Stock Units Statement and these terms and conditions. Until such time (if any) as Shares are delivered to you, you will not have any of the rights of a common stockholder of the Company with respect to those Shares, your rights with respect to the Units and those Shares will be those of a general creditor of the Company, and you may not sell, assign, transfer, pledge, hypothecate, give away, or otherwise dispose of the Units. Any attempt on your part to dispose of the Units will result in their being forfeited. However, you shall have the right to receive a cash payment (the “Dividend Equivalent Payment”) with respect to the Units (if any) that vest pursuant to this Award, subject to withholding pursuant to paragraph 6 below, in an amount equal to the aggregate cash dividends that would have been paid to you if you had been the record owner, on each record date for a cash dividend during the period from the Grant Date through the settlement date of the Units, of a number of Shares equal to the number of Units that vest under this Award. The Dividend Equivalent Payment shall be made on such settlement date. You shall not be entitled to receive any payments with respect to any non-cash dividends or other distributions that may be made with respect to the Shares.

3.Vesting of Units. (a) 162(m) Performance Goal. Subject to Section 5, in order to vest in any number of Units under this Award, the 162(m) Performance Goal must be met (as determined and certified by the Committee following the conclusion of the Company’s fiscal year that concludes on August 31, _____ [generally the next fiscal year]). The “162(m) Performance Goal” is that the Company’s Net Income, as defined in the next sentence, must exceed zero for the period from September 1, ____ through August 31, _____ [generally the next three fiscal years]. “Net Income” means gross profit (i) minus (A) sales, general and administrative expenses, (B) research and development expense, (C) amortization, (D) net interest expense, and (E) income taxes and (ii) plus or minus other income and expense; all as reported in the Company’s financial statements; but excluding positive or negative effects of (I) restructuring charges and reversals, (II) the outcome of lawsuits, (III) research and development write-offs on acquisitions, (IV) impact of liabilities, expenses or settlements related to Solutia, Inc. or agreements associated with a Solutia, Inc. plan of reorganization, (V)

unbudgeted business sales and divestitures, and (VI) the cumulative effects of changes in accounting methodology made after August 31, _____ [generally the next fiscal year].

(b)Vesting Date. If the Section 162(m) Performance Goal is met, then the Units shall vest on _________________ [approximately four years from grant date] (the “Scheduled Vesting Date”), subject to your not incurring a Termination of Service prior to the Scheduled Vesting Date. Subject to Sections 3(c) and 5(c), if the Section 162(m) Performance Goal is not met, or if you incur a Termination of Service prior to the Scheduled Vesting Date, all Units shall be forfeited and cease to be outstanding, effective as of the date it is first determined that such goal will not be met, or as of the date of such Termination of Service, as applicable.

(c) Effect of Termination of Service. If you incur a Termination of Service before the Scheduled Vesting Date due to a Termination without Cause (other than a Termination without Cause subsequent to a Change of Control, which shall be governed by Section 5(c)) or due to your Disability or death, then effective as of the Scheduled Vesting Date, so long as the Section 162(m) Performance Goal is met, a number of Units shall vest, equal to (i) the total number of Units, times (ii) a fraction, the numerator of which is the number of days from the Grant Date through the date of your Termination of Service, and the denominator of which is the number of days from the Grant Date through the Scheduled Vesting Date. Effective as of the date of a Termination of Service governed by the preceding sentence, all Units in excess of the amount that are eligible for vesting by operation of the preceding sentence shall be forfeited and cease to be outstanding.

4.Delivery of Shares. The Company shall deliver to you a number of Shares equal to the number of Units (if any) that vest pursuant to this Award (except that in the event of settlement following conversion of this Award into a cash account pursuant to Section 5(a), delivery shall be in cash), subject to withholding as provided in paragraph 6 below. Such delivery shall take place as soon as practicable, but in no event more than 90 days, after the Scheduled Vesting Date. Notwithstanding the foregoing, with respect to a Termination of Service that is a “separation from service” within the meaning of Section 409A of the Code and that occurs during the two-year period following a Change of Control that qualifies as an event described in Section 409A(a)(2)(A)(v) of the Code and the regulations thereunder, such delivery shall take place as soon as practicable following the date of the applicable Termination of Service. Nothing in this Agreement, including Section 5, shall preclude the Company from settling upon a Change of Control an Award that is not replaced by a Replacement Award (as defined below), to the extent effectuated in accordance with Treas. Regs. § 1.409A-3(j)(ix).

5.Change of Control. The provisions of this Section 5 shall govern vesting of this Award upon a Change of Control, notwithstanding the provisions of Section 11.17 of the Plan.

(a) Upon the occurrence of a Change of Control, notwithstanding any other provision of this Award Certificate, the number of Units subject to this Award that remain outstanding as of such Change of Control shall vest in full, except to the extent that another award meeting the requirements of Section 5(b) is provided to you to replace this Award (any award meeting the requirements of Section 5(b), a “Replacement Award”). In the event that no Replacement Award is so provided to you, this Award shall be converted into a cash account (based on the number of Units as of the date of the Change of Control and the value per Share as of the Change of Control), which shall accrue interest at the applicable federal short-term rate provided for in Section 1274(d)(1)(A) of the Code, and be settled in accordance with Section 4 above. For clarity, such account shall be fully vested as of the Change of Control, in no event shall the amount of such account be increased or decreased as a result of the circumstances of a subsequent Termination of Service, and the provisions of Section 2 relating to Dividend Equivalent Payments shall cease to apply following conversion of this Award into a cash

2

account.

(b) An award shall meet the conditions of this Section 5(b) (and hence qualify as a Replacement Award) if: (i) it is a restricted stock unit in respect of publicly traded equity securities of the Company or the surviving corporation following the Change of Control, (ii) it has a value at least equal to the value of the Units subject to this Award as of the date of the Change of Control and provides for vesting based solely on continued service (with no performance conditions), (iii) it contains terms relating to vesting (including with respect to Termination of Service) that are substantially identical to those of this Award, and (iv) its other terms and conditions are not less favorable to you than the terms and conditions of this Award as of the date of the Change of Control. Without limiting the generality of the foregoing, a Replacement Award may take the form of a continuation of this Award if the requirements of the preceding sentence are satisfied. If a Replacement Award is granted, the Units shall not vest upon the Change of Control. The determination of whether the conditions of this Section 5(b) are satisfied shall be made by the Committee, as constituted immediately before the Change of Control, in its sole discretion.

(c)If you experience (x) a Termination without Cause or (y) a termination under circumstances entitling you to severance benefits under a constructive termination provision (including, without limitation, a “good reason” provision or a constructive “involuntary termination” provision) of an agreement, plan or program covering you, in either case, at any time following a Change of Control, the applicable Replacement Award shall vest in full.

6.Withholding. Notwithstanding any other provision of this Award Certificate, your right to receive the Dividend Equivalent Payment and to receive Shares or cash in settlement of any Units is subject to withholding of all taxes that are required to be paid or withheld in connection with such Dividend Equivalent Payment or the delivery of such Shares or cash. With respect to the delivery of Shares, you must make arrangements satisfactory to the Company for the payment of any such taxes.

7.Recoupment Policy. Notwithstanding any other provision of this Award Certificate, this Award shall be subject to the terms of the Company’s Recoupment Policy, which is hereby incorporated herein by reference.

8.No Right to Continued Employment or Service. This Award Certificate shall not limit or restrict the right of the Company or any Affiliate to terminate your employment or service at any time or for any reason.

9.Effect of Award Certificate; Severability. This Award Certificate shall be binding upon and shall inure to the benefit of any successor of the Company. The invalidity or enforceability of any provision of this Award Certificate shall not affect the validity or enforceability of any other provision of this Award Certificate.

10.Amendment. The terms and conditions of this Award Certificate may not be amended in any manner adverse to you without your consent.

11.Plan Interpretation. This Award Certificate is subject to the provisions of the Plan, and all of the provisions of the Plan are hereby incorporated into this Award Certificate. If there is a conflict between the provisions of this Award Certificate and the Plan, the provisions of the Plan govern. If there is any ambiguity in this Award Certificate, any term that is not defined in this Award Certificate, or any matters as to which this Award Certificate is silent, the Plan shall govern, including, without limitation, the provisions of the Plan addressing construction and governing law, as well as the powers

3

of the Committee, among others, to (a) interpret the Plan, (b) prescribe, amend and rescind rules and regulations relating to the Plan, (c) make appropriate adjustments to the Units in the event of a corporate transaction, and (d) make all other determinations necessary or advisable for the administration of the Plan.

4

EX-12

Exhibit 12

MONSANTO COMPANY

COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES⁽¹⁾⁽²⁾ 

(Dollars in millions)

	Three Months Ended Nov. 30,			Year Ended Aug. 31,
	2013			2013			2012			2011			2010			2009
EARNINGS:
Income from Continuing Operations Before Income Taxes	$	516		$	3,429		$	2,988		$	2,374		$	1,490		$	2,918
Add:
Fixed charges	73			246			257			234			227			178
Equity affiliate income — net	3			(15		)	(10		)	(21		)	(16		)	(17		)
Amortization of capitalized interest	4			16			15			15			14			13
Less:
Capitalized interest	(7		)	(23		)	(21		)	(22		)	(25		)	(34		)
Earnings available for fixed charges	$	589		$	3,653		$	3,229		$	2,580		$	1,690		$	3,058
FIXED CHARGES:
Interest expense(3)	$	54		$	176		$	191		$	172		$	167		$	107
Capitalized interest	7			23			21			22			25			34
Portion of rents representative of interest factor	12			47			45			40			35			37
Total fixed charges	$	73		$	246		$	257		$	234		$	227		$	178
Ratio of Earnings to Fixed Charges	8.07			14.85			12.56			11.03			7.44			17.18

(1) Monsanto has not paid any preference security dividends and, therefore, has not included the ratio of combined fixed charges and preference security dividends to earnings for the relevant periods.

(2) The operating results of the Dairy business has been conformed to discontinued operations presentation for all relevant fiscal years presented.

(3) Includes amortization of deferred debt issuance costs and the interest component of the income tax provision.

EX-31.1

EXHIBIT 31.1

CERTIFICATIONS

I, Hugh Grant, certify that:

1. I have reviewed this report on Form 10-Q of Monsanto Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: January 8, 2014

/s/ Hugh Grant

Hugh Grant

Chairman and Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATIONS

I, Pierre Courduroux, certify that:

1. I have reviewed this report on Form 10-Q of Monsanto Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: January 8, 2014

/s/ Pierre Courduroux

Pierre Courduroux

Senior Vice President and Chief Financial Officer

EX-32

EXHIBIT 32

CERTIFICATIONS PURSUANT TO

EXCHANGE ACT RULE 13a-14(b) AND 18 U.S.C. SECTION 1350

In connection with the report of Monsanto Company (the “Company”) on Form 10-Q for the period ended Nov. 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), and pursuant to Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350, each of the undersigned officers of the Company does hereby certify that, to the best of such officer’s knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Hugh Grant

Hugh Grant

Chairman and Chief Executive Officer

/s/ Pierre Courduroux

Pierre Courduroux

Senior Vice President and Chief Financial Officer

January 8, 2014

XML

GOODWILL AND OTHER INTANGIBLE ASSETS

3 Months Ended

Nov. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND OTHER INTANGIBLE ASSETS

Changes in the net carrying amount of goodwill for the first three months of fiscal year 2014, by segment, are as follows:

(Dollars in millions)	Seeds and Genomics		Agricultural Productivity			Total
Balance as of Aug. 31, 2013	$	3,461	$	59		$	3,520
Acquisition activity (see Note 3)	785		—			785
Effect of foreign currency translation adjustments	21		(1		)	20
Balance as of Nov. 30, 2013	$	4,267	$	58		$	4,325

Goodwill increased during the three months endedNov. 30, 2013, due to the acquisition of The Climate Corporation. See Note 3 - Business Combinations - for further information. There were no events or circumstances indicating that goodwill might be impaired as of Nov. 30, 2013. The fiscal year 2014 annual goodwill impairment test will be performed as of March 1, 2014.

Information regarding the company’s other intangible assets is as follows:

	As of Nov. 30, 2013							As of Aug. 31, 2013
(Dollars in millions)	Carrying Amount		Accumulated Amortization			Net		Carrying Amount		Accumulated Amortization			Net
Acquired Intellectual Property	$	1,259	$	(799	)	$	460	$	1,095	$	(791	)	$	304
Acquired Germplasm	1,120		(728		)	392		1,113		(717		)	396
Trademarks	343		(135		)	208		341		(131		)	210
Customer Relationships	314		(186		)	128		306		(179		)	127
Other	170		(95		)	75		177		(91		)	86
Total Other Intangible Assets, Finite Lives	$	3,206	$	(1,943	)	$	1,263	$	3,032	$	(1,909	)	$	1,123
In Process Research & Development, Indefinite Lives	104		—			104		103		—			103
Total Other Intangible Assets	$	3,310	$	(1,943	)	$	1,367	$	3,135	$	(1,909	)	$	1,226

The increase in the carrying amount of acquired intellectual property during the three months endedNov. 30, 2013, is primarily related to the acquisition of The Climate Corporation. Total amortization expense of other intangible assets was $27 million and $28 million for the three months endedNov. 30, 2013, and Nov. 30, 2012, respectively. The estimated intangible asset amortization expense for fiscal year 2014 through fiscal year 2018 is as follows:

(Dollars in millions)	Amount
2014	$	173
2015	171
2016	123
2017	97
2018	87

XML

GOODWILL AND OTHER INTANGIBLE ASSETS Schedule of net carrying amount of goodwill (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013
Goodwill [Roll Forward]
Balance	$ 3,520
Acquisition activity (see Note 3)	785
Effect of foreign currency translation adjustments	20
Balance	4,325
Seeds And Genomics [Member]
Goodwill [Roll Forward]
Balance	3,461
Acquisition activity (see Note 3)	785
Effect of foreign currency translation adjustments	21
Balance	4,267
Agricultural Productivity [Member]
Goodwill [Roll Forward]
Balance	59
Acquisition activity (see Note 3)	0
Effect of foreign currency translation adjustments	(1)
Balance	$ 58

XML

Statements of Consolidated Comprehensive Income (Loss) (Unaudited) (Parenthetical) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013	Nov. 30, 2012
Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]
Foreign currency translation, tax expense (benefit)	$ (8)	$ 0
Postretirement benefit plan activity, tax expense (benefit)	5	7
Unrealized net gains (losses) on investment holdings, tax (expense) benefit	3	3
Realized net gains on investment holdings, tax (expense) benefit	0	1
Unrealized net derivative gains (losses), tax (expense) benefit	(25)	(6)
Realized net derivative losses (gains), tax (expense) benefit	$ (3)	$ 5

XML

BACKGROUND AND BASIS OF PRESENTATION

3 Months Ended

Nov. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BACKGROUND AND BASIS OF PRESENTATION

BACKGROUND AND BASIS OF PRESENTATION

Monsanto Company, along with its subsidiaries, is a leading global provider of agricultural products for farmers. Monsanto’s seeds, biotechnology trait products, and herbicides provide farmers with solutions that improve productivity, reduce the costs of farming, and produce better foods for consumers and better feed for animals.

Monsanto manages its business in two segments: Seeds and Genomics and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and related traits businesses, biotechnology platforms and precision agriculture. Through the Seeds and Genomics segment, Monsanto produces leading seed brands, including DEKALB, Asgrow, Deltapine, Seminis and De Ruiter, and Monsanto develops biotechnology traits that assist farmers in controlling insects and weeds. Monsanto also provides other seed companies with genetic material and biotechnology traits for their seed brands. Through the Agricultural Productivity segment, the company manufactures Roundup and Harness brand herbicides and other herbicides. See Note 21 — Segment Information — for further details.

In the fourth quarter of 2008, the company announced plans to divest its animal agricultural products business, which focused on dairy cow productivity (the Dairy business) and was previously reported as part of the Agricultural Productivity segment. This transaction was consummated on Oct. 1, 2008. As a result, financial data for this business has been presented as discontinued operations.

Certain reclassifications of prior year amounts within the operating activities section of the Statement of Consolidated Cash Flows have been made to conform to current year presentation. The company has evaluated the impact and does not consider the reclassifications to be material to the consolidated financial statements.

The accompanying consolidated financial statements have not been audited but have been prepared in conformity with accounting principles generally accepted in the United States for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods reported. This Report on Form 10-Q should be read in conjunction with Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013. Financial information for the first three months of fiscal year 2014 should not be annualized because of the seasonality of the company’s business.

XML

POSTRETIREMENT BENEFITS - PENSIONS, HEALTH CARE AND OTHER

3 Months Ended

Nov. 30, 2013

Compensation and Retirement Disclosure [Abstract]

POSTRETIREMENT BENEFITS-PENSIONS, HEALTH CARE AND OTHER

POSTRETIREMENT BENEFITS — PENSIONS, HEALTH CARE AND OTHER

Most of Monsanto’s U.S. employees hired prior to July 8, 2012, are covered by noncontributory pension plans sponsored by the company. Effective July 8, 2012, the U.S. pension plan was closed to new entrants; there were no changes to the U.S. pension plan for eligible employees hired prior to that date. The company also provides certain postretirement health care and life insurance benefits for retired employees through insurance contracts. The company’s net periodic benefit cost for pension benefits and health care and other postretirement benefits include the following components:

	Three Months Ended Nov. 30, 2013									Three Months Ended Nov. 30, 2012
Pension Benefits (Dollars in millions)	U.S.			Outside the U.S.			Total			U.S.			Outside the U.S.			Total
Service Cost for Benefits Earned During the Period	$	15		$	3		$	18		$	20		$	3		$	23
Interest Cost on Benefit Obligation	23			2			25			22			2			24
Assumed Return on Plan Assets	(35		)	(2		)	(37		)	(40		)	(2		)	(42		)
Amortization of Unrecognized Net Loss	16			1			17			21			1			22
Curtailment and Settlement Charge	—			1			1			—			1			1
Total Net Periodic Benefit Cost	$	19		$	5		$	24		$	23		$	5		$	28

Health Care and Other Postretirement Benefits	Three Months Ended
(Dollars in millions)	Nov. 30, 2013			Nov. 30, 2012
Service Cost for Benefits Earned During the Period	$	3		$	5
Interest Cost on Benefit Obligation	3			3
Amortization of Unrecognized Net Gain	(4		)	(3		)
Total Net Periodic Benefit Cost	$	2		$	5

Monsanto contributed $15 million to its U.S. qualified plan in the three month period ended Nov. 30, 2013, and $11 million in the three month period ended Nov. 30, 2012. Monsanto contributed $5 million to plans outside the United States in the three month period ended Nov. 30, 2013, and $3 million in the three month period ended Nov. 30, 2012. As of Nov. 30, 2013, management expects to make additional contributions of approximately $45 million and $10 million to the company’s pension plans in the United States and outside the United States, respectively, during the remainder of fiscal year 2014.

XML

STOCK BASED COMPENSATION PLANS Schedule of Stock-based Compensation Expense (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended	12 Months Ended	3 Months Ended
	Nov. 30, 2013	Aug. 31, 2012	Nov. 30, 2013 Cost of Goods Sold [Member]	Nov. 30, 2012 Cost of Goods Sold [Member]	Nov. 30, 2013 Selling, General and Administrative Expenses [Member]	Nov. 30, 2012 Selling, General and Administrative Expenses [Member]	Nov. 30, 2013 Research and Development Expenses [Member]	Nov. 30, 2012 Research and Development Expenses [Member]	Nov. 30, 2013 Pre-Tax Stock-Based Compensation Expense [Member]	Nov. 30, 2012 Pre-Tax Stock-Based Compensation Expense [Member]	Nov. 30, 2013 Income Tax Benefit [Member]	Nov. 30, 2012 Income Tax Benefit [Member]	Nov. 30, 2013 Net Stock Based Compensation [Member]	Nov. 30, 2012 Net Stock Based Compensation [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Allocated Stock Based Compensation Expense			$ 2	$ 4	$ 20	$ 15	$ 5	$ 5	$ 27	$ 24	$ (9)	$ (8)	$ 18	$ 16
Compensation cost capitalized	$ 3	$ 3

XML

INVESTMENTS Investments (Details) (USD $)	3 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Aug. 31, 2013
Schedule of Investments and Equity Affiliates [Line Items]
Short-term investments	$ 249,000,000		$ 254,000,000
Fair Value	43,000,000		22,000,000
Available-for-sale Securities [Member]
Schedule of Investments and Equity Affiliates [Line Items]
Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net, Available-for-sale Securities	0	0
Fair Value	43,000,000		22,000,000
Cost-method Investments [Member]
Schedule of Investments and Equity Affiliates [Line Items]
Recorded cost	68,000,000		67,000,000
Cost-method Investments, Other than Temporary Impairment	$ 0	$ 0

XML

INVESTMENTS

3 Months Ended

Nov. 30, 2013

Equity Method Investments and Joint Ventures [Abstract]

INVESTMENTS AND EQUITY AFFILIATES

INVESTMENTS

As of Nov. 30, 2013, and Aug. 31, 2013, Monsanto has short-term investments outstanding of $249 million and $254 million, respectively. The investments at Nov. 30, 2013, and Aug. 31, 2013, are comprised of commercial paper with original maturities of one year or less. See Note 13 — Fair Value Measurements.

Monsanto has investments in long-term equity securities, which are considered available-for-sale. As of Nov. 30, 2013, and Aug. 31, 2013, these long-term equity securities are recorded in other assets in the Statements of Consolidated Financial Position at a fair value of $43 million and $22 million, respectively. See Note 17 — Accumulated Other Comprehensive Loss.

Monsanto has cost basis investments recorded in other assets in the Statements of Consolidated Financial Position. As of Nov. 30, 2013, and Aug. 31, 2013, these investments were recorded at $68 million and $67 million, respectively. Due to the nature of these investments, the fair market value is not readily determinable. These investments are reviewed for impairment indicators.

No significant impairments were recorded on any investments for each of the three month periods ended Nov. 30, 2013, and Nov. 30, 2012.

XML

CUSTOMER FINANCING PROGRAMS (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013		Nov. 30, 2012		Aug. 31, 2013
US agreement to sell trade receivables [Member]
Customer Financing Programs [Line Items]
Outstanding balance	$ 128	[1]			$ 348	[1]
Maximum future payout under recourse provisions	9	[1]			19	[1]
Transactions that Qualify for Sales Treatment	23	[1]	2	[1]
Maximum Amount of Potential Sales of Receivables	500
Other agreements to sell trade receivables [Member]
Customer Financing Programs [Line Items]
Outstanding balance	28	[2]			44	[2]
Maximum future payout under recourse provisions	28	[2]			41	[2]
Transactions that Qualify for Sales Treatment	7	[2]	0	[2]
Agreements With Lenders [Member]
Customer Financing Programs [Line Items]
Outstanding balance	60	[3]			45	[3]
Maximum future payout under recourse provisions	44	[3]			32	[3]
Brazil Revolving Financing Program [Member]
Customer Financing Programs [Line Items]
Maximum Amount of Potential Sales of Receivables	$ 430

[1] Monsanto has an agreement in the United States to sell trade receivables up to a maximum outstanding balance of $500 million and to service such accounts. These receivables qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The agreement includes recourse provisions and thus a liability is established at the time of sale that approximates fair value based upon the company’s historical collection experience and a current assessment of credit exposure.

[2] Monsanto has various agreements in European and Latin American countries to sell trade receivables, both with and without recourse. The sales within these programs qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The liability for the guarantees for sales with recourse is recorded at an amount that approximates fair value, based on the company’s historical collection experience for the customers associated with the sale of the receivables and a current assessment of credit exposure.

[3] Monsanto has additional agreements with lenders to establish programs that provide financing for select customers in the United States, Brazil, Latin America and Europe. Monsanto provides various levels of recourse through guarantees of the accounts in the event of customer default. The term of the guarantee is equivalent to the term of the customer loans. The liability for the guarantees is recorded at an amount that approximates fair value, based on the company’s historical collection experience with customers that participate in the program and a current assessment of credit exposure. If performance is required under the guarantee, Monsanto may retain amounts that are subsequently collected from customers.

XML

DEFERRED REVENUE (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Aug. 31, 2013	Nov. 30, 2008
Deferred Revenue Arrangement [Line Items]
Short-Term Deferred Revenue	$ 2,866		$ 517
Receivable Balance	153		237
Accounts Receivable, Net, Current	2,283		1,715
Deferred Revenue	113		138
Interest income	24	23
Pioneer Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Short-Term Deferred Revenue	79	79
Total Receivable Under Agreement				635
Cumulative Cash Receipts Under Agreement	725
Deferred Revenue, Revenue Recognized	20	20
Receivable Balance	168		230
Accounts Receivable, Net, Current	85	85
Total Deferred Revenue	139		159	635
Interest income	1	2
Deferred Revenue, Length of Time	8 years
Syngenta Agreement [Member]
Deferred Revenue Arrangement [Line Items]
Short-Term Deferred Revenue	24	24
Deferred Revenue, Revenue Recognized	3	4
Receivable Balance	37		58
Deferred Revenue	31		34
Minimum Obligation Under Agreement	$ 81
Deferred Revenue, Length of Time	9 years

XML

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Nov. 30, 2013

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on a Recurring Basis

	Fair Value Measurements at Nov. 30, 2013, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	3,762	$	—	$	—	$	3,762
Short-term investments	249		—		—		249
Equity securities	43		—		—		43
Derivative assets related to:
Foreign currency contracts	—		18		—		18
Commodity contracts	1		2		—		3
Total Assets at Fair Value	$	4,055	$	20	$	—	$	4,075
Liabilities at Fair Value:
Derivative liabilities related to:
Foreign currency contracts	$	—	$	8	$	—	$	8
Commodity contracts	61		4		—		65
Total Liabilities at Fair Value	$	61	$	12	$	—	$	73
Liabilities Not Recorded at Fair Value:
Short-term debt instruments(1)	$	—	$	262	$	—	$	262
Long-term debt instruments(1)	—		3,216		—		3,216
Total Liabilities Not Recorded at Fair Value	$	—	$	3,478	$	—	$	3,478
Total Liabilities Recorded and Not Recorded at Fair Value	$	61	$	3,490	$	—	$	3,551

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

	Fair Value Measurements at Aug. 31, 2013, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	2,865	$	—	$	—	$	2,865
Short-term investments	254		—		—		254
Equity securities	22		—		—		22
Derivative assets related to:
Foreign currency contracts	—		5		—		5
Commodity contracts	13		6		—		19
Total Assets at Fair Value	$	3,154	$	11	$	—	$	3,165
Liabilities at Fair Value:
Contingent consideration	$	—	$	—	$	40	$	40
Derivative liabilities related to:
Foreign currency contracts	—		8		—		8
Commodity contracts	73		12		—		85
Total Liabilities at Fair Value:	$	73	$	20	$	40	$	133
Liabilities Not Recorded at Fair Value:
Short-term debt instrument(1)	$	—	$	51	$	—	$	51
Long-term debt instruments(1)	—		2,231		—		2,231
Total Liabilities Not Recorded at Fair Value	$	—	$	2,282	$	—	$	2,282
Total Liabilities Recorded and Not Recorded at Fair Value	$	73	$	2,302	$	40	$	2,415

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

Level 3 Rollforward

The following table summarizes the change in fair value of the Level 3 liability for the three months endedNov. 30, 2013.

(Dollars in millions)	Contingent Consideration
Balance as of Aug. 31, 2013	$	40
Settlement	(40		)
Balance as of Nov. 30, 2013	$	—

XML

EARNINGS PER SHARE

3 Months Ended

Nov. 30, 2013

Earnings Per Share [Abstract]

EARNINGS PER SHARE

EARNINGS PER SHARE

Basic earnings per share (EPS) was computed using the weighted-average number of common shares outstanding during the periods shown in the table below. The diluted EPS computation takes into account the effect of dilutive potential common shares, as shown in the table below. Potential common shares consist primarily of stock options, restricted stock, restricted stock units and directors’ deferred shares calculated using the treasury stock method and are excluded if their effect is antidilutive. Of those antidilutive options, certain options were excluded from the computations of dilutive potential common shares as their exercise prices were greater than the average market price of the common shares for the period.

	Three Months Ended
(Shares in millions)	Nov. 30, 2013	Nov. 30, 2012
Weighted-Average Number of Common Shares	526.9	534.8
Dilutive Potential Common Shares	5.7	5.6
Antidilutive Potential Common Shares	1.8	4.2
Shares Excluded From Computation of Dilutive Potential Shares with Exercise Prices greater than the Average Market Price of Common Shares for the Period	0.1	4.1

XML

ACCUMULATED OTHER COMPREHENSIVE LOSS

3 Months Ended

Nov. 30, 2013

Equity [Abstract]

ACCUMULATED OTHER COMPREHENSIVE LOSS

ACCUMULATED OTHER COMPREHENSIVE LOSS

The following table sets forth the after-tax components of accumulated other comprehensive loss and changes thereto recorded during the three months ended Nov. 30, 2013:

(Dollars in millions)	Foreign Currency Translation Adjustments			Net Unrealized Gain on Available for Sale Securities		Cash Flow Hedges			Postretirement Benefit Items			Total Accumulated Other Comprehensive Loss
Balance as of Aug. 31, 2013	$	(831	)	$	8	$	(115	)	$	(340	)	$	(1,278	)
Other comprehensive income (loss) before reclassifications	127			5		(43		)	—			89
Amounts reclassified from accumulated other comprehensive loss	—			—		5			8			13
Net current-period other comprehensive income (loss)	127			5		(38		)	8			102
Balance as of Nov. 30, 2013	$	(704	)	$	13	$	(153	)	$	(332	)	$	(1,176	)

The following table provides additional information regarding items reclassified out of accumulated other comprehensive loss into earnings during the three months ended Nov. 30, 2013:

Details about Accumulated Other Comprehensive Loss components	Amount Reclassified from Accumulated Other Comprehensive Loss			Affected Line Item in the Statement of Consolidated Operations
Cash Flow Hedges:
Foreign Exchange Contracts Net Loss	$	2		Net sales
Commodity Contracts Net Loss	3			Cost of goods sold
Interest Rate Contracts Net Loss	3			Interest expense
	8			Total before income taxes
	(3		)	Income tax provision
	$	5		Net of tax
Postretirement Benefit Items:
Amortization of Unrecognized Net Loss	$	3		Inventory / Cost of goods sold(1)
Amortization of Unrecognized Net Loss	10			Selling and administrative expenses
	13			Total before income taxes
	(5		)	Income tax provision
	$	8		Net of tax
Total Reclassifications For The Period	$	13		Net of tax

(1) The amortization of unrecognized net loss is recorded to net periodic benefit cost, which is allocated to selling, general and administrative expenses and to inventory, which is recognized through cost of goods sold. The company recorded $3 million of net periodic benefit cost to inventory, of which approximately $1 million was recognized in cost of goods sold during the three months ended Nov. 30, 2013. See Note 15 - Postretirement Benefits - Pensions, Health Care and Other - for additional information.

XML

BACKGROUND AND BASIS OF PRESENTATION BACKGROUND AND BASIS OF PRESENTATION (Details)	3 Months Ended
	Nov. 30, 2013 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Operating Segments	2

XML

VARIABLE INTEREST ENTITIES (Tables)

3 Months Ended

Nov. 30, 2013

VARIABLE INTEREST ENTITIES [Abstract]

Schedule of Consolidated Variable Interest Entity, Amount of Assets, Liabilities, and Maximum Exposure to Loss

The following table presents the carrying value of assets and liabilities, which are identified as restricted assets and liabilities on the company’s Statements of Consolidated Financial Position, and the maximum exposure to loss relating to the VIE for which Monsanto is the primary beneficiary.

	Financing Program VIE
	As of
(Dollars in millions)	Nov. 30, 2013		Aug. 31, 2013
Cash and cash equivalents	$	31	$	140
Trade receivables, net	116		—
Total Assets	$	147	$	140
Total Liabilities	—		—
Maximum Exposure to Loss	$	14	$	—

XML

POSTRETIREMENT BENEFITS - PENSIONS, HEALTH CARE AND OTHER (Tables)

3 Months Ended

Nov. 30, 2013

Compensation and Retirement Disclosure [Abstract]

Components of Net Periodic Benefit Cost

The company’s net periodic benefit cost for pension benefits and health care and other postretirement benefits include the following components:

	Three Months Ended Nov. 30, 2013									Three Months Ended Nov. 30, 2012
Pension Benefits (Dollars in millions)	U.S.			Outside the U.S.			Total			U.S.			Outside the U.S.			Total
Service Cost for Benefits Earned During the Period	$	15		$	3		$	18		$	20		$	3		$	23
Interest Cost on Benefit Obligation	23			2			25			22			2			24
Assumed Return on Plan Assets	(35		)	(2		)	(37		)	(40		)	(2		)	(42		)
Amortization of Unrecognized Net Loss	16			1			17			21			1			22
Curtailment and Settlement Charge	—			1			1			—			1			1
Total Net Periodic Benefit Cost	$	19		$	5		$	24		$	23		$	5		$	28

Net Periodic Cost Postretirement

Health Care and Other Postretirement Benefits	Three Months Ended
(Dollars in millions)	Nov. 30, 2013			Nov. 30, 2012
Service Cost for Benefits Earned During the Period	$	3		$	5
Interest Cost on Benefit Obligation	3			3
Amortization of Unrecognized Net Gain	(4		)	(3		)
Total Net Periodic Benefit Cost	$	2		$	5

XML

VARIABLE INTEREST ENTITIES Narrative (Details)	3 Months Ended	12 Months Ended
	Nov. 30, 2013	Aug. 31, 2013
Revolving Financing Programs [Line Items]
Variable Interest Entity, Financial or Other Support, Percentage	9.00%
Senior Interest [Member]
Revolving Financing Programs [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	91.00%	91.00%
Monsanto Interest [Member]
Revolving Financing Programs [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	9.00%	9.00%

XML

SUBSEQUENT EVENTS

3 Months Ended

Nov. 30, 2013

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

On Dec. 9, 2013, the board of directors declared a quarterly dividend on its common shares of 43 cents per share. The dividend is payable on Jan. 31, 2014, to shareholders of record on Jan. 10, 2014.

Other subsequent events are described in Note 5 — Variable Interest Entities.

In December 2013, Monsanto executed the first of a series of incentive agreements with the County of St. Louis, Missouri. Under these agreements the company has transferred the Chesterfield, Missouri facility to St. Louis County and received Industrial Revenue Bonds in the amount of up to $470 million which enables the company to reduce the cost of constructing and operating the expansion by reducing certain state and local tax expenditures. Monsanto will then lease the facility from the County of St. Louis. The payments due to the company in relation to the Industrial Revenue Bonds and owed by the company in relation to the lease of the facilities qualify for the right of offset under the Balance Sheet topic of the ASC, on the Statements of Consolidated Financial Position, and as a result Monsanto will treat the Chesterfield facilities and the expansion as being owned by Monsanto and not include the Industrial Revenue Bonds on the Statements of Consolidated Financial Position as an asset.

XML

FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS Fair Value of Derivatives Outstanding (Details) (USD $) In Millions, unless otherwise specified	Nov. 30, 2013		Aug. 31, 2013
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	$ 21		$ 24
Derivative Asset, Collateral, Obligation to Return Cash, Offset	(62)		(80)
Derivative Asset, Fair Value, Amount Offset Against Collateral	(41)		(56)
Derivative Asset, Fair Value of Collateral	61		66
Derivative Asset	20		10
Accounts Receivable, Net, Current	2,283		1,715
Miscellaneous receivables	774		748
Other Assets, Current	190		166
Other Assets, Noncurrent	566		496
Derivative Liability, Fair Value, Gross Liability	73		93
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	(62)		(80)
Derivative Liability, Fair Value, Amount Offset Against Collateral	11		13
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	11		13
Miscellaneous short-term accruals	943		812
Other Liabilities, Noncurrent	392		382
Trade Accounts Receivable [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset			1
Derivative Asset, Collateral, Obligation to Return Cash, Offset			(6)
Derivative Asset, Fair Value, Amount Offset Against Collateral			(5)
Derivative Asset, Fair Value of Collateral			5
Derivative Asset			0
Non-derivative Balances			1,715
Derivative Liability, Fair Value, Gross Liability			6
Derivative Liability, Collateral, Right to Reclaim Cash, Offset			(6)
Derivative Liability, Fair Value, Amount Offset Against Collateral			0
Derivative Liability, Fair Value of Collateral			0
Derivative Liability			0
Miscellaneous receivables
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	19		9
Derivative Asset, Collateral, Obligation to Return Cash, Offset	0		0
Derivative Asset, Fair Value, Amount Offset Against Collateral	19		9
Derivative Asset, Fair Value of Collateral	0		0
Derivative Asset	19		9
Non-derivative Balances	755		739
Other Assets
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	0		0
Derivative Asset, Collateral, Obligation to Return Cash, Offset	(23)		(9)
Derivative Asset, Fair Value, Amount Offset Against Collateral	(23)		(9)
Derivative Asset, Fair Value of Collateral	23		9
Derivative Asset	0		0
Non-derivative Balances	566		496
Derivative Liability, Fair Value, Gross Liability	23		9
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	(23)		(9)
Derivative Liability, Fair Value, Amount Offset Against Collateral	0		0
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	0		0
Other current assets
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	2		14
Derivative Asset, Collateral, Obligation to Return Cash, Offset	(39)		(65)
Derivative Asset, Fair Value, Amount Offset Against Collateral	(37)		(51)
Derivative Asset, Fair Value of Collateral	38		52
Derivative Asset	1		1
Non-derivative Balances	189		165
Derivative Liability, Fair Value, Gross Liability	39		65
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	(39)		(65)
Derivative Liability, Fair Value, Amount Offset Against Collateral	0		0
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	0		0
Miscellaneous short term accruals
Derivatives, Fair Value [Line Items]
Non-derivative Balances	932		800
Derivative Liability, Fair Value, Gross Liability	11		12
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0		0
Derivative Liability, Fair Value, Amount Offset Against Collateral	11		12
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	11		12
Other liabilities
Derivatives, Fair Value [Line Items]
Non-derivative Balances			381
Derivative Liability, Fair Value, Gross Liability			1
Derivative Liability, Collateral, Right to Reclaim Cash, Offset			0
Derivative Liability, Fair Value, Amount Offset Against Collateral			1
Derivative Liability, Fair Value of Collateral			0
Derivative Liability			1
Foreign Exchange Contract [Member] | Miscellaneous receivables | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	3		3
Derivative Asset, Collateral, Obligation to Return Cash, Offset	0		0
Derivative Asset, Fair Value, Amount Offset Against Collateral	3		3
Derivative Asset, Fair Value of Collateral	0		0
Derivative Asset	3		3
Foreign Exchange Contract [Member] | Miscellaneous receivables | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	15		2
Derivative Asset, Collateral, Obligation to Return Cash, Offset	0		0
Derivative Asset, Fair Value, Amount Offset Against Collateral	15		2
Derivative Asset, Fair Value of Collateral	0		0
Derivative Asset	15		2
Foreign Exchange Contract [Member] | Miscellaneous short term accruals | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	3		1
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0		0
Derivative Liability, Fair Value, Amount Offset Against Collateral	3		1
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	3		1
Foreign Exchange Contract [Member] | Miscellaneous short term accruals | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	5		7
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0		0
Derivative Liability, Fair Value, Amount Offset Against Collateral	5		7
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	5		7
Commodity Contract [Member] | Trade Accounts Receivable [Member] | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset			1	[1]
Derivative Asset, Collateral, Obligation to Return Cash, Offset			(6)	[1]
Derivative Asset, Fair Value, Amount Offset Against Collateral			(5)	[1]
Derivative Asset, Fair Value of Collateral			5	[1]
Derivative Asset			0	[1]
Derivative Liability, Fair Value, Gross Liability			6	[1]
Derivative Liability, Collateral, Right to Reclaim Cash, Offset			(6)	[1]
Derivative Liability, Fair Value, Amount Offset Against Collateral			0	[1]
Derivative Liability, Fair Value of Collateral			0	[1]
Derivative Liability			0	[1]
Commodity Contract [Member] | Miscellaneous receivables | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	1		4
Derivative Asset, Collateral, Obligation to Return Cash, Offset	0		0
Derivative Asset, Fair Value, Amount Offset Against Collateral	1		4
Derivative Asset, Fair Value of Collateral	0		0
Derivative Asset	1		4
Commodity Contract [Member] | Other Assets | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	0	[1]	0	[1]
Derivative Asset, Collateral, Obligation to Return Cash, Offset	(23)	[1]	(9)	[1]
Derivative Asset, Fair Value, Amount Offset Against Collateral	(23)	[1]	(9)	[1]
Derivative Asset, Fair Value of Collateral	23	[1]	9	[1]
Derivative Asset	0	[1]	0	[1]
Derivative Liability, Fair Value, Gross Liability	23	[1]	9	[1]
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	(23)	[1]	(9)	[1]
Derivative Liability, Fair Value, Amount Offset Against Collateral	0	[1]	0	[1]
Derivative Liability, Fair Value of Collateral	0	[1]	0	[1]
Derivative Liability	0	[1]	0	[1]
Commodity Contract [Member] | Other current assets | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	1	[1]	9	[1]
Derivative Asset, Collateral, Obligation to Return Cash, Offset	(39)	[1]	(61)	[1]
Derivative Asset, Fair Value, Amount Offset Against Collateral	(38)	[1]	(52)	[1]
Derivative Asset, Fair Value of Collateral	38	[1]	52	[1]
Derivative Asset	0	[1]	0	[1]
Derivative Liability, Fair Value, Gross Liability	39	[1]	61	[1]
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	(39)	[1]	(61)	[1]
Derivative Liability, Fair Value, Amount Offset Against Collateral	0	[1]	0	[1]
Derivative Liability, Fair Value of Collateral	0	[1]	0	[1]
Derivative Liability	0	[1]	0	[1]
Commodity Contract [Member] | Other current assets | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset	1		5	[1]
Derivative Asset, Collateral, Obligation to Return Cash, Offset	0		(4)	[1]
Derivative Asset, Fair Value, Amount Offset Against Collateral	1		1	[1]
Derivative Asset, Fair Value of Collateral	0		0	[1]
Derivative Asset	1		1	[1]
Derivative Liability, Fair Value, Gross Liability			4	[1]
Derivative Liability, Collateral, Right to Reclaim Cash, Offset			(4)	[1]
Derivative Liability, Fair Value, Amount Offset Against Collateral			0	[1]
Derivative Liability, Fair Value of Collateral			0	[1]
Derivative Liability			0	[1]
Commodity Contract [Member] | Miscellaneous short term accruals | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	2		4
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0		0
Derivative Liability, Fair Value, Amount Offset Against Collateral	2		4
Derivative Liability, Fair Value of Collateral	0		0
Derivative Liability	2		4
Commodity Contract [Member] | Miscellaneous short term accruals | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability	1
Derivative Liability, Collateral, Right to Reclaim Cash, Offset	0
Derivative Liability, Fair Value, Amount Offset Against Collateral	1
Derivative Liability, Fair Value of Collateral	0
Derivative Liability	1
Commodity Contract [Member] | Other liabilities | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability			1
Derivative Liability, Collateral, Right to Reclaim Cash, Offset			0
Derivative Liability, Fair Value, Amount Offset Against Collateral			1
Derivative Liability, Fair Value of Collateral			0
Derivative Liability			$ 1

[1] As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

XML

COMMITMENTS AND CONTINGENCIES (Details) (USD $) In Millions, unless otherwise specified			3 Months Ended
	Nov. 30, 2013	Aug. 31, 2013	Nov. 30, 2013 Medical Monitoring Program [Member]	Nov. 30, 2013 Medical Monitoring Program [Member] Primary Fund [Member]	Nov. 30, 2013 Medical Monitoring Program [Member] Additional Fund [Member]	Nov. 30, 2013 Property Remediation Plan [Member]
Accrual For Environmental And Litigation Loss Contingencies [Abstract]
Accrual For Environmental And Litigation Loss Contingencies	$ 270	$ 271
Gain (Loss) Related to Litigation Settlement [Abstract]
Litigation Settlement, Gross				$ 21	$ 63	$ 9
Loss Contingency, Settlement Agreement, Terms			30 years			3 years

XML

FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS Notional Amounts of Derivative Instruments Outstanding (Details) (USD $) In Millions, unless otherwise specified	Nov. 30, 2013	Aug. 31, 2013
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	$ 1,231	$ 1,133
Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	1,918	1,405
Foreign Exchange Contract [Member] | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	315	261
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	1,667	1,188
Commodity Contracts | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	916	872
Commodity Contracts | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	113	217
Interest Rate Contracts [Member] | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Total Derivatives	$ 138	$ 0

XML

EARNINGS PER SHARE (Tables)

3 Months Ended

Nov. 30, 2013

Earnings Per Share [Abstract]

Basic Earnings Per Share Table

	Three Months Ended
(Shares in millions)	Nov. 30, 2013	Nov. 30, 2012
Weighted-Average Number of Common Shares	526.9	534.8
Dilutive Potential Common Shares	5.7	5.6
Antidilutive Potential Common Shares	1.8	4.2
Shares Excluded From Computation of Dilutive Potential Shares with Exercise Prices greater than the Average Market Price of Common Shares for the Period	0.1	4.1

XML

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013	Nov. 30, 2012
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Other comprehensive income (loss) before reclassifications	$ 89
Beginning balance	(1,278)
Amounts reclassified from accumulated other comprehensive loss	13
Total Other Comprehensive Income, Net of Tax	102	48
Ending balance	(1,176)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax	(3)	5
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Tax	(5)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Other comprehensive income (loss) before reclassifications	127
Beginning balance	(831)
Amounts reclassified from accumulated other comprehensive loss	0
Total Other Comprehensive Income, Net of Tax	127
Ending balance	(704)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Other comprehensive income (loss) before reclassifications	5
Beginning balance	8
Amounts reclassified from accumulated other comprehensive loss	0
Total Other Comprehensive Income, Net of Tax	5
Ending balance	13
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Other comprehensive income (loss) before reclassifications	(43)
Beginning balance	(115)
Amounts reclassified from accumulated other comprehensive loss	5
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	8
Total Other Comprehensive Income, Net of Tax	(38)
Ending balance	(153)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Other comprehensive income (loss) before reclassifications	0
Beginning balance	(340)
Amounts reclassified from accumulated other comprehensive loss	8
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	13
Total Other Comprehensive Income, Net of Tax	8
Ending balance	(332)
Cost of Sales [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Defined Benefit Plan, Amortization of Gains (Losses)	1
Cost of Sales [Member] | Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	3
Selling, General and Administrative Expenses [Member] | Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	10
Foreign Exchange Contract [Member] | Net Sales [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	2
Commodity Contract [Member] | Cost of Sales [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	3
Interest Rate Contracts [Member] | Interest Expense [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	3
Inventory [Member]
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Defined Benefit Plan, Amortization of Gains (Losses)	$ 3

XML

STOCK BASED COMPENSATION PLANS STOCK BASED COMPENSATION PLANS

3 Months Ended

Nov. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK BASED COMPENSATION PLANS

STOCK-BASED COMPENSATION PLANS

The following table shows total stock-based compensation expense included in the Statements of Consolidated Operations for the three months ended Nov. 30,2013, and Nov. 30, 2012. Stock-based compensation cost capitalized in inventory was $3 million and $3 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively.

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013			Nov. 30, 2012
Cost of Goods Sold	$	2		$	4
Selling, General and Administrative Expenses	20			15
Research and Development Expenses	5			5
Pre-Tax Stock-Based Compensation Expense	27			24
Income Tax Benefit	(9		)	(8		)
Net Stock-Based Compensation Expense	$	18		$	16

The following table summarizes stock-based compensation activity for and as of the three months endedNov. 30, 2013, for employees under the Monsanto Company 2005 Long-Term Incentive Plan, as amended and restated effective Jan. 24, 2012; for employees under the Climate Corporation 2006 Stock Plan, as amended on Oct. 30, 2013, collectively defined as Monsanto Stock Plans; and for directors under the Monsanto Non-Employee Director Equity Incentive Compensation Plan (Director Plan):

	Monsanto Stock Plans				Director Plan
	Stock Options		Restricted Stock Units		Deferred Stock		Restricted Stock
Granted	2,264,046		826,959		18,520		2,554
Weighted-average grant date fair value per share	$	38.44	$	101.08	$	97.89	$	97.89
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable in millions	$	105.1	$	120.9	$	1.4	$	0.2
Remaining weighted-average period of expense recognition/requisite service periods in years	3		3		1		1

XML

Statements of Consolidated Financial Position (Parenthetical) (Unaudited) (USD $) In Millions, except Share data, unless otherwise specified	Nov. 30, 2013	Aug. 31, 2013
Current Assets:
Cash and cash equivalents (variable interest entity restricted)	$ 31	$ 140
Trade receivables, net (variable interest entity restricted)	$ 116	$ 0
Shareowners’ Equity:
Common Stock, Authorized	1,500,000,000	1,500,000,000
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Issued	602,861,098	601,631,267
Common Stock, Outstanding	524,936,480	529,029,712
Treasury Stock, at Cost	77,924,618	72,601,555

XML

Statements of Consolidated Shareholders Equity (Unaudited) (USD $) In Millions, unless otherwise specified	Total	Common Stock	Treasury Stock	Additional Contributed Capital	Retained Earnings	Accumulated Other Comprehensive (Loss)		NonControlling Interests
Beginning Balance at Aug. 31, 2012	$ 12,036	$ 6	$ (3,045)	$ 10,371	$ 5,537	$ (1,036)	[1]	$ 203
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,525				2,482			43
Other comprehensive income (loss)	(269)					(242)	[1]	(27)
Treasury stock purchases	(1,095)		(1,095)
Restricted stock withholding	(10)			(10)
Issuance of shares under employee stock plans	257			257
Excess tax benefits from stock-based compensation	69			69
Stock-based compensation expense	97			97
Cash dividends per common share ($1.56 for 2013)	(831)				(831)
Dividend payments to noncontrolling interest	(174)							(174)
Acquisition of noncontrolling interest	(10)			(1)				(9)
Proceeds from noncontrolling interest	133							133
Ending Balance at Aug. 31, 2013	12,728	6	(4,140)	10,783	7,188	(1,278)	[1]	169
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	373				368			5
Other comprehensive income (loss)	107					102	[1]	5
Treasury stock purchases	(561)		(561)
Restricted stock withholding	(2)			(2)
Issuance of shares under employee stock plans	64			64
Excess tax benefits from stock-based compensation	15			15
Stock-based compensation expense	27			27
Dividend payments to noncontrolling interest	(12)							(12)
Ending Balance at Nov. 30, 2013	$ 12,739	$ 6	$ (4,701)	$ 10,887	$ 7,556	$ (1,176)	[1]	$ 167

[1] See Note 17 — Accumulated Other Comprehensive Loss — for further details of the components of accumulated other comprehensive income (loss).

XML

NEW ACCOUNTING STANDARDS

3 Months Ended

Nov. 30, 2013

NEW ACCOUNTING STANDARDS [Abstract]

NEW ACCOUNTING STANDARDS

NEW ACCOUNTING STANDARDS

In July 2013, the FASB issued accounting guidance requiring entities to present unrecognized tax benefits as a reduction to any related deferred tax assets for net operating losses, similar tax losses, or tax credit carryforwards if such settlement is required or expected in the event an uncertain tax position is disallowed. Currently, U.S. Generally Accepted Accounting Principles ("U.S. GAAP") does not provide explicit guidance on the topic. This new presentation guidance will become effective prospectively for fiscal years, and interim periods within those years, beginning after Dec. 15, 2013. Accordingly, Monsanto will adopt this standard in the first quarter of fiscal year 2015. While the company is evaluating the impact this standard will have on the presentation of unrecognized tax benefits in the company's consolidated balance sheet, it will not affect the company's results of operations, financial condition or cash flows.

In February 2013, the Financial Accounting Standards Board ("FASB") issued "Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income," which requires entities to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, entities are required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, entities are required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail on these amounts. This standard is effective prospectively for reporting periods beginning after Dec. 15, 2012. Accordingly, Monsanto adopted this standard in the first quarter of fiscal year 2014. See Note 17 - Accumulated Other Comprehensive Loss - for additional disclosures.

In December 2011 and February 2013, the FASB issued an amendment to the Balance Sheet topic of the Accounting Standards Codification ("ASC"), which requires entities to disclose both gross and net information about both derivatives and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting agreement. The objective of the disclosure is to facilitate comparison between those entities that prepare their financial statements on the basis of U.S. GAAP and those entities that prepare their financial statements on the basis of International Financial Reporting Standards. This standard is effective for fiscal years, and interim periods within those years, beginning on or after Jan. 1, 2013. Retrospective presentation for all comparative periods presented is required. Accordingly, Monsanto adopted this amendment in the first quarter of fiscal year 2014. See Note 14 - Financial Instruments - for additional disclosures.

XML

SEGMENT AND GEOGRAPHIC DATA (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013 segment		Nov. 30, 2012
Segment Reporting Information [Line Items]
Number of Operating Segments	2
Net Sales	$ 3,143	[1]	$ 2,939	[1]
Gross Profit	1,563		1,397
EBIT	554	[2],[3],[4]	490	[2],[3],[4]
Depreciation and Amortization Expense	162		152
Income from operations of discontinued businesses	14		11
Reconciliation of EBIT to Net Income [Abstract]
EBIT	554	[2],[3],[4]	490	[2],[3],[4]
Interest Expense — Net	29		28
Income Tax Provision	157	[5]	123	[5]
Net Income Attributable to Monsanto Company	368		339
Corn seed and traits [Member]
Segment Reporting Information [Line Items]
Net Sales	1,054	[1]	1,139	[1]
Gross Profit	650		686
Soybean seed and traits [Member]
Segment Reporting Information [Line Items]
Net Sales	267	[1]	231	[1]
Gross Profit	168		118
Cotton seed and traits [Member]
Segment Reporting Information [Line Items]
Net Sales	137	[1]	185	[1]
Gross Profit	92		127
Vegetable seeds [Member]
Segment Reporting Information [Line Items]
Net Sales	157	[1]	156	[1]
Gross Profit	68		83
All other crops seeds and traits [Member]
Segment Reporting Information [Line Items]
Net Sales	61	[1]	44	[1]
Gross Profit	27		11
Total Seeds and Genomics [Member]
Segment Reporting Information [Line Items]
Net Sales	1,676	[1]	1,755	[1]
Gross Profit	1,005		1,025
EBIT	104	[2],[4]	220	[2],[4]
Depreciation and Amortization Expense	131		123
Reconciliation of EBIT to Net Income [Abstract]
EBIT	104	[2],[4]	220	[2],[4]
Agricultural Productivity [Member]
Segment Reporting Information [Line Items]
Net Sales	1,467	[1]	1,184	[1]
Gross Profit	558		372
Total Agricultural Productivity [Member]
Segment Reporting Information [Line Items]
Net Sales	1,467	[1]	1,184	[1]
Gross Profit	558		372
EBIT	450	[2],[4]	270	[2],[4]
Depreciation and Amortization Expense	31		29
Reconciliation of EBIT to Net Income [Abstract]
EBIT	$ 450	[2],[4]	$ 270	[2],[4]

[1] Represents net sales from continuing operations.

[2] EBIT is defined as earnings before interest and taxes; see the following table for reconciliation. Earnings is intended to mean net income as presented in the Statements of Consolidated Operations under generally accepted accounting principles. EBIT is an operating performance measure for the two reportable segments.

[3] Includes the income from operations of discontinued businesses and pre-tax noncontrolling interests.

[4] Agricultural Productivity EBIT includes income from operations of discontinued businesses of $14 million and $11 million for the three months ended Nov. 30, 2013, and Nov. 30, 2012

[5] Includes the income tax benefit on noncontrolling interest and the income tax provision on discontinued operations.

XML

Statements of Consolidated Shareholders Equity (Parenthetical) (Unaudited) (USD $)	3 Months Ended		12 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Aug. 31, 2013
Statement of Stockholders' Equity [Abstract]
Cash dividends per common share	$ 0.00	$ 0.00	$ 1.56

XML

STOCK BASED COMPENSATION PLANS (Tables)

3 Months Ended

Nov. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Components of Stock Based Compensation

The following table shows total stock-based compensation expense included in the Statements of Consolidated Operations for the three months ended Nov. 30,2013, and Nov. 30, 2012. Stock-based compensation cost capitalized in inventory was $3 million and $3 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively.

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013			Nov. 30, 2012
Cost of Goods Sold	$	2		$	4
Selling, General and Administrative Expenses	20			15
Research and Development Expenses	5			5
Pre-Tax Stock-Based Compensation Expense	27			24
Income Tax Benefit	(9		)	(8		)
Net Stock-Based Compensation Expense	$	18		$	16

Restricted Stock

The following table summarizes stock-based compensation activity for and as of the three months endedNov. 30, 2013, for employees under the Monsanto Company 2005 Long-Term Incentive Plan, as amended and restated effective Jan. 24, 2012; for employees under the Climate Corporation 2006 Stock Plan, as amended on Oct. 30, 2013, collectively defined as Monsanto Stock Plans; and for directors under the Monsanto Non-Employee Director Equity Incentive Compensation Plan (Director Plan):

	Monsanto Stock Plans				Director Plan
	Stock Options		Restricted Stock Units		Deferred Stock		Restricted Stock
Granted	2,264,046		826,959		18,520		2,554
Weighted-average grant date fair value per share	$	38.44	$	101.08	$	97.89	$	97.89
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable in millions	$	105.1	$	120.9	$	1.4	$	0.2
Remaining weighted-average period of expense recognition/requisite service periods in years	3		3		1		1

XML

SUPPLEMENTAL CASH FLOW INFORMATION

3 Months Ended

Nov. 30, 2013

Supplemental Cash Flow Information [Abstract]

SUPPLEMENTAL CASH FLOW INFORMATION

SUPPLEMENTAL CASH FLOW INFORMATION

Cash payments for interest and taxes were as follows:

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
Interest	$	42	$	49
Taxes	102		147

XML

BUSINESS COMBINATIONS (Tables)

3 Months Ended

Nov. 30, 2013

Business Combinations [Abstract]

Schedule of Business Acquisitions, by Acquisition

The estimated fair value of the assets and liabilities, summarized in the table below, represents the preliminary purchase price allocation. This allocation will be finalized as soon as the information becomes available, however, not to exceed one year from the acquisition date.

(Dollars in millions)	2014 Acquisition
Current Assets	$	59
Property, Plant & Equipment	9
Goodwill	785
Other Intangible Assets	145
Total Assets Acquired	998
Current Liabilities	10
Other Liabilities	56
Total Liabilities Assumed	66
Net Assets Acquired	$	932
Supplemental Information:
Net assets acquired	$	932
Cash acquired	15
Cash paid, net of cash acquired	$	917

Schedule of Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

The following table presents details of the definite life acquired identifiable intangible assets:

(Dollars in millions)	Weighted-Average Life (Years)	Useful Life (Years)	2014 Acquisition
Acquired Intellectual Property	10	10	$	141
Customer Relationships	1	1	4
Other Intangible Assets			$	145

XML

SUPPLEMENTAL CASH FLOW INFORMATION (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013	Nov. 30, 2012
Supplemental Cash Flow Information [Abstract]
Interest	$ 42	$ 49
Taxes	$ 102	$ 147

XML

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

3 Months Ended

Nov. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Net Carrying Amount of Goodwill

Changes in the net carrying amount of goodwill for the first three months of fiscal year 2014, by segment, are as follows:

(Dollars in millions)	Seeds and Genomics		Agricultural Productivity			Total
Balance as of Aug. 31, 2013	$	3,461	$	59		$	3,520
Acquisition activity (see Note 3)	785		—			785
Effect of foreign currency translation adjustments	21		(1		)	20
Balance as of Nov. 30, 2013	$	4,267	$	58		$	4,325

Other Intangible Assets Information

Information regarding the company’s other intangible assets is as follows:

	As of Nov. 30, 2013							As of Aug. 31, 2013
(Dollars in millions)	Carrying Amount		Accumulated Amortization			Net		Carrying Amount		Accumulated Amortization			Net
Acquired Intellectual Property	$	1,259	$	(799	)	$	460	$	1,095	$	(791	)	$	304
Acquired Germplasm	1,120		(728		)	392		1,113		(717		)	396
Trademarks	343		(135		)	208		341		(131		)	210
Customer Relationships	314		(186		)	128		306		(179		)	127
Other	170		(95		)	75		177		(91		)	86
Total Other Intangible Assets, Finite Lives	$	3,206	$	(1,943	)	$	1,263	$	3,032	$	(1,909	)	$	1,123
In Process Research & Development, Indefinite Lives	104		—			104		103		—			103
Total Other Intangible Assets	$	3,310	$	(1,943	)	$	1,367	$	3,135	$	(1,909	)	$	1,226

Intangible Assets Future Amortization Expense

The estimated intangible asset amortization expense for fiscal year 2014 through fiscal year 2018 is as follows:

(Dollars in millions)	Amount
2014	$	173
2015	171
2016	123
2017	97
2018	87

XML

EARNINGS PER SHARE (Details) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013	Nov. 30, 2012
Earnings Per Share [Abstract]
Weighted-Average Number of Common Shares	526.9	534.8
Dilutive Potential Common Shares	5.7	5.6
Antidilutive Potential Common Shares	1.8	4.2
Shares Excluded From Computation of Dilutive Potential Shares with Exercise Prices greater than the Average Market Price of Common Shares for the Period	0.1	4.1

XML

GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Schedule of estimated amortization expense (Details) (USD $) In Millions, unless otherwise specified	Nov. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
2014	$ 173
2015	171
2016	123
2017	97
2018	$ 87

XML

VARIABLE INTEREST ENTITIES VARIABLE INTEREST ENTITIES Schedules (Details) (USD $)	3 Months Ended	12 Months Ended
	Nov. 30, 2013	Aug. 31, 2013
Variable Interest Entity [Line Items]
Cash and cash equivalents	$ 31,000,000	$ 140,000,000
Trade receivables, net	116,000,000	0
Biotechnology Company [Member]
Variable Interest Entity [Line Items]
Maximum Exposure to Loss	11,000,000
Variable Interest Entity, Qualitative or Quantitative Information, Maximum Future Ownership Percentage	35.00%
Variable Interest Entity, Financial or Other Support, Maximum Commitment Amount	16,000,000
Variable Interest Entity, Financial or Other Support, Number of Funding Phases	3
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage from Call Option	100.00%
Variable Interest Entity, Call Option Total Aggregate Payments	15,000,000
Variable Interest Entity, Call Option Consideration Paid	7,000,000
Brazil Revolving Financing Program [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	31,000,000	140,000,000
Trade receivables, net	116,000,000	0
Total Assets	147,000,000	140,000,000
Total Liabilities	0	0
Maximum Exposure to Loss	$ 14,000,000	$ 0
Maximum [Member] | Biotechnology Company [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	4.00%	1.00%

XML

SEGMENT AND GEOGRAPHIC DATA (Tables)

3 Months Ended

Nov. 30, 2013

Segment Reporting [Abstract]

Operating Segment Information

Data for the Seeds and Genomics and Agricultural Productivity reportable segments, as well as for Monsanto’s significant operating segments, is presented in the table that follows:

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
Net Sales(1)
Corn seed and traits	$	1,054	$	1,139
Soybean seed and traits	267		231
Cotton seed and traits	137		185
Vegetable seeds	157		156
All other crops seeds and traits	61		44
Total Seeds and Genomics	$	1,676	$	1,755
Agricultural productivity	1,467		1,184
Total Agricultural Productivity	$	1,467	$	1,184
Total	$	3,143	$	2,939

Gross Profit
Corn seed and traits	$	650	$	686
Soybean seed and traits	168		118
Cotton seed and traits	92		127
Vegetable seeds	68		83
All other crops seeds and traits	27		11
Total Seeds and Genomics	$	1,005	$	1,025
Agricultural productivity	558		372
Total Agricultural Productivity	$	558	$	372
Total	$	1,563	$	1,397

EBIT(2)(3)
Seeds and Genomics	$	104	$	220
Agricultural Productivity	450		270
Total	$	554	$	490

Depreciation and Amortization Expense
Seeds and Genomics	$	131	$	123
Agricultural Productivity	31		29
Total	$	162	$	152

(1) Represents net sales from continuing operations.

(2) EBIT is defined as earnings before interest and taxes; see the following table for reconciliation. Earnings is intended to mean net income as presented in the Statements of Consolidated Operations under generally accepted accounting principles. EBIT is an operating performance measure for the two reportable segments.

(3) Agricultural Productivity EBIT includes income from operations of discontinued businesses of $14 million and $11 million for the three months ended Nov. 30, 2013, and Nov. 30, 2012

The reconciliation of EBIT to Net Income

A reconciliation of EBIT to net income for each period follows:

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
EBIT(1)	$	554	$	490
Interest Expense — Net	29		28
Income Tax Provision(2)	157		123
Net Income Attributable to Monsanto Company	$	368	$	339

(1) Includes the income from operations of discontinued businesses and pre-tax noncontrolling interests.

(2) Includes the income tax benefit on noncontrolling interest and the income tax provision on discontinued operations.

XML

Statements of Consolidated Comprehensive Income (Loss) (Unaudited) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013	Nov. 30, 2012
Comprehensive Income Attributable to Monsanto Company
Net Income Attributable to Monsanto Company	$ 368	$ 339
Other Comprehensive Income, Net of Tax:
Foreign currency translation, net of tax of $(8) and $0, respectively	127	52
Postretirement benefit plan activity, net of tax of $5 and $7, respectively	8	11
Unrealized net gains on investment holdings, net of tax of $3 and $3, respectively	5	6
Realized net gains on investment holdings, net of tax of $0 and $1, respectively	0	1
Unrealized net derivative losses, net of tax of $(25) and $(6), respectively	(43)	(12)
Realized net derivative gains (losses), net of tax of $3 and $(5), respectively	5	(10)
Total Other Comprehensive Income, Net of Tax	102	48
Comprehensive Income Attributable to Monsanto Company	470	387
Comprehensive Income (Loss) Attributable to Noncontrolling Interests
Net Income Attributable to Noncontrolling Interests	5	10
Other Comprehensive (Income) Loss
Foreign currency translation	5	(4)
Total Other Comprehensive Income (Loss)	5	(4)
Comprehensive Income Attributable to Noncontrolling Interests	10	6
Total Comprehensive Income	$ 480	$ 393

XML

VARIABLE INTEREST ENTITIES

3 Months Ended

Nov. 30, 2013

VARIABLE INTEREST ENTITIES [Abstract]

VARIABLE INTEREST ENTITIES

VARIABLE INTEREST ENTITIES

Monsanto is involved with entities that are deemed to be variable interest entities (VIEs). Monsanto has determined that the company holds variable interests in an entity that is established as a revolving financing program. In addition, Monsanto has various variable interests in biotechnology companies that focus on plant gene and agricultural fungicide research, development and commercialization. These variable interests have also been determined to be VIEs.

In December 2013, Monsanto entered into an agreement with a newly founded company that is focused on agricultural solutions that may enhance Monsanto’s biologicals platform. Monsanto is evaluating the accounting treatment of the transaction, including whether the newly founded entity will be deemed a VIE.

Consolidated VIEs

Monsanto has a financing program in Brazil that is recorded as a consolidated VIE. For the most part, the VIE consists of a revolving financing program that is funded by investments from the company and other third parties, primarily investment funds, and have been established to service Monsanto’s customer receivables. A 91 percent senior interest in the entity is held by third parties, primarily investment funds, as of Nov. 30, 2013, and Aug. 31, 2013, and Monsanto holds the remaining 9 percent interest. Under the arrangement, Monsanto is required to maintain an investment in the VIE of at least 9 percent and could be required to provide additional contributions to the VIE. Monsanto currently has no unfunded commitments to the VIE. See Note 4 — Customer Financing Programs — for additional information regarding the revolving financing arrangement.

Creditors have no recourse against Monsanto in the event of default by the VIE. The company’s financial or other support provided to the VIE is limited to its investment. Even though Monsanto holds a subordinate interest in the VIE, the VIE was established to service transactions involving the company and the company determines the receivables that are included in the revolving financing program. Therefore, the determination is that Monsanto has the power to direct the activities most significant to the economic performance of the VIE. As a result, the company is the primary beneficiary of the VIE and the VIE has been consolidated in Monsanto’s Consolidated Financial Statements. The assets of the VIE may only be used to settle the obligations of the respective entity. Third-party investors in the VIE do not have recourse to the general assets of Monsanto other than the maximum exposure to loss relating to the VIE. The following table presents the carrying value of assets and liabilities, which are identified as restricted assets and liabilities on the company’s Statements of Consolidated Financial Position, and the maximum exposure to loss relating to the VIE for which Monsanto is the primary beneficiary.

	Financing Program VIE
	As of
(Dollars in millions)	Nov. 30, 2013		Aug. 31, 2013
Cash and cash equivalents	$	31	$	140
Trade receivables, net	116		—
Total Assets	$	147	$	140
Total Liabilities	—		—
Maximum Exposure to Loss	$	14	$	—

In June 2013, Monsanto entered into an agreement with a biotechnology company to establish a jointly-owned subsidiary to focus on research and development specifically related to agricultural fungicides. The subsidiary is recorded as a consolidated VIE of Monsanto. Monsanto's ownership interest in the VIE was 4% as of Nov. 30, 2013, and was less than 1% as of Aug. 31, 2013, with the remaining interest held by a third party. Under the arrangement, Monsanto will fund the operations of the VIE in return for additional equity interests up to 35%. The funding, which may total up to $16 million, will be provided in three separate research phases if research milestones are met. Monsanto also holds a call option to acquire 100% of the equity interests in the VIE from the third party majority owner. The call option was granted by the third party majority owner to Monsanto in return for total aggregate payments of $15 million, of which $7 million had been paid by Monsanto as of Nov. 30, 2013, and Aug. 31, 2013. The remaining payments will be made upon achievement of research milestones by the VIE. Even though Monsanto holds a minority interest in the VIE, the VIE was established to perform agricultural-based research and development activities for the benefit of Monsanto, and Monsanto provides all funding of the VIE's activities. Further, Monsanto has the power to direct the activities most significant to the VIE. As a result, Monsanto is the primary beneficiary of the VIE and the VIE has been consolidated in Monsanto's Consolidated Financial Statements. As of Nov. 30, 2013, and Aug. 31, 2013, the VIE had no significant assets or liabilities. Monsanto's maximum exposure to loss as of Nov. 30, 2013, and Aug. 31, 2013, was $11 million, which includes our current investment in the VIE, the funding required to be provided to the VIE during the current research phase and the initial consideration paid related to the call option. The third party majority owner of the VIE does not have recourse to the general assets of Monsanto beyond Monsanto's maximum exposure to loss at any given time relating to the VIE.

Non-Consolidated VIE

Monsanto has a variable interest through an investment with a software company that develops software with agricultural applications. The company has not provided financial or other support other than its original investment, has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity and is not significant. There were no significant assets or liabilities for the VIE as of Nov. 30, 2013, and Aug. 31, 2013.

XML

Statements of Consolidated Financial Position (Unaudited) (USD $) In Millions, unless otherwise specified	Nov. 30, 2013	Aug. 31, 2013
Current Assets:
Cash and cash equivalents (variable interest entity restricted - 2014: $31 and 2013: $140)	$ 4,496	$ 3,668
Short-term investments	249	254
Trade receivables, net (variable interest entity restricted - 2014: $116 and 2013: $0)	2,283	1,715
Miscellaneous receivables	774	748
Deferred tax assets	631	579
Inventory, net	3,873	2,947
Other current assets	190	166
Total Current Assets	12,496	10,077
Total property, plant and equipment	9,660	9,491
Less accumulated depreciation	4,974	4,837
Property, Plant and Equipment, Net	4,686	4,654
Goodwill	4,325	3,520
Other Intangible Assets, Net	1,367	1,226
Noncurrent Deferred Tax Assets	484	454
Long-Term Receivables, Net	153	237
Other Assets	566	496
Total Assets	24,077	20,664
Current Liabilities:
Short-term debt, including current portion of long-term debt	262	51
Accounts payable	853	995
Income taxes payable	101	91
Accrued compensation and benefits	281	492
Accrued marketing programs	756	1,078
Deferred revenues	2,866	517
Grower production accruals	634	60
Dividends payable	0	228
Customer payable	2	12
Miscellaneous short-term accruals	943	812
Total Current Liabilities	6,698	4,336
Long-Term Debt	3,057	2,061
Postretirement Liabilities	348	357
Long-Term Deferred Revenue	113	138
Noncurrent Deferred Tax Liabilities	544	469
Long-Term Portion of Environmental and Litigation Liabilities	186	193
Other Liabilities	392	382
Shareowners’ Equity:
Common stock (authorized: 1,500,000,000 shares, par value $0.01) Issued 602,861,098 and 601,631,267 shares, respectively; Outstanding 524,936,480 and 529,029,712 shares, respectively	6	6
Treasury stock 77,924,618 and 72,601,555 shares, respectively, at cost	(4,701)	(4,140)
Additional contributed capital	10,887	10,783
Retained earnings	7,556	7,188
Accumulated other comprehensive loss	(1,176)	(1,278)
Total Monsanto Company Shareowners’ Equity	12,572	12,559
Noncontrolling Interest	167	169
Total Shareowners’ Equity	12,739	12,728
Total Liabilities and Shareowners’ Equity	$ 24,077	$ 20,664

XML

INCOME TAXES (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013
Income Tax Disclosure [Abstract]
Other Tax Benefit	$ 22

XML

Statements of Consolidated Operations (Unaudited) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended
	Nov. 30, 2013		Nov. 30, 2012
Income Statement [Abstract]
Net Sales	$ 3,143	[1]	$ 2,939	[1]
Cost of goods sold	1,580		1,542
Gross Profit	1,563		1,397
Operating Expenses:
Selling, general and administrative expenses	589		542
Research and development expenses	409		346
Total Operating Expenses	998		888
Income from Operations	565		509
Interest expense	53		51
Interest income	(24)		(23)
Other expense, net	20		17
Income from Continuing Operations Before Income Taxes	516		464
Income tax provision	152		122
Income from Continuing Operations Including Portion Attributable to Noncontrolling Interest	364		342
Discontinued Operations:
Income from operations of discontinued businesses	14		11
Income tax provision	5		4
Income from Discontinued Operations	9		7
Net Income	373		349
Less: Net income attributable to noncontrolling interest	5		10
Net Income Attributable to Monsanto Company	368		339
Amounts Attributable to Monsanto Company:
Income from continuing operations	359		332
Income from discontinued operations	9		7
Net Income Attributable to Monsanto Company	$ 368		$ 339
Basic Earnings per Share Attributable to Monsanto Company:
Income from continuing operations (in dollars per share)	$ 0.68		$ 0.62
Income on discontinued operations (in dollars per share)	$ 0.02		$ 0.01
Net Income Attributable to Monsanto Company (in dollars per share)	$ 0.70		$ 0.63
Diluted Earnings per Share Attributable to Monsanto Company:
Income from continuing operations (in dollars per share)	$ 0.67		$ 0.62
Income on discontinued operations (in dollars per share)	$ 0.02		$ 0.01
Net Income Attributable to Monsanto Company (in dollars per share)	$ 0.69		$ 0.63
Weighted Average Shares Outstanding:
Basic (in shares)	526.9		534.8
Diluted (in shares)	532.6		540.4
Common Stock, Dividends, Per Share, Declared	$ 0.00		$ 0.00

[1] Represents net sales from continuing operations.

XML

RECEIVABLES (Details) (USD $) In Millions, unless otherwise specified	Nov. 30, 2013		Aug. 31, 2013		Aug. 31, 2012
Allowance For Doubtful Accounts Current [Abstract]
Net allowances	$ 70		$ 68
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning Balance	112		104		141
Incremental Provision	4		7
Recoveries	0		(1)
Write-offs	(1)		(47)
Other	5	[1]	4	[1]
Ending Balance	112		104		141
Long Term Receivables [Abstract]
Long term customer receivables, gross	131		112
Long term contractual receivables, gross	$ 134		$ 229

[1] Includes reclassifications from current receivables and foreign currency translation adjustments.

XML

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Nov. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

Environmental and Litigation Liabilities: Monsanto is involved in environmental remediation and legal proceedings to which we are party in our own name and proceedings to which our former parent Pharmacia LLC or its former subsidiary Solutia, Inc. is a party but that we manage and for which we are responsible. In addition, Monsanto has liabilities established for various product claims. With respect to certain of these proceedings, Monsanto has a liability recorded of $270 million and $271 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively, for the estimated contingent liabilities. Information regarding the environmental liabilities appears in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

Litigation: The above liability includes amounts related to certain third-party litigation with respect to Monsanto’s business, as well as tort litigation related to Pharmacia’s former chemical business, including lawsuits involving polychlorinated biphenyls (PCBs), dioxins, and other chemical and premises liability litigation. Additional matters that are not reflected in the liability may arise in the future, and Monsanto may manage, settle, or pay judgments or damages with respect thereto in order to mitigate contesting potential liability. Following is a description of one of the more significant litigation matters reflected in the liability.

• As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2013, on Dec. 17, 2004, 15 plaintiffs filed a purported class action lawsuit, styled Virdie Allen, et al. v. Monsanto, et al., in the Putnam County, West Virginia, state court against Monsanto, Pharmacia and seven other defendants. Monsanto is named as the successor in interest to the liabilities of Pharmacia. The alleged class consists of all current and former residents, workers, and students who, between 1949 and the present, were allegedly exposed to dioxins/furans contamination in counties surrounding Nitro, West Virginia. The complaint alleges that the source of the contamination is a chemical plant in Nitro, formerly owned and operated by Pharmacia and later by Flexsys, a joint venture between Solutia and Akzo Nobel Chemicals, Inc. (Akzo Nobel). Akzo Nobel and Flexsys were named defendants in the case but Solutia was not, due to its then pending bankruptcy proceeding. The suit seeks damages for property cleanup costs, loss of real estate value, funds to test property for contamination levels, funds to test for human exposure, and future medical monitoring costs. The complaint also seeks an injunction against further contamination and punitive damages. Monsanto has agreed to indemnify and defend Akzo Nobel and the Flexsys defendant group, but on May 27, 2011, the judge dismissed both Akzo Nobel and Flexsys from the case. The class action certification hearing was held on Oct. 29, 2007. On Jan. 8, 2008, the trial court issued an order certifying the Allen (now Zina G. Bibb et al. v. Monsanto et al., because Bibb replaced Allen as class representative) case as a class action for property damage and for medical monitoring. On Nov. 2, 2011, the court, in response to defense motions, entered an order decertifying the property class. After the trial for the Bibb medical monitoring class action began on Jan. 3, 2012, the parties reached a settlement in principle as to both the medical monitoring and the property class claims. The proposed settlement provides for a 30 year medical monitoring program consisting of a primary fund of up to $21 million and an additional fund of up to $63 million over the life of the program, and a three year property remediation plan with funding up to $9 million. On Feb. 24, 2012, the court preliminarily approved the parties’ proposed settlement. A fairness hearing was held June 18, 2012, resulting in the trial court's final approval of the settlement. Certain plaintiffs objected to the approval of the settlement and appealed to the West Virginia Supreme Court of Appeals. On Nov. 22, 2013, the West Virginia Supreme Court of Appeals dismissed the appeal and upheld the fairness of the class action settlements. On Dec. 20, 2013, the objector moved for a stay, pending his petition for writ of certiorari with the U.S. Supreme Court.

In October 2007 and November 2009, a total of approximately 200 separate, single plaintiff civil actions were filed in Putnam County, West Virginia, against Monsanto, Pharmacia, Akzo Nobel (and several of its affiliates), Flexsys America Co. (and several of its affiliates), Solutia, and Apogee Coal Company, LLC. These cases allege personal injury occasioned by exposure to dioxin generated by the Nitro Plant during production of 2,4,5T (1949-1969) and thereafter. Monsanto has agreed to accept the tenders of defense in the matters by Pharmacia, Solutia, Akzo Nobel, Flexsys America, and Apogee Coal under a reservation of rights. During the discovery phase of these several claims, the parties reached an agreement in principle to resolve all pending personal injury claims which is reflected in the above liability.

Including litigation reflected in the liability, Monsanto is involved in various legal proceedings that arise in the ordinary course of its business or pursuant to Monsanto’s indemnification obligations to Pharmacia, as well as proceedings that management has considered to be material under SEC regulations. Some of the lawsuits seek damages in very large amounts, or seek to restrict the company’s business activities. Monsanto believes that it has meritorious legal arguments and will continue to represent its interests vigorously in all of the proceedings that it is defending or prosecuting. Management does not anticipate the ultimate liabilities resulting from such proceedings, or the proceedings reflected in the above liability, will have a material adverse effect on Monsanto’s consolidated results of operations, financial position, cash flows or liquidity.

Legal actions have been filed in Brazil that raise issues challenging the right to collect certain royalties for Roundup Ready soybeans. Although Brazilian law clearly states that the pipeline patents protecting these products have the duration of the corresponding U.S. patent (2014 for Roundup Ready soybeans), the duration (and application) of these pipeline patents is currently under judicial review in Brazil. Monsanto believes it has meritorious legal arguments and will continue to represent its interests vigorously in these proceedings. The current estimate of the company’s reasonably possible loss contingency is not material to consolidated results of operations, financial position, cash flows or liquidity.

Other Contingencies: The staff of the SEC is conducting an investigation of financial reporting associated with our customer incentive programs for glyphosate products for the fiscal years 2009 and 2010, and we have received subpoenas in connection therewith.  It is not reasonably possible to assess the outcome of the investigation at this time, but potential outcomes could include the filing of an enforcement proceeding and the imposition of civil penalties as well as non-monetary remedies, which may require the Company to incur future costs. We continue cooperating with the investigation.

Guarantees: Disclosures regarding the guarantees Monsanto provides for certain customer loans in the United States, Brazil, Europe, and Argentina can be found in Note 4 — Customer Financing Programs — of this Form 10-Q. Except as described in that note, there have been no significant changes to guarantees made by Monsanto since Aug. 31, 2013. Disclosures regarding these guarantees made by Monsanto can be found in Note 26 — Commitments and Contingencies — of the notes to the consolidated financial statements contained in Monsanto’s Report on Form 10-K for the fiscal year ended Aug. 31, 2013.

XML

FINANCIAL INSTRUMENTS

3 Months Ended

Nov. 30, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS

Cash Flow Hedges

The company uses foreign currency forward and foreign currency option contracts as hedges of anticipated sales or purchases denominated in foreign currencies. The company enters into these contracts to protect itself against the risk that the eventual net cash flows will be adversely affected by changes in exchange rates.

Monsanto’s commodity price risk management strategy is to use derivative instruments to minimize significant unanticipated earnings fluctuations that may arise from volatility in commodity prices. Price fluctuations in commodities, mainly in corn and soybeans, can cause the actual prices paid to production growers for corn and soybean seeds to differ from anticipated cash outlays. Monsanto uses commodity futures and options contracts to manage these risks. Monsanto’s energy and raw material risk management strategy is to use derivative instruments to minimize significant unanticipated manufacturing cost fluctuations that may arise from volatility in natural gas, diesel and ethylene prices.

Monsanto’s interest rate risk management strategy is to use derivative instruments, such as forward-starting interest rate swaps, to minimize significant unanticipated earnings fluctuations that may arise from volatility in interest rates of the company’s borrowings and to manage the interest rate sensitivity of its debt.

For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

The maximum term over which the company is hedging exposures to the variability of cash flow (for all forecasted transactions) is 21 months for foreign currency hedges and 42 months for commodity hedges. During the next 12 months, a pretax net loss of approximately $34 million is expected to be reclassified from accumulated other comprehensive loss into earnings. During the three months endedNov. 30, 2013, and Nov. 30, 2012, no cash flow hedges were discontinued.

Fair Value Hedges

The company uses commodity futures and options contracts as fair value hedges to manage the value of its soybean inventory. For derivative instruments that are designated and qualify as fair value hedges, both the gain or loss on the derivative and the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings. No fair value hedges were discontinued during the three months endedNov. 30, 2013, and Nov. 30, 2012.

Derivatives Not Designated as Hedging Instruments

The company uses foreign exchange contracts to hedge the effects of fluctuations in exchange rates on foreign currency denominated third-party and intercompany receivables and payables. Both the gain or loss on the derivative and the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings.

The company uses commodity contracts to hedge anticipated cash payments to growers in the United States, Argentina, Mexico and Brazil, which can fluctuate with changes in commodity price. Because these contracts do not meet the provisions specified by the Derivatives and Hedging topic of the ASC, they do not qualify for hedge accounting treatment. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

To reduce credit exposure in Latin America, Monsanto collects payments on certain customer accounts in grain. Such payments in grain are negotiated at or near the time Monsanto’s products are sold to the customers and are valued at the prevailing grain commodity prices. By entering into forward sales contracts related to grain, Monsanto mitigates the commodity price exposure from the time a contract is signed with a customer until the time a grain merchant collects the grain from the customer on Monsanto’s behalf. The forward sales contracts do not qualify for hedge accounting treatment under the Derivatives and Hedging topic of the ASC. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

Monsanto uses interest rate contracts to minimize the variability of forecasted cash flows arising from the company’s VIE. The interest rate contracts do not qualify for hedge accounting treatment under the Derivatives and Hedging Topic of the ASC. Accordingly, the gain or loss on these derivatives is recognized in current earnings.

Financial instruments are neither held nor issued by the company for trading purposes.

The notional amounts of the company’s derivative instruments outstanding as of Nov. 30, 2013, and Aug. 31, 2013, were as follows:

	As of
(Dollars in millions)	Nov. 30, 2013		Aug. 31, 2013
Derivatives Designated as Hedges:
Foreign exchange contracts	$	315	$	261
Commodity contracts	916		872
Total Derivatives Designated as Hedges	$	1,231	$	1,133
Derivatives Not Designated as Hedges:
Foreign exchange contracts	$	1,667	$	1,188
Commodity contracts	113		217
Interest rate contracts	138		—
Total Derivatives Not Designated as Hedges	$	1,918	$	1,405

The net presentation of the company’s derivative instruments outstanding were as follows:

			As of Nov. 30, 2013
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Miscellaneous receivables
	Derivatives designated as hedges:
		Foreign exchange contracts	$	3	$	—		$	3		$	—	$	3
	Derivatives not designated as hedges:
		Foreign exchange contracts	15		—			15			—		15
		Commodity contracts	1		—			1			—		1
Total miscellaneous receivables			19		—			19			—		19		$	755	$	774
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	1		(39		)	(38		)	38		—
	Derivatives not designated as hedges:
		Commodity contracts	1		—			1			—		1
Total other current assets			2		(39		)	(37		)	38		1		189		190
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	—		(23		)	(23		)	23		—
Total other assets			—		(23		)	(23		)	23		—		566		566
Total Asset Derivatives			$	21	$	(62	)	$	(41	)	$	61	$	20
Liability Derivatives:
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	$	39	$	(39	)	$	—		$	—	$	—
Total other current assets			39		(39		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	23		(23		)	—			—		—
Total other assets			23		(23		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
		Commodity contracts	2		—			2			—		2
	Derivatives not designated as hedges:
		Foreign exchange contracts	5		—			5			—		5
		Commodity contracts	1		—			1			—		1
Total miscellaneous short-term accruals			11		—			11			—		11		$	932	$	943
Total Liability Derivatives			$	73	$	(62	)	$	11		$	—	$	11

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

			As of Aug. 31, 2013
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	1	$	(6	)	$	(5	)	$	5	$	—
Total trade receivables, net			1		(6		)	(5		)	5		—		$	1,715	$	1,715
Miscellaneous receivables
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
	Derivatives not designated as hedges:
		Foreign exchange contracts	2		—			2			—		2
		Commodity contracts	4		—			4			—		4
Total miscellaneous receivables			9		—			9			—		9		739		748
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(61		)	(52		)	52		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	5		(4		)	1			—		1
Total other current assets			14		(65		)	(51		)	52		1		165		166
Other assets
	Derivatives designated as hedges
		Commodity contracts(1)	—		(9		)	(9		)	9		—
Total other assets			—		(9		)	(9		)	9		—		496		496
Total Asset Derivatives			$	24	$	(80	)	$	(56	)	$	66	$	10
Liability Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	6	$	(6	)	$	—		$	—	$	—
Total trade receivables, net			6		(6		)	—			—		—
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	61		(61		)	—			—		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	4		(4		)	—			—		—
Total other current assets			65		(65		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(9		)	—			—		—
Total other assets			9		(9		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	1		—			1			—		1
		Commodity contracts	4		—			4			—		4
	Derivatives not designated as hedges:
		Foreign exchange contracts	7		—			7			—		7

Total miscellaneous short-term accruals			12		—			12		—		12		$	800	$	812
Other liabilities
	Derivatives designated as hedges:
		Commodity contracts	1		—			1		—		1
Total other liabilities			1		—			1		—		1		381		382
Total Liability Derivatives			$	93	$	(80	)	$	13	$	—	$	13

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

The gains and losses on the company’s derivative instruments were as follows:

	Amount of Gain  (Loss) Recognized in AOCI(1) (Effective Portion)						Amount of Gain (Loss) Recognized in Income(2)
	Three Months Ended						Three Months Ended						Statement of Consolidated Operations Classification
(Dollars in millions)	Nov. 30, 2013			Nov. 30, 2012			Nov. 30, 2013			Nov. 30, 2012
Derivatives Designated as Hedges:
Fair value hedges:
Commodity contracts(3)							$	(2	)	$	6		Cost of goods sold
Cash flow hedges:
Foreign currency contracts	$	(2	)	$	(1	)	(2		)	(2		)	Net sales
Foreign currency contracts	(3		)	(4		)	—			3			Cost of goods sold
Commodity contracts(4)	(61		)	(13		)	(3		)	17			Cost of goods sold
Interest rate contracts(5)	(2		)	—			(3		)	(3		)	Interest expense
Total Derivatives Designated as Hedges	(68		)	(18		)	(10		)	21
Derivatives Not Designated as Hedges:
Foreign currency contracts(6)							22			31			Other expense, net
Commodity contracts							2			5			Net sales
Commodity contracts							5			4			Cost of goods sold
Total Derivatives Not Designated as Hedges							29			40
Total Derivatives	$	(68	)	$	(18	)	$	19		$	61

(1) Accumulated other comprehensive income (loss) (AOCI).

(2) For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCI into income during the period.

(3) Loss and gain on fair value hedges includes a loss of $1 million and a loss of less than $1 million from ineffectiveness during the three months endedNov. 30, 2013, and Nov. 30, 2012, respectively.

(4) Loss and gain on commodity cash flow hedges includes a loss of $1 million and a loss of less than $1 million from ineffectiveness for the three months endedNov. 30, 2013, and Nov. 30, 2012, respectively. No gains or losses were excluded from the assessment of hedge effectiveness during the three months endedNov. 30, 2013, and Nov. 30, 2012.

(5) Loss on interest rate cash flow hedges includes a loss of less than $1 million from ineffectiveness for the three months endedNov. 30, 2013.

(6) Gain on foreign currency contracts not designated as hedges is offset by a foreign currency transaction loss of $41 million and $48 million during the three months endedNov. 30, 2013, and Nov. 30, 2012, respectively.

Several of the company’s outstanding foreign currency derivatives are covered by International Swap Dealers’ Association (ISDA) Master Agreements with the counterparties. There are no requirements to post collateral under these agreements; however, should Monsanto’s credit rating fall below a specified rating immediately following the merger of the company with another entity, the counterparty may require all outstanding derivatives under the ISDA Master Agreement to be settled immediately at current market value, which equals carrying value. Foreign currency derivatives that are not covered by ISDA Master Agreements do not have credit-risk-related contingent provisions. Most of Monsanto’s outstanding commodity derivatives are listed commodity futures, and the company is required by the relevant commodity exchange to post collateral each day to cover the change in the fair value of these futures in the case of an unrealized loss position. Non-exchange-traded commodity derivatives may be covered by the aforementioned ISDA Master Agreements and would be subject to the same credit-risk-related contingent provisions. The aggregate fair value of all derivative instruments under ISDA Master Agreements that are in a liability position was $4 million and $7 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively, which is the amount that would be required for settlement if the credit-risk-related contingent provisions underlying these agreements were triggered.

Credit Risk Management

Monsanto invests its excess cash in deposits with major banks or money market funds throughout the world in high-quality short-term debt instruments. Such investments are made only in instruments issued or enhanced by high-quality institutions. As of Nov. 30, 2013, and Aug. 31, 2013, the company had no financial instruments that represented a significant concentration of credit risk. Limited amounts are invested in any single institution to minimize risk. The company has not incurred any credit risk losses related to those investments.

The company sells a broad range of agricultural products to a diverse group of customers throughout the world. In the United States, the company makes substantial sales to relatively few large wholesale customers. The company’s business is highly seasonal, and it is subject to weather conditions that affect commodity prices and seed yields. Credit limits, ongoing credit evaluation and account monitoring procedures are used to minimize the risk of loss. Collateral is secured when it is deemed appropriate by the company.

Monsanto regularly evaluates its business practices to minimize its credit risk and periodically engages multiple banks in the United States, Argentina, Brazil and Europe in the development of customer financing options that involve direct bank financing of customer purchases. For further information on these programs, see Note 4 — Customer Financing Programs.

XML

SUPPLEMENTAL CASH FLOW INFORMATION SUPPLEMENTAL CASH FLOW INFORMATION (Tables)

3 Months Ended

Nov. 30, 2013

Supplemental Cash Flow Information [Abstract]

Cash Payments For Interest And Taxes

Cash payments for interest and taxes were as follows:

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
Interest	$	42	$	49
Taxes	102		147

XML

GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Information of other intangible assets (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Aug. 31, 2013
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	$ 3,206		$ 3,032
Accumulated Amortization	(1,943)		(1,909)
Net	1,263		1,123
Total Other Intangible Assets, Carrying Amount	3,310		3,135
Total Other Intangible Assets, net	1,367		1,226
Amortization expense	27	28
Acquired Intellectual Property [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	1,259		1,095
Accumulated Amortization	(799)		(791)
Net	460		304
Acquired Germplasm [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	1,120		1,113
Accumulated Amortization	(728)		(717)
Net	392		396
Trademarks [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	343		341
Accumulated Amortization	(135)		(131)
Net	208		210
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	314		306
Accumulated Amortization	(186)		(179)
Net	128		127
Other Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Carrying Amount	170		177
Accumulated Amortization	(95)		(91)
Net	75		86
In Process Research and Development [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
In Process Research & Development, Indefinite Lives	$ 104		$ 103

XML

FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS Gain (Loss) from Derivatives (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013		Nov. 30, 2012
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ (68)		$ (18)
Amount of Gain (Loss) Recognized in Income	19		61
Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net	0		0
Foreign Currency Transaction Gain (Loss) Realized	(41)		(48)
Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	(68)	[1]	(18)	[1]
Amount of Gain (Loss) Recognized in Income	(10)		21
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income	29		40
Cost of Sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Loss on Fair Value Hedge Ineffectiveness	1		1
Commodity Contracts
Derivative Instruments, Gain (Loss) [Line Items]
Loss on Cash Flow Hedge Ineffectiveness	1		1
Commodity Contracts | Cost of Sales [Member] | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income	5		4
Commodity Contracts | Net Sales [Member] | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income	2		5
Foreign Exchange Contract [Member] | Other expense, net | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income	22	[2]	31	[2]
Interest Rate Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Loss on Cash Flow Hedge Ineffectiveness	1
Fair Value Hedges | Commodity Contracts | Cost of Sales [Member] | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income	(2)	[3]	6	[3]
Cash Flow Hedging [Member] | Commodity Contracts | Cost of Sales [Member] | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	(61)	[1],[4]	(13)	[1],[4]
Amount of Gain (Loss) Recognized in Income	(3)	[4],[5]	17	[4],[5]
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Cost of Sales [Member] | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	(3)	[1]	(4)	[1]
Amount of Gain (Loss) Recognized in Income	0	[5]	3	[5]
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Net Sales [Member] | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	(2)	[1]	(1)	[1]
Amount of Gain (Loss) Recognized in Income	(2)	[5]	(2)	[5]
Cash Flow Hedging [Member] | Interest Rate Contracts [Member] | Interest Expense [Member] | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	(2)	[1],[6]	0	[1],[6]
Amount of Gain (Loss) Recognized in Income	$ (3)	[5],[6]	$ (3)	[5],[6]

[1] Accumulated other comprehensive income (loss) (AOCI)

[2] Gain on foreign currency contracts not designated as hedges is offset by a foreign currency transaction loss of $41 million and $48 million during the three months ended Nov. 30, 2013, and Nov. 30, 2012, respectively.

[3] Loss and gain on fair value hedges includes a loss of $1 million and a loss of less than $1 million from ineffectiveness during the three months ended Nov. 30, 2013, and Nov. 30, 2012, respectively.

[4] Loss and gain on commodity cash flow hedges includes a loss of $1 million and a loss of less than $1 million from ineffectiveness for the three months ended Nov. 30, 2013, and Nov. 30, 2012, respectively. No gains or losses were excluded from the assessment of hedge effectiveness during the three months ended Nov. 30, 2013, and Nov. 30, 2012.

[5] For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCI into income during the period.

[6] Loss on interest rate cash flow hedges includes a loss of less than $1 million from ineffectiveness for the three months ended Nov. 30, 2013.

XML

FINANCIAL INSTRUMENTS (Tables)

3 Months Ended

Nov. 30, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments (Notional Amounts)

The notional amounts of the company’s derivative instruments outstanding as of Nov. 30, 2013, and Aug. 31, 2013, were as follows:

	As of
(Dollars in millions)	Nov. 30, 2013		Aug. 31, 2013
Derivatives Designated as Hedges:
Foreign exchange contracts	$	315	$	261
Commodity contracts	916		872
Total Derivatives Designated as Hedges	$	1,231	$	1,133
Derivatives Not Designated as Hedges:
Foreign exchange contracts	$	1,667	$	1,188
Commodity contracts	113		217
Interest rate contracts	138		—
Total Derivatives Not Designated as Hedges	$	1,918	$	1,405

Fair Values of Derivative Instruments

The net presentation of the company’s derivative instruments outstanding were as follows:

			As of Nov. 30, 2013
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Miscellaneous receivables
	Derivatives designated as hedges:
		Foreign exchange contracts	$	3	$	—		$	3		$	—	$	3
	Derivatives not designated as hedges:
		Foreign exchange contracts	15		—			15			—		15
		Commodity contracts	1		—			1			—		1
Total miscellaneous receivables			19		—			19			—		19		$	755	$	774
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	1		(39		)	(38		)	38		—
	Derivatives not designated as hedges:
		Commodity contracts	1		—			1			—		1
Total other current assets			2		(39		)	(37		)	38		1		189		190
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	—		(23		)	(23		)	23		—
Total other assets			—		(23		)	(23		)	23		—		566		566
Total Asset Derivatives			$	21	$	(62	)	$	(41	)	$	61	$	20
Liability Derivatives:
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	$	39	$	(39	)	$	—		$	—	$	—
Total other current assets			39		(39		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	23		(23		)	—			—		—
Total other assets			23		(23		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
		Commodity contracts	2		—			2			—		2
	Derivatives not designated as hedges:
		Foreign exchange contracts	5		—			5			—		5
		Commodity contracts	1		—			1			—		1
Total miscellaneous short-term accruals			11		—			11			—		11		$	932	$	943
Total Liability Derivatives			$	73	$	(62	)	$	11		$	—	$	11

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

			As of Aug. 31, 2013
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	1	$	(6	)	$	(5	)	$	5	$	—
Total trade receivables, net			1		(6		)	(5		)	5		—		$	1,715	$	1,715
Miscellaneous receivables
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
	Derivatives not designated as hedges:
		Foreign exchange contracts	2		—			2			—		2
		Commodity contracts	4		—			4			—		4
Total miscellaneous receivables			9		—			9			—		9		739		748
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(61		)	(52		)	52		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	5		(4		)	1			—		1
Total other current assets			14		(65		)	(51		)	52		1		165		166
Other assets
	Derivatives designated as hedges
		Commodity contracts(1)	—		(9		)	(9		)	9		—
Total other assets			—		(9		)	(9		)	9		—		496		496
Total Asset Derivatives			$	24	$	(80	)	$	(56	)	$	66	$	10
Liability Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	6	$	(6	)	$	—		$	—	$	—
Total trade receivables, net			6		(6		)	—			—		—
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	61		(61		)	—			—		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	4		(4		)	—			—		—
Total other current assets			65		(65		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(9		)	—			—		—
Total other assets			9		(9		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	1		—			1			—		1
		Commodity contracts	4		—			4			—		4
	Derivatives not designated as hedges:
		Foreign exchange contracts	7		—			7			—		7

Total miscellaneous short-term accruals			12		—			12		—		12		$	800	$	812
Other liabilities
	Derivatives designated as hedges:
		Commodity contracts	1		—			1		—		1
Total other liabilities			1		—			1		—		1		381		382
Total Liability Derivatives			$	93	$	(80	)	$	13	$	—	$	13

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

The net presentation of the company’s derivative instruments outstanding were as follows:

			As of Nov. 30, 2013
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Miscellaneous receivables
	Derivatives designated as hedges:
		Foreign exchange contracts	$	3	$	—		$	3		$	—	$	3
	Derivatives not designated as hedges:
		Foreign exchange contracts	15		—			15			—		15
		Commodity contracts	1		—			1			—		1
Total miscellaneous receivables			19		—			19			—		19		$	755	$	774
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	1		(39		)	(38		)	38		—
	Derivatives not designated as hedges:
		Commodity contracts	1		—			1			—		1
Total other current assets			2		(39		)	(37		)	38		1		189		190
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	—		(23		)	(23		)	23		—
Total other assets			—		(23		)	(23		)	23		—		566		566
Total Asset Derivatives			$	21	$	(62	)	$	(41	)	$	61	$	20
Liability Derivatives:
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	$	39	$	(39	)	$	—		$	—	$	—
Total other current assets			39		(39		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	23		(23		)	—			—		—
Total other assets			23		(23		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
		Commodity contracts	2		—			2			—		2
	Derivatives not designated as hedges:
		Foreign exchange contracts	5		—			5			—		5
		Commodity contracts	1		—			1			—		1
Total miscellaneous short-term accruals			11		—			11			—		11		$	932	$	943
Total Liability Derivatives			$	73	$	(62	)	$	11		$	—	$	11

(1) As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative assets and liabilities have been offset by collateral subject to an enforceable master netting arrangement or similar arrangement. Therefore, these commodity contracts that are in an asset or liability position are included in asset accounts within the Statements of Consolidated Financial Position.

			As of Aug. 31, 2013
(in millions)			Gross Amounts Recognized		Gross Amounts Offset in the Statement of Consolidated Financial Position			Net Amounts Included in the Statement of Consolidated Financial Position			Collateral Pledged		Net Amounts Reported in the Statement of Consolidated Financial Position		Other Items Included in the Statement of Consolidated Financial Position		Statement of Consolidated Financial Position Balance
Asset Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	1	$	(6	)	$	(5	)	$	5	$	—
Total trade receivables, net			1		(6		)	(5		)	5		—		$	1,715	$	1,715
Miscellaneous receivables
	Derivatives designated as hedges:
		Foreign exchange contracts	3		—			3			—		3
	Derivatives not designated as hedges:
		Foreign exchange contracts	2		—			2			—		2
		Commodity contracts	4		—			4			—		4
Total miscellaneous receivables			9		—			9			—		9		739		748
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(61		)	(52		)	52		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	5		(4		)	1			—		1
Total other current assets			14		(65		)	(51		)	52		1		165		166
Other assets
	Derivatives designated as hedges
		Commodity contracts(1)	—		(9		)	(9		)	9		—
Total other assets			—		(9		)	(9		)	9		—		496		496
Total Asset Derivatives			$	24	$	(80	)	$	(56	)	$	66	$	10
Liability Derivatives:
Trade receivables, net
	Derivatives not designated as hedges:
		Commodity contracts(1)	$	6	$	(6	)	$	—		$	—	$	—
Total trade receivables, net			6		(6		)	—			—		—
Other current assets
	Derivatives designated as hedges:
		Commodity contracts(1)	61		(61		)	—			—		—
	Derivatives not designated as hedges:
		Commodity contracts(1)	4		(4		)	—			—		—
Total other current assets			65		(65		)	—			—		—
Other assets
	Derivatives designated as hedges:
		Commodity contracts(1)	9		(9		)	—			—		—
Total other assets			9		(9		)	—			—		—
Miscellaneous short-term accruals
	Derivatives designated as hedges:
		Foreign exchange contracts	1		—			1			—		1
		Commodity contracts	4		—			4			—		4
	Derivatives not designated as hedges:
		Foreign exchange contracts	7		—			7			—		7

Total miscellaneous short-term accruals			12		—			12		—		12		$	800	$	812
Other liabilities
	Derivatives designated as hedges:
		Commodity contracts	1		—			1		—		1
Total other liabilities			1		—			1		—		1		381		382
Total Liability Derivatives			$	93	$	(80	)	$	13	$	—	$	13

Gains Losses of Derivative Instruments

The gains and losses on the company’s derivative instruments were as follows:

	Amount of Gain  (Loss) Recognized in AOCI(1) (Effective Portion)						Amount of Gain (Loss) Recognized in Income(2)
	Three Months Ended						Three Months Ended						Statement of Consolidated Operations Classification
(Dollars in millions)	Nov. 30, 2013			Nov. 30, 2012			Nov. 30, 2013			Nov. 30, 2012
Derivatives Designated as Hedges:
Fair value hedges:
Commodity contracts(3)							$	(2	)	$	6		Cost of goods sold
Cash flow hedges:
Foreign currency contracts	$	(2	)	$	(1	)	(2		)	(2		)	Net sales
Foreign currency contracts	(3		)	(4		)	—			3			Cost of goods sold
Commodity contracts(4)	(61		)	(13		)	(3		)	17			Cost of goods sold
Interest rate contracts(5)	(2		)	—			(3		)	(3		)	Interest expense
Total Derivatives Designated as Hedges	(68		)	(18		)	(10		)	21
Derivatives Not Designated as Hedges:
Foreign currency contracts(6)							22			31			Other expense, net
Commodity contracts							2			5			Net sales
Commodity contracts							5			4			Cost of goods sold
Total Derivatives Not Designated as Hedges							29			40
Total Derivatives	$	(68	)	$	(18	)	$	19		$	61

(1) Accumulated other comprehensive income (loss) (AOCI).

(2) For derivatives designated as cash flow hedges under the Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain (loss) reclassified from AOCI into income during the period.

(3) Loss and gain on fair value hedges includes a loss of $1 million and a loss of less than $1 million from ineffectiveness during the three months endedNov. 30, 2013, and Nov. 30, 2012, respectively.

(4) Loss and gain on commodity cash flow hedges includes a loss of $1 million and a loss of less than $1 million from ineffectiveness for the three months endedNov. 30, 2013, and Nov. 30, 2012, respectively. No gains or losses were excluded from the assessment of hedge effectiveness during the three months endedNov. 30, 2013, and Nov. 30, 2012.

(5) Loss on interest rate cash flow hedges includes a loss of less than $1 million from ineffectiveness for the three months endedNov. 30, 2013.

(6) Gain on foreign currency contracts not designated as hedges is offset by a foreign currency transaction loss of $41 million and $48 million during the three months endedNov. 30, 2013, and Nov. 30, 2012, respectively.

XML

RECEIVABLES (Tables)

3 Months Ended

Nov. 30, 2013

Receivables [Abstract]

Allowance For Doubtful Long Term Receivables

The following table displays a roll forward of the allowance for credit losses related to long-term customer receivables.

(Dollars in millions)
Balance as of Aug. 31, 2012	$	141
Incremental Provision	7
Recoveries	(1		)
Write-offs	(47		)
Other(1)	4
Balance as of Aug. 31, 2013	$	104
Incremental Provision	4
Recoveries	—
Write-offs	(1		)
Other(1)	5
Balance as of Nov. 30, 2013	$	112

(1)Includes reclassifications from current receivables and foreign currency translation adjustments.

XML

INVENTORY (Tables)

3 Months Ended

Nov. 30, 2013

Inventory Disclosure [Abstract]

Components of Inventory

Components of inventory are:

	As of
(Dollars in millions)	Nov. 30, 2013			Aug. 31, 2013
Finished Goods	$	1,820		$	1,079
Goods In Process	1,744			1,619
Raw Materials and Supplies	477			418
Inventory at FIFO Cost	4,041			3,116
Excess of FIFO over LIFO Cost	(168		)	(169		)
Total	$	3,873		$	2,947

XML

CUSTOMER FINANCING PROGRAMS

3 Months Ended

Nov. 30, 2013

CUSTOMER FINANCING PROGRAMS [Abstract]

CUSTOMER FINANCING PROGRAMS

CUSTOMER FINANCING PROGRAMS

Monsanto participates in customer financing programs as follows:

	As of
(Dollars in millions)	Nov. 30, 2013		Aug. 31, 2013
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)
Outstanding balance	$	128	$	348
Maximum future payout under recourse provisions	9		19
European and Latin American agreements to sell trade receivables(2)
Outstanding balance	$	28	$	44
Maximum future payout under recourse provisions	28		41
Agreements with Lenders(3)
Outstanding balance	$	60	$	45
Maximum future payout under the guarantee	44		32

The gross amount of receivables sold under transactions that qualify for sales treatment were:

	Gross Amount of Receivables Sold
	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)	$	23	$	2
European and Latin American agreements to sell trade receivables(2)	7		—

(1) Monsanto has an agreement in the United States to sell trade receivables up to a maximum outstanding balance of $500 million and to service such accounts. These receivables qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The agreement includes recourse provisions and thus a liability is established at the time of sale that approximates fair value based upon the company’s historical collection experience and a current assessment of credit exposure.

(2) Monsanto has various agreements in European and Latin American countries to sell trade receivables, both with and without recourse. The sales within these programs qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The liability for the guarantees for sales with recourse is recorded at an amount that approximates fair value, based on the company’s historical collection experience for the customers associated with the sale of the receivables and a current assessment of credit exposure.

(3) Monsanto has additional agreements with lenders to establish programs that provide financing for select customers in the United States, Brazil, Latin America and Europe. Monsanto provides various levels of recourse through guarantees of the accounts in the event of customer default. The term of the guarantee is equivalent to the term of the customer loans. The liability for the guarantees is recorded at an amount that approximates fair value, based on the company’s historical collection experience with customers that participate in the program and a current assessment of credit exposure. If performance is required under the guarantee, Monsanto may retain amounts that are subsequently collected from customers.

In addition to the arrangements in the above table, Monsanto also participates in a financing program in Brazil that allowed Monsanto to transfer up to 1 billion Brazilian reais (approximately $430 million) for select customers in Brazil to a revolving financing program. Under the arrangement, a recourse provision requires Monsanto to cover the first credit losses within the program up to the amount of our investment. The company evaluated its relationship with the entity under the guidance within the Consolidation topic of the ASC and, as a result, the entity has been consolidated. For further information on this topic, see Note 5 — Variable Interest Entities.

There were no significant recourse or non-recourse liabilities for all programs as of Nov. 30, 2013, and Aug. 31, 2013. There were no significant delinquent loans for all programs as of Nov. 30, 2013, and Aug. 31, 2013.

XML

FINANCIAL INSTRUMENTS Narrative (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended			3 Months Ended
	Nov. 30, 2013	Nov. 30, 2013 subject to master netting arrangement, or similar agreement [Member]	Aug. 31, 2013 subject to master netting arrangement, or similar agreement [Member]	Nov. 30, 2013 Foreign Exchange Contract [Member]	Nov. 30, 2013 Commodity Contracts
Derivatives, Fair Value [Line Items]
Maximum Length of Time Hedged in Cash Flow Hedge				21 months	42 months
Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion	$ (34)
Derivative, Net Liability Position, Aggregate Fair Value		$ 4	$ 7

XML

SEGMENT AND GEOGRAPHIC DATA

3 Months Ended

Nov. 30, 2013

Segment Reporting [Abstract]

SEGMENT INFORMATION

SEGMENT INFORMATION

Monsanto conducts its worldwide operations through global businesses, which are aggregated into reportable segments based on similarity of products, production processes, customers, distribution methods and economic characteristics. The operating segments are aggregated into two reportable segments: Seeds and Genomics and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and related traits businesses, biotechnology platforms and precision agriculture. Within the Seeds and Genomics segment, Monsanto’s significant operating segments are corn seed and traits, soybean seed and traits, cotton seed and traits, vegetable seeds and all other crops seeds and traits. The Agricultural Productivity reportable segment consists of the Agricultural Productivity operating segment. EBIT is defined as earnings before interest and taxes and is an operating performance measure for the two reportable segments. EBIT is useful to management in demonstrating the operational profitability of the segments by excluding interest and taxes, which are generally accounted for across the entire company on a consolidated basis. Sales between segments were not significant. Certain SG&A expenses are allocated between segments based on the segment’s relative contribution to total Monsanto operations. Allocation percentages remain relatively consistent for fiscal years 2013 and 2014.

Data for the Seeds and Genomics and Agricultural Productivity reportable segments, as well as for Monsanto’s significant operating segments, is presented in the table that follows:

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
Net Sales(1)
Corn seed and traits	$	1,054	$	1,139
Soybean seed and traits	267		231
Cotton seed and traits	137		185
Vegetable seeds	157		156
All other crops seeds and traits	61		44
Total Seeds and Genomics	$	1,676	$	1,755
Agricultural productivity	1,467		1,184
Total Agricultural Productivity	$	1,467	$	1,184
Total	$	3,143	$	2,939

Gross Profit
Corn seed and traits	$	650	$	686
Soybean seed and traits	168		118
Cotton seed and traits	92		127
Vegetable seeds	68		83
All other crops seeds and traits	27		11
Total Seeds and Genomics	$	1,005	$	1,025
Agricultural productivity	558		372
Total Agricultural Productivity	$	558	$	372
Total	$	1,563	$	1,397

EBIT(2)(3)
Seeds and Genomics	$	104	$	220
Agricultural Productivity	450		270
Total	$	554	$	490

Depreciation and Amortization Expense
Seeds and Genomics	$	131	$	123
Agricultural Productivity	31		29
Total	$	162	$	152

(1) Represents net sales from continuing operations.

(2) EBIT is defined as earnings before interest and taxes; see the following table for reconciliation. Earnings is intended to mean net income as presented in the Statements of Consolidated Operations under generally accepted accounting principles. EBIT is an operating performance measure for the two reportable segments.

(3) Agricultural Productivity EBIT includes income from operations of discontinued businesses of $14 million and $11 million for the three months ended Nov. 30, 2013, and Nov. 30, 2012, respectively.

A reconciliation of EBIT to net income for each period follows:

	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
EBIT(1)	$	554	$	490
Interest Expense — Net	29		28
Income Tax Provision(2)	157		123
Net Income Attributable to Monsanto Company	$	368	$	339

(1) Includes the income from operations of discontinued businesses and pre-tax noncontrolling interests.

(2) Includes the income tax benefit on noncontrolling interest and the income tax provision on discontinued operations.

XML

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)

3 Months Ended

Nov. 30, 2013

Equity [Abstract]

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]

The following table provides additional information regarding items reclassified out of accumulated other comprehensive loss into earnings during the three months ended Nov. 30, 2013:

Details about Accumulated Other Comprehensive Loss components	Amount Reclassified from Accumulated Other Comprehensive Loss			Affected Line Item in the Statement of Consolidated Operations
Cash Flow Hedges:
Foreign Exchange Contracts Net Loss	$	2		Net sales
Commodity Contracts Net Loss	3			Cost of goods sold
Interest Rate Contracts Net Loss	3			Interest expense
	8			Total before income taxes
	(3		)	Income tax provision
	$	5		Net of tax
Postretirement Benefit Items:
Amortization of Unrecognized Net Loss	$	3		Inventory / Cost of goods sold(1)
Amortization of Unrecognized Net Loss	10			Selling and administrative expenses
	13			Total before income taxes
	(5		)	Income tax provision
	$	8		Net of tax
Total Reclassifications For The Period	$	13		Net of tax

(1) The amortization of unrecognized net loss is recorded to net periodic benefit cost, which is allocated to selling, general and administrative expenses and to inventory, which is recognized through cost of goods sold. The company recorded $3 million of net periodic benefit cost to inventory, of which approximately $1 million was recognized in cost of goods sold during the three months ended Nov. 30, 2013. See Note 15 - Postretirement Benefits - Pensions, Health Care and Other - for additional information.

Components of Accumulated Other Comprehensive Income

The following table sets forth the after-tax components of accumulated other comprehensive loss and changes thereto recorded during the three months ended Nov. 30, 2013:

(Dollars in millions)	Foreign Currency Translation Adjustments			Net Unrealized Gain on Available for Sale Securities		Cash Flow Hedges			Postretirement Benefit Items			Total Accumulated Other Comprehensive Loss
Balance as of Aug. 31, 2013	$	(831	)	$	8	$	(115	)	$	(340	)	$	(1,278	)
Other comprehensive income (loss) before reclassifications	127			5		(43		)	—			89
Amounts reclassified from accumulated other comprehensive loss	—			—		5			8			13
Net current-period other comprehensive income (loss)	127			5		(38		)	8			102
Balance as of Nov. 30, 2013	$	(704	)	$	13	$	(153	)	$	(332	)	$	(1,176	)

XML

INVENTORY

3 Months Ended

Nov. 30, 2013

Inventory Disclosure [Abstract]

INVENTORY

INVENTORY

Components of inventory are:

	As of
(Dollars in millions)	Nov. 30, 2013			Aug. 31, 2013
Finished Goods	$	1,820		$	1,079
Goods In Process	1,744			1,619
Raw Materials and Supplies	477			418
Inventory at FIFO Cost	4,041			3,116
Excess of FIFO over LIFO Cost	(168		)	(169		)
Total	$	3,873		$	2,947

XML

SUBSEQUENT EVENTS Subsequent Events (Details) (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended		12 Months Ended	0 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Aug. 31, 2013	Dec. 09, 2013 Subsequent Event [Member]	Dec. 31, 2013 Bond [Member] Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Dividends, Per Share, Declared	$ 0.00	$ 0.00	$ 1.56	$ 0.43
Fair Value Disclosure, Off-balance Sheet Risks, Face Amount, Asset					$ 470

XML

BUSINESS COMBINATIONS

3 Months Ended

Nov. 30, 2013

Business Combinations [Abstract]

BUSINESS COMBINATIONS

BUSINESS COMBINATIONS

2014 Acquisitions: In November 2013, Monsanto acquired 100 percent of the outstanding stock of The Climate Corporation, a San Francisco, California based company. The Climate Corporation is a leading data analytics company with core capabilities around hyper local weather monitoring, weather simulation and agronomic modeling which has allowed them to develop risk management tools and agronomic decision support tools for growers. The acquisition will combine The Climate Corporation's expertise in agriculture risk-management with Monsanto’s R&D capabilities, and is expected to further enable farmers to significantly improve productivity and better manage risk from variables that could limit agriculture production. The acquisition of the company qualifies as a business under the Business Combinations topic of the ASC. Acquisition costs were $17 million, of which $1 million was recorded in the first quarter of 2014. These costs were classified as selling, general and administrative expenses. The total fair value of the acquisition was $932 million and the total cash paid for the acquisition was $917 million (net of cash acquired). The fair value was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is not deductible for tax purposes.

The business operations and employees of the acquired entity described above were included in the Seeds and Genomics reportable segment results upon acquisition. The estimated fair value of the assets and liabilities, summarized in the table below, represents the preliminary purchase price allocation. This allocation will be finalized as soon as the information becomes available, however, not to exceed one year from the acquisition date.

(Dollars in millions)	2014 Acquisition
Current Assets	$	59
Property, Plant & Equipment	9
Goodwill	785
Other Intangible Assets	145
Total Assets Acquired	998
Current Liabilities	10
Other Liabilities	56
Total Liabilities Assumed	66
Net Assets Acquired	$	932
Supplemental Information:
Net assets acquired	$	932
Cash acquired	15
Cash paid, net of cash acquired	$	917

Pro forma information related to the 2014 acquisition is not presented because the impact of the acquisition on Monsanto's consolidated results of operations is not significant.

The following table presents details of the definite life acquired identifiable intangible assets:

(Dollars in millions)	Weighted-Average Life (Years)	Useful Life (Years)	2014 Acquisition
Acquired Intellectual Property	10	10	$	141
Customer Relationships	1	1	4
Other Intangible Assets			$	145

2013 Acquisitions: In August 2013, Monsanto acquired certain assets and manufacturing capabilities of Dieckmann GmbH & Co. KG, a business based in Germany which specializes in the breeding of oilseed rape and rye seeds. The acquisition, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing activities in the breeding, production and marketing of oilseed rape in Europe. Acquisition costs were approximately $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations.  The total fair value and cash paid for the acquisition was $30 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles.  The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology.  The goodwill is deductible for tax purposes.

In June 2013, Monsanto acquired 100 percent of the outstanding stock of GrassRoots Biotechnology, Inc., a business based in Durham, North Carolina that is focused on gene expression and other agriculture technologies. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. Acquisition costs were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total fair value and cash paid for the acquisition was $15 million (net of cash acquired). The fair value of the acquisition was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is not deductible for tax purposes.

In March 2013, Monsanto acquired substantially all of the assets of Rosetta Green Ltd., a business based in Israel which specializes in the identification and use of unique genes to guide key processes in major crops including corn, soybeans and cotton. The acquisition of the company, which qualifies as a business under the Business Combinations topic of the ASC, is expected to complement Monsanto's existing research platforms. Acquisition costs were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total fair value and cash paid for the acquisition was $35 million. The fair value of the acquisition was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is deductible for tax purposes.

In January 2013, Monsanto acquired select assets of Agradis, Inc., a business focused on developing sustainable agricultural solutions. The acquisition, which qualifies as a business under the Business Combinations topic of the ASC, is intended to support Monsanto's efforts to provide farmers with sustainable biological products to improve crop health and productivity. Acquisition costs incurred were less than $1 million and were classified as selling, general and administrative expenses in the Statements of Consolidated Operations. The total cash paid and the fair value of the acquisition was $85 million, and the purchase price was primarily allocated to goodwill and intangibles. The primary item that generated goodwill was the premium paid by the company for the right to control the acquired business and technology. The goodwill is deductible for tax purposes.

For the acquisitions described above, the business operations and employees of the acquired entities were included in the Seeds and Genomics reportable segment results upon acquisition.

Pro forma information related to the 2013 acquisitions is not presented because the impact of these acquisitions, either individually or in the aggregate, on Monsanto's consolidated results of operations is not expected to be significant.

XML

Statements of Consolidated Cash Flows (Unaudited) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013	Nov. 30, 2012
Operating Activities:
Net Income	$ 373	$ 349
Items that did not require (provide) cash:
Depreciation and amortization	162	152
Bad-debt expense	11	7
Stock-based compensation expense	27	24
Excess tax benefits from stock-based compensation	(15)	(15)
Deferred income taxes	(6)	13
Equity affiliate (income) expense, net	3	(2)
Net gain on sales of a business or other assets	(1)	(12)
Other items	20	(16)
Changes in assets and liabilities that required cash, net of acquisitions:
Trade receivables, net	(478)	(196)
Inventory, net	(898)	(740)
Deferred revenues	2,319	2,426
Accounts payable and other accrued liabilities	332	(341)
Pension contributions	(23)	(16)
Other items	(128)	(64)
Net Cash Provided by Operating Activities	1,698	1,569
Cash Flows (Required) Provided by Investing Activities:
Purchases of short-term investments	(105)	(118)
Maturities of short-term investments	110	110
Capital expenditures	(303)	(133)
Acquisition of businesses, net of cash acquired	(917)	0
Purchases of long-term debt and equity securities	(12)	0
Technology and other investments	(21)	(23)
Other proceeds	7	68
Net Cash Required by Investing Activities	(1,241)	(96)
Cash Flows Provided (Required) by Financing Activities:
Net change in financing with less than 90-day maturities	117	60
Short-term debt proceeds	2	0
Short-term debt reductions	0	(7)
Long-term debt proceeds	999	16
Long-term debt reductions	(1)	0
Payments on other financing	(39)	0
Debt issuance costs	(8)	0
Treasury stock purchases	(561)	(27)
Stock option exercises	64	31
Excess tax benefits from stock-based compensation	15	16
Tax withholding on restricted stock and restricted stock units	(2)	(3)
Dividend payments	(228)	(201)
Dividend payments to noncontrolling interests	(12)	(1)
Net Cash Provided (Required) by Financing Activities	346	(116)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	25	(3)
Net Increase in Cash and Cash Equivalents	828	1,354
Cash and Cash Equivalents at Beginning of Period	3,668	3,283
Cash and Cash Equivalents at End of Period	$ 4,496	$ 4,637

XML

INVENTORY (Details) (USD $) In Millions, unless otherwise specified	Nov. 30, 2013	Aug. 31, 2013
Inventory Disclosure [Abstract]
Finished Goods	$ 1,820	$ 1,079
Goods In Process	1,744	1,619
Raw Materials and Supplies	477	418
Inventory at FIFO Cost	4,041	3,116
Excess of FIFO over LIFO Cost	(168)	(169)
Total	$ 3,873	$ 2,947

XML

BUSINESS COMBINATIONS (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended			1 Months Ended		3 Months Ended	1 Months Ended				3 Months Ended
	Nov. 30, 2013	Nov. 30, 2012	Aug. 31, 2013	Nov. 30, 2013 The Climate Corporation [Member]	Nov. 29, 2013 The Climate Corporation [Member]	Nov. 30, 2013 Twenty Fourteen Acquisitions [Member]	Aug. 31, 2013 Diekmann GMBH & Co. KG [Member]	Jun. 30, 2013 GrassRoots Biotechnology, Inc. [Member]	Mar. 31, 2013 Rosetta Green Ltd. [Member]	Jan. 31, 2013 Agradis, Inc. [Member]	Nov. 30, 2013 Acquired Biotechnology [Member] Twenty Fourteen Acquisitions [Member]	Nov. 30, 2013 Customer Relationships [Member] Twenty Fourteen Acquisitions [Member]	Nov. 30, 2013 Other Intangible Assets [Member] Twenty Fourteen Acquisitions [Member]
Business Acquisition [Line Items]
Acquiree percentage					100.00%			100.00%
Transaction cost				$ 17	$ 1		$ 1	$ 1	$ 1	$ 1
Business Acquisition, Cost of Acquired Entity, Cash Paid				932			30		35	85
Payments to Acquire Businesses, Net of Cash Acquired	917	0		917		917		15
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets						59
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment						9
Goodwill	4,325		3,520			785
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill						145					141	4	145
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets						998
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities						10
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other						56
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities						66
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net						932
Cash Acquired from Acquisition						15
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life											10 years	1 year
Finite-Lived Intangible Asset, Useful Life											10 years	1 year
Fair Value of Acquisition					$ 932		$ 30	$ 15	$ 35	$ 85

XML

CUSTOMER FINANCING PROGRAMS (Tables)

3 Months Ended

Nov. 30, 2013

CUSTOMER FINANCING PROGRAMS (Tables) [Abstract]

Customer Financing Programs

Monsanto participates in customer financing programs as follows:

	As of
(Dollars in millions)	Nov. 30, 2013		Aug. 31, 2013
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)
Outstanding balance	$	128	$	348
Maximum future payout under recourse provisions	9		19
European and Latin American agreements to sell trade receivables(2)
Outstanding balance	$	28	$	44
Maximum future payout under recourse provisions	28		41
Agreements with Lenders(3)
Outstanding balance	$	60	$	45
Maximum future payout under the guarantee	44		32

Customer Financing Programs, Sales of Receivables

The gross amount of receivables sold under transactions that qualify for sales treatment were:

	Gross Amount of Receivables Sold
	Three Months Ended
(Dollars in millions)	Nov. 30, 2013		Nov. 30, 2012
Transactions that Qualify for Sales Treatment
U.S. agreement to sell trade receivables(1)	$	23	$	2
European and Latin American agreements to sell trade receivables(2)	7		—

(1) Monsanto has an agreement in the United States to sell trade receivables up to a maximum outstanding balance of $500 million and to service such accounts. These receivables qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The agreement includes recourse provisions and thus a liability is established at the time of sale that approximates fair value based upon the company’s historical collection experience and a current assessment of credit exposure.

(2) Monsanto has various agreements in European and Latin American countries to sell trade receivables, both with and without recourse. The sales within these programs qualify for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The liability for the guarantees for sales with recourse is recorded at an amount that approximates fair value, based on the company’s historical collection experience for the customers associated with the sale of the receivables and a current assessment of credit exposure.

(3) Monsanto has additional agreements with lenders to establish programs that provide financing for select customers in the United States, Brazil, Latin America and Europe. Monsanto provides various levels of recourse through guarantees of the accounts in the event of customer default. The term of the guarantee is equivalent to the term of the customer loans. The liability for the guarantees is recorded at an amount that approximates fair value, based on the company’s historical collection experience with customers that participate in the program and a current assessment of credit exposure. If performance is required under the guarantee, Monsanto may retain amounts that are subsequently collected from customers.

XML

POSTRETIREMENT BENEFITS - PENSIONS, HEALTH CARE AND OTHER (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013	Nov. 30, 2012
United States Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost for Benefits Earned During the Period	$ 15	$ 20
Interest Cost on Benefit Obligation	23	22
Assumed Return on Plan Assets	(35)	(40)
Amortization of Unrecognized Net Loss (Gain)	16	21
Curtailment and Settlement Charge	0	0
Total Net Periodic Benefit Cost	19	23
Defined Benefit Plan Additional Information [Abstract]
Employer Contributions	15	11
Estimated Future Employer Contributions	45
Foreign Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost for Benefits Earned During the Period	3	3
Interest Cost on Benefit Obligation	2	2
Assumed Return on Plan Assets	(2)	(2)
Amortization of Unrecognized Net Loss (Gain)	1	1
Curtailment and Settlement Charge	1	1
Total Net Periodic Benefit Cost	5	5
Defined Benefit Plan Additional Information [Abstract]
Employer Contributions	5	3
Estimated Future Employer Contributions	10
Pension Plan, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost for Benefits Earned During the Period	18	23
Interest Cost on Benefit Obligation	25	24
Assumed Return on Plan Assets	(37)	(42)
Amortization of Unrecognized Net Loss (Gain)	17	22
Curtailment and Settlement Charge	1	1
Total Net Periodic Benefit Cost	24	28
Postretirement and ESOP Liabilities [Member]
Defined Benefit Plan Disclosure [Line Items]
Service Cost for Benefits Earned During the Period	3	5
Interest Cost on Benefit Obligation	3	3
Amortization of Unrecognized Net Loss (Gain)	(4)	(3)
Total Net Periodic Benefit Cost	$ 2	$ 5

XML

DEBT AND OTHER CREDIT ARRANGEMENTS (Details) (USD $)					1 Months Ended
	Nov. 30, 2013		Aug. 31, 2013		Nov. 30, 2013 Floating Rate Notes Due Twenty Sixteen [Member]	Nov. 30, 2013 Senior Notes Due Twenty Eighteen [Member]	Nov. 30, 2013 Senior Notes Due Twenty Forty Three [Member]	Jul. 31, 2012 Senior Notes Due 2022 [Member]	Jul. 31, 2012 Senior Notes Due 2042 [Member]	Nov. 30, 2013 Credit Facility Agreement 2011 [Member]	Nov. 30, 2013 Commercial Paper [Member]
Debt Instrument [Line Items]
Face Amount					$ 400,000,000	$ 300,000,000	$ 300,000,000	$ 250,000,000	$ 250,000,000	$ 2,000,000,000
Interest Rate						1.85%	4.65%	2.20%	3.60%
Maturity Date					Nov. 07, 2016	Nov. 15, 2018	Nov. 15, 2043	Jul. 15, 2022	Jul. 15, 2042
Short-term debt, including current portion of long-term debt	262,000,000		51,000,000								195,000,000
Long-term Debt, Fair Value	$ 3,216,000,000	[1]	$ 2,231,000,000	[1]

[1] Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

XML

DEFERRED REVENUE

3 Months Ended

Nov. 30, 2013

Deferred Revenue Disclosure [Abstract]

DEFERRED REVENUE

DEFERRED REVENUE

As of Nov. 30, 2013, and Aug. 31, 2013, short-term deferred revenue was $2,866 million and $517 million, respectively. This balance primarily consists of cash received related to Monsanto's prepayment programs in the United States and Brazil. These programs allow Monsanto's customers to receive a discount if they prepay by a certain date, and the short-term deferred revenue balance is consistent with the seasonality of Monsanto's business. Prepayment options are attractive to customers given the discounted pricing and the ability to utilize cash flow from the current year grain harvest to pay for the next season seed purchases. The deferred revenue balance related to these prepayment programs is considered short-term in nature and thus classified in current liabilities as the prepayments are for products to be shipped within the next 12 months.

In 2008, Monsanto entered into a corn herbicide tolerance and insect control trait technologies agreement with Pioneer Hi-Bred International, Inc. Among its provisions, the agreement modified certain existing corn license agreements between the parties. Under the agreement, which requires fixed annual payments, the company recorded a receivable and deferred revenue of $635 million in first quarter 2008. Cumulative cash receipts will be $725 million over an eight-year period. Revenue of $20 million was recorded for each of the three months ended Nov. 30, 2013, and Nov. 30, 2012. As of Nov. 30, 2013, and Aug. 31, 2013, the remaining receivable balance is $168 million and $230 million, respectively, of which $85 million is current in both periods and is included in trade receivables, net. The remaining balance is included in long-term receivables, net on the Statements of Consolidated Financial Position. As of Nov. 30, 2013, and Aug. 31, 2013, the remaining deferred revenue balance is $139 million and $159 million, respectively, of which $79 million is included in current deferred revenue in both periods. Interest income recorded on this receivable is $1 million and $2 million for the three months ended Nov. 30, 2013, and Nov. 30, 2012, respectively.    

In 2008, Monsanto and Syngenta entered into a Genuity Roundup Ready 2 Yield Soybean License Agreement, which grants Syngenta access to Monsanto’s Genuity Roundup Ready 2 Yield Soybean technology in consideration of royalty payments from Syngenta, based on sales. The minimum obligation from Syngenta over the nine-year contract period is $81 million. Revenue of $3 million and $4 million related to this agreement was recorded for the three months ended Nov. 30, 2013, and Nov. 30, 2012, respectively. As of Nov. 30, 2013, and Aug. 31, 2013, the remaining receivable balance is $37 million and $58 million, respectively. The majority of this balance is current and is included in trade receivables, net. The remaining balance is included in long-term receivables, net on the Statements of Consolidated Financial Position. As of Nov. 30, 2013, and Aug. 31, 2013, the remaining deferred revenue balance is $31 million and $34 million, respectively, of which $24 million is included in current deferred revenue in both periods.

XML

RECEIVABLES

3 Months Ended

Nov. 30, 2013

Receivables [Abstract]

RECEIVABLES

RECEIVABLES

Trade receivables on the Statements of Consolidated Financial Position are net of allowances of $70 million and $68 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively.

The company has financing receivables that represent long-term customer receivable balances related to past due accounts which are not expected to be collected within the current year. The long-term customer receivables were $131 million and $112 million with a corresponding allowance for credit losses on these receivables of $112 million and $104 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively. These long-term customer receivable balances and the corresponding allowance are included in long-term receivables, net on the Statements of Consolidated Financial Position. For these long-term customer receivables, interest is no longer accrued when the receivable is determined to be delinquent and classified as long-term based on estimated timing of collection.

The following table displays a roll forward of the allowance for credit losses related to long-term customer receivables.

(Dollars in millions)
Balance as of Aug. 31, 2012	$	141
Incremental Provision	7
Recoveries	(1		)
Write-offs	(47		)
Other(1)	4
Balance as of Aug. 31, 2013	$	104
Incremental Provision	4
Recoveries	—
Write-offs	(1		)
Other(1)	5
Balance as of Nov. 30, 2013	$	112

(1)Includes reclassifications from current receivables and foreign currency translation adjustments.

In addition, the company has long-term contractual receivables. These receivables are collected at fixed and determinable dates in accordance with the customer long-term agreement. The long-term contractual receivables were $134 million and $229 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively, and did not have any allowance recorded related to these balances. These receivables are included in long-term receivables, net on the Statements of Consolidated Financial Position. There are no balances related to these long-term contractual receivables that are past due. These receivables are outstanding with large, reputable companies who have been timely with scheduled payments thus far and are considered to be fully collectible. Interest is accrued on these receivables in accordance with the agreements and is included within interest income in the Statements of Consolidated Operations.

On an ongoing basis, the company evaluates credit quality of its financing receivables utilizing aging of receivables, collection experience and write-offs, as well as evaluating existing economic conditions, to determine if an allowance is necessary.

XML

STOCK BASED COMPENSATION PLANS STOCK BASED COMPENSATION PLANS Restricted Stock (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended
	Nov. 30, 2013
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	2,264,046
Weighted-average grant date fair value per share	$ 38.44
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable in millions	$ 105.1
Remaining weighted-average period of expense recognition/requisite service periods in years	3 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	826,959
Weighted-average grant date fair value per share	$ 101.08
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable in millions	120.9
Remaining weighted-average period of expense recognition/requisite service periods in years	3 years
Directors Deferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	18,520
Weighted-average grant date fair value per share	$ 97.89
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable in millions	1.4
Remaining weighted-average period of expense recognition/requisite service periods in years	1 year
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted	2,554
Weighted-average grant date fair value per share	$ 97.89
Pre-tax unrecognized compensation expense, net of estimated forfeitures as applicable in millions	$ 0.2
Remaining weighted-average period of expense recognition/requisite service periods in years	1 year

XML

FAIR VALUE MEASUREMENTS

3 Months Ended

Nov. 30, 2013

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

Monsanto determines the fair market value of its financial assets and liabilities based on quoted market prices, estimates from brokers, and other appropriate valuation techniques. The company uses the fair value hierarchy established in the Fair Value Measurements and Disclosures topic of the ASC, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The hierarchy contains three levels as follows, with Level 3 representing the lowest level of input:

Level 1 — Values based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities.

Level 2 — Values based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, discounted cash flow models, or model-based valuation techniques adjusted, as necessary, for credit risk.

Level 3 — Values generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions would reflect our own estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques could include use of option pricing models, discounted cash flow models and similar techniques.

The following tables set forth by level Monsanto’s assets and liabilities that were accounted for at fair value on a recurring basis as of Nov. 30, 2013, and Aug. 31, 2013. As required by the Fair Value Measurements and Disclosures topic of the ASC, assets and liabilities are classified in their entirety based on the lowest level of input that is a significant component of the fair value measurement. Monsanto’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the classification of fair value assets and liabilities within the fair value hierarchy levels.

	Fair Value Measurements at Nov. 30, 2013, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	3,762	$	—	$	—	$	3,762
Short-term investments	249		—		—		249
Equity securities	43		—		—		43
Derivative assets related to:
Foreign currency contracts	—		18		—		18
Commodity contracts	1		2		—		3
Total Assets at Fair Value	$	4,055	$	20	$	—	$	4,075
Liabilities at Fair Value:
Derivative liabilities related to:
Foreign currency contracts	$	—	$	8	$	—	$	8
Commodity contracts	61		4		—		65
Total Liabilities at Fair Value	$	61	$	12	$	—	$	73
Liabilities Not Recorded at Fair Value:
Short-term debt instruments(1)	$	—	$	262	$	—	$	262
Long-term debt instruments(1)	—		3,216		—		3,216
Total Liabilities Not Recorded at Fair Value	$	—	$	3,478	$	—	$	3,478
Total Liabilities Recorded and Not Recorded at Fair Value	$	61	$	3,490	$	—	$	3,551

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

	Fair Value Measurements at Aug. 31, 2013, Using
(Dollars in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Cash equivalents	$	2,865	$	—	$	—	$	2,865
Short-term investments	254		—		—		254
Equity securities	22		—		—		22
Derivative assets related to:
Foreign currency contracts	—		5		—		5
Commodity contracts	13		6		—		19
Total Assets at Fair Value	$	3,154	$	11	$	—	$	3,165
Liabilities at Fair Value:
Contingent consideration	$	—	$	—	$	40	$	40
Derivative liabilities related to:
Foreign currency contracts	—		8		—		8
Commodity contracts	73		12		—		85
Total Liabilities at Fair Value:	$	73	$	20	$	40	$	133
Liabilities Not Recorded at Fair Value:
Short-term debt instrument(1)	$	—	$	51	$	—	$	51
Long-term debt instruments(1)	—		2,231		—		2,231
Total Liabilities Not Recorded at Fair Value	$	—	$	2,282	$	—	$	2,282
Total Liabilities Recorded and Not Recorded at Fair Value	$	73	$	2,302	$	40	$	2,415

(1) Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.

The company’s derivative contracts are measured at fair value, including forward commodity purchase and sale contracts, exchange-traded commodity futures and option contracts, and over the counter (OTC) instruments related primarily to agricultural commodities, energy and raw materials, interest rates, and foreign currencies. Exchange-traded futures and options contracts are valued based on unadjusted quoted prices in active markets and are classified as Level 1. Fair value for forward commodity purchase and sale contracts is estimated based on exchange-quoted prices adjusted for differences in local markets. These differences are generally determined using inputs from broker or dealer quotations or market transactions in either the listed or OTC markets. When observable inputs are available for substantially the full term of the contract, it is classified as Level 2. Based on historical experience with the company’s suppliers and customers, the company’s own credit risk and knowledge of current market conditions, the company does not view nonperformance risk to be a significant input to the fair value for the majority of its forward commodity purchase and sale contracts. The effective portions of changes in the fair value of derivatives designated as cash flow hedges are recognized in the Statements of Consolidated Financial Position as a component of accumulated other comprehensive loss until the hedged items are recorded in earnings or it is probable the hedged transaction will no longer occur. Changes in the fair value of derivatives are recognized in the Statements of Consolidated Operation as a component of net sales, cost of goods sold and other expense, net.

The company’s short-term investments are comprised of commercial paper. The company’s equity securities are comprised of publicly traded equity investments. Commercial paper and publicly traded equity investments are valued using quoted market prices and are classified as Level 1.

The fair value of short-term and long-term debt was determined based on current market yields for our debt traded in the secondary market.

The company’s contingent consideration relates to the Precision Planting acquisition and was settled during the three months endedNov. 30, 2013.

For the three months endedNov. 30, 2013, and Nov. 30, 2012, the company had no transfers between Level 1, Level 2 and Level 3. Monsanto does not have any assets with fair value determined using Level 3 inputs as of Nov. 30, 2013, and Aug. 31, 2013. The following table summarizes the change in fair value of the Level 3 liability for the three months endedNov. 30, 2013.

(Dollars in millions)	Contingent Consideration
Balance as of Aug. 31, 2013	$	40
Settlement	(40		)
Balance as of Nov. 30, 2013	$	—

There were no significant measurements of assets or liabilities to their implied fair value on a nonrecurring basis during the three months endedNov. 30, 2013, and Nov. 30, 2012.

The recorded amounts of cash, trade receivables, miscellaneous receivables, third-party guarantees, accounts payable, grower production accruals, accrued marketing programs and miscellaneous short-term accruals approximate their fair values as of Nov. 30, 2013, and Aug. 31, 2013.

Management is ultimately responsible for all fair values presented in the company’s consolidated financial statements. The company performs analysis and review of the information and prices received from third parties to ensure that the prices represent a reasonable estimate of fair value. This process involves quantitative and qualitative analysis. As a result of the analysis, if the company determines there is a more appropriate fair value based upon the available market data, the price received from the third party is adjusted accordingly.

XML

INCOME TAXES

3 Months Ended

Nov. 30, 2013

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

Monsanto recorded a tax benefit of $22 million in first quarter 2013 primarily as a result of a capital loss from a deemed liquidation of a subsidiary.

XML

Document and Entity Information	3 Months Ended
	Nov. 30, 2013	Jan. 06, 2014
Document and Entity Information [Abstract]
Document type	10-Q
Document period end date	Nov. 30, 2013
Amendment flag	false
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Entity Registrant Name	MONSANTO CO /NEW/
Entity Central Index Key	0001110783
Current Fiscal Year End Date	--08-31
Entity Filer Category	Large Accelerated Filer
Entity common stock shares outstanding		524,876,699
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

XML

DEBT AND OTHER CREDIT ARRANGEMENTS

3 Months Ended

Nov. 30, 2013

Debt Disclosure [Abstract]

DEBT AND OTHER CREDIT ARRANGEMENTS

DEBT AND OTHER CREDIT ARRANGEMENTS

In November 2011, Monsanto filed a new shelf registration with the SEC (2011 shelf registration) that allows the company to issue an unlimited capacity of debt, equity and hybrid offerings. The 2011 shelf registration will expire in November 2014.

In November 2013, Monsanto issued $400 million of Floating Rate Senior Notes which are due on November 7, 2016, (Floating Rate Notes), $300 million of 1.85% Senior Notes which are due on November 15, 2018, (2018 Senior Notes) and $300 million of 4.65% Senior Notes which are due on November 15, 2043, (2043 Senior Notes). All notes were issued under the 2011 shelf registration.

The net proceeds from the sale of the Floating Rate, 2018, and 2043 Senior Notes were used for the acquisition of The Climate Corporation and general corporate purposes.

In July 2012, Monsanto issued $250 million of 2.20% Senior Notes which are due on July 15, 2022, (2022 Senior Notes) and $250 million of 3.60% Senior Notes which are due on July 15, 2042, (2042 Senior Notes). Both were issued under the 2011 shelf registration.

The net proceeds from the sale of the 2022 and 2042 Senior Notes were used for general corporate purposes, including refinancing of the company’s indebtedness.

Monsanto has a $2 billion credit facility agreement with a group of banks that provides a senior unsecured revolving credit facility through April 1, 2016.

As of Nov. 30, 2013, Monsanto had commercial paper borrowings outstanding of $195 million which is included in short-term debt on the Statements of Consolidated Financial Position.

The fair value of the total short-term debt was $262 million and $51 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively. The fair value of the total long-term debt was $3,216 million and $2,231 million as of Nov. 30, 2013, and Aug. 31, 2013, respectively.

XML

FAIR VALUE MEASUREMENTS Summary of the Change in Level 3 Liability (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Nov. 30, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 40
Settlement	(40)
Ending Balance	$ 0

XML

FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS Fair Value Hierarchy Levels (Details) (USD $) In Millions, unless otherwise specified	Nov. 30, 2013		Aug. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 3,762		$ 2,865
Short-term investments	249		254
Equity securities	43		22
Foreign currency contracts	18		5
Commodity contracts	3		19
Total Assets at Fair Value	4,075		3,165
Contingent consideration			40
Foreign currency contracts	8		8
Commodity contracts	65		85
Total Liabilities at Fair Value	73		133
Short-term Debt, Fair Value	262	[1]	51	[1]
Long-term Debt, Fair Value	3,216	[1]	2,231	[1]
Total Liabilities Not Recorded at Fair Value	3,478		2,282
Total Liabilities Recorded and Not Recorded at Fair Value	3,551		2,415
Assets, Fair Value Disclosure, Nonrecurring	0		0
Liabilities, Fair Value Disclosure, Nonrecurring	0		0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	3,762		2,865
Short-term investments	249		254
Equity securities	43		22
Foreign currency contracts	0		0
Commodity contracts	1		13
Total Assets at Fair Value	4,055		3,154
Contingent consideration			0
Foreign currency contracts	0		0
Commodity contracts	61		73
Total Liabilities at Fair Value	61		73
Short-term Debt, Fair Value	0	[1]	0	[1]
Long-term Debt, Fair Value	0	[1]	0	[1]
Total Liabilities Not Recorded at Fair Value	0		0
Total Liabilities Recorded and Not Recorded at Fair Value	61		73
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0		0
Short-term investments	0		0
Equity securities	0		0
Foreign currency contracts	18		5
Commodity contracts	2		6
Total Assets at Fair Value	20		11
Contingent consideration			0
Foreign currency contracts	8		8
Commodity contracts	4		12
Total Liabilities at Fair Value	12		20
Short-term Debt, Fair Value	262	[1]	51	[1]
Long-term Debt, Fair Value	3,216	[1]	2,231	[1]
Total Liabilities Not Recorded at Fair Value	3,478		2,282
Total Liabilities Recorded and Not Recorded at Fair Value	3,490		2,302
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0		0
Short-term investments	0		0
Equity securities	0		0
Foreign currency contracts	0		0
Commodity contracts	0		0
Total Assets at Fair Value	0		0
Contingent consideration			40
Foreign currency contracts	0		0
Commodity contracts	0		0
Total Liabilities at Fair Value	0		40
Short-term Debt, Fair Value	0	[1]	0	[1]
Long-term Debt, Fair Value	0	[1]	0	[1]
Total Liabilities Not Recorded at Fair Value	0		0
Total Liabilities Recorded and Not Recorded at Fair Value	$ 0		$ 40

[1] Short-term and long-term debt instruments are not recorded at fair value on a recurring basis; however, they are measured at fair value for disclosure purposes, as required by the Fair Value Measurements and Disclosures topic of the ASC.